

Index

Note: page numbers in *italics* refer to figures; those in **bold** to tables.

a

- ABC approach, obstetric emergencies 336, 339
- abdomen
 surface anatomy 477, 478
 ultrasound imaging 500
- abdominal circumference (AC), fetal
 defining growth restriction 221, **222**
 growth curve 35
 measurement 32–33, 33, 234, 234
- abdominal examination
 chronic pelvic pain 745
 infertility 695
 miscarriage 561
- abdominal pain
 ectopic pregnancy 589, 591
 medical abortion 606
 ovarian cyst torsion 821
- abdominal wall
 anterior 477, 478
 defects 259–261, 456
 pain 745
- abnormal uterine bleeding
 chlamydia infection 655, 913
 diagnostic hysteroscopy **528**
 endometrial cancer 878
 imaging methods 502–505
 IUCD users 942
 PALM-COEIN system 502, 653–655, 654
 sexually transmitted infections 909
 see also intermenstrual bleeding;
 post-coital bleeding;
 postmenopausal bleeding
- abortion
 illegal 988
 induced *see* termination of pregnancy
- septic 618
 spontaneous *see* miscarriage
- Abortion Act 1967 598–599, 988–989
- doctor's role 1001–1004
 outdated nature 989–990
 sex-selective terminations 990
- abrasion injuries, sexual assault 977
- academic attainment, preterm survivors 390, 449
- acanthosis nigricans
 secondary amenorrhoea 633, 634
 vulval 807–808
- aciclovir
 genital herpes 923, 924, 925
 pregnant women 173, 174
- acidaemia, fetal *see* fetal acidaemia
- ACOG *see* American College of Obstetricians and Gynecologists
- acrochordia, vulval 808–809
- acrodermatitis enteropathica 807
- actin 290, 291, 292, 293
- Actinomyces*, pelvic infection 613, 617
- Actinomyces*-like organisms (ALOs) 942
- actinomycin D, gestational trophoblastic tumours 582, **582**
- action potentials, myometrial smooth muscle 292, 292–293
- acupuncture
 chronic pelvic pain 747
 endometriosis 737
 obstetric patients 316, 356
- acute abdomen, pregnancy 203–204
- acute coronary syndromes, pregnancy 92
- acute fatty liver of pregnancy (AFLP) **117**, 118–119, **119**
- adalimumab 195
- Addison's disease 125–126
- adenocarcinoma
 cervix 866, 868
 vulva **839**
- adenomyosis, uterine 823–824
 endometriosis and 725, 726
 heavy menstrual bleeding 654
 imaging 503–504, 823–824, 824
 treatment 700–701, 824
- adenomyosis externa 726
- adenosine 94
- adenosine triphosphate (ATP) 290, 291
- adenosis, vaginal 816
- adenosquamous carcinoma, cervical 866, 868
- adenylyl cyclase (ADCY) 295, 296, **296**, 297
- adhesiolysis
 adnexal, fertility benefits 700
 chronic pelvic pain 746–747
 hysteroscopic 531, 700
- adhesions
 adnexal, infertility 692–693, 700
 intraperitoneal, chronic pelvic pain 746–747
 intrauterine *see* intrauterine adhesions
 labial, in childhood 554
 pelvic inflammatory disease 510
- adiponectin 12–13
- adnexal masses
 complications 509, 509
 imaging 505, 505–507, 506, 508
 IOTA Simple Rules **506**, 506–507
 pattern recognition 506
 prediction of histology 507, 508

- adnexal masses (*cont'd*)
 - risk of malignancy index (RMI) 506, 507
 - tubal ectopic pregnancy 513
- adnexal torsion 509, 509
- ADNEX (Assessment of Different NEoplasias in the adneXa) model 507, 508
- adolescents
 - abortion rates 597
 - growth 544
 - gynaecological disorders 554–556
 - pregnancy 39
 - sexually transmitted infections 908–909
 - see also* puberty
- ADP-ribosylation factor 6 (ARF6) **296**
- adrenal disease, pregnancy in 125–126
- adrenal gland
 - fetal, onset of labour 287
 - pregnancy 14
- adrenaline, in labour 423
- adrenal insufficiency
 - maternal collapse **340**
 - in pregnancy 125–126
- adrenal tumours 126, 633
- adrenarche 543
- premature 544
- adrenocorticotrophic hormone (ACTH) 14, 633
- Adults with Incapacity (Scotland) Act 2000 599
- age
 - of capacity to consent to
 - abortion 599
 - conception rates and 702, **702**
 - IVF success rates and **712**
 - maternal *see* maternal age
 - at puberty 543
- age at natural menopause (ANM), prediction 674
- ageing, sexual activity and 958
- agenesis of corpus callosum 257
- agnus castus 671
- agoraphobia 181
- AGO score 897
- AGREE collaboration 1010
- air embolism, hysteroscopic surgery 533
- airway problems, maternal collapse 341
- A kinase anchor proteins (AKAP) 295
- alanine aminotransferase (ALT) 116, **117**
- alcohol consumption
 - antenatal advice 48
 - infertile couples 698
 - pre-pregnancy advice 41
- aldosterone
 - biosynthesis 497
 - pregnancy 11, 14
- alkaline phosphatase 116, **117**
- allergic contact dermatitis, vulva 802
- allopregnanolone 667
- α -fetoprotein (AFP), pre-eclampsia and 77
- alpha-2 agonists, menopausal symptoms 684
- ALSO (Advanced Life Support in Obstetrics) 338
- alternative therapies *see* complementary therapies
- Alzheimer's disease 674, 681
- ambulation
 - in labour 425
 - puerperium 435
- ambulatory gynaecology 519–537
- amenorrhoea 632
 - exclusion of pregnancy 632
 - exercise-related 547–548, 650–651
 - hypothalamic 626, **635**, 649, 692, 699
 - iatrogenic 651
 - lactational 434, 440, 951
 - levonorgestrel-releasing intrauterine system (LNG-IUS) users 942
 - Mayer-Rokitansky-Küster-Hauser syndrome 490, 547
 - primary 546–551
 - aetiology 546–549
 - classification **546**
 - evaluation and management 549–551
 - secondary 645–651
 - aetiology **645**
 - classification **635**, 645
 - definition 632
 - history and examination 632–634
 - investigations 633, **634**, 634–636
 - management 645–651
 - weight-related 547, 650
- American College of Obstetricians and Gynecologists (ACOG)
 - induction of labour 329
 - post-term pregnancy 320
- American College of Radiology 562–563
- American Society for Reproductive Medicine classification of endometriosis, revised (r-ASRM) 726, 727
- AMH *see* anti-Müllerian hormone
- amino acids
 - placental transfer 222
 - urinary excretion 11
- 5-aminosalicylic acid **196**, 204
- amiodarone 94
- amniocentesis 63–65, 66–67
 - multiple pregnancy 64, 271
 - red cell alloimmunization 249
- amnion 20, 22
 - layers 25, 25
- amniotic epithelium 25, 25
- amniotic mesoderm 25, 25
- amniotic cavity 22, 25
- amniotic fluid embolism **340**, 427
- amniotic fluid index (AFI) 235, 236
 - post-term pregnancy **314**, 315
- amniotic fluid volume
 - intrapartum assessment 377
 - post-term pregnancy 315
 - see also* oligohydramnios; polyhydramnios
- amniotomy 329–330
- amoxicillin 94, 916
- amphotericin B 922
- anaemia
 - antenatal screening 52
 - chronic kidney disease 134, 138
 - fetal *see* fetal anaemia
 - heavy menstrual bleeding 555
 - postpartum 148
 - pregnancy 9, 148–150
- anaerobic bacteria, pelvic inflammatory disease 613
- anaesthesia
 - caesarean section 426–427
 - obesity 213, 214
 - pre-eclampsia 80
 - surgical abortion 602–603, 604
- analgesia
 - labour 423–426
 - medical abortion 606, 607
 - surgical abortion 602–603
- anal sphincter injuries, obstetric (OASI) 368, 369–370, 437–438
- anaphylaxis, maternal collapse **340**
- anatomy, clinical 477–484
- androgens
 - adrenal secretion 543
 - biosynthesis 497
 - congenital deficiency 496
 - disorders of synthesis 489, **489**

- excess *see* hyperandrogenism
 free androgen index 633, **634**
 insensitivity syndromes 489–490, 547
 precocious puberty 545
 secreting tumours 549, 633
 serum levels 633, **634**
 supplements, postmenopause 679–680
 androstenedione **634**
 aneuploidies
 abdominal wall defects 259
 Dandy–Walker malformation 257
 first-trimester combined screening 63
 multiple pregnancy 270–271
 non-invasive prenatal testing 67–68
 pre-implantation genetic screening 716–717
 see also chromosomal abnormalities;
 Down's syndrome
 angioedema, vulval 809
 angiogenic factors
 early pregnancy 6, 13
 endometrium 629
 pre-eclampsia 73–74, 76–77
 angiokeratomas, vulval 796, 796
 angiopoietin 2 (*ANG2*) 6, 13
 angiotensin 1–7 14
 angiotensin-converting enzyme (ACE)
 inhibitors
 peripartum cardiomyopathy 93
 safety in pregnancy 136
 angiotensin II, normal pregnancy 7
 angiotensin receptor blockers 136
 angiotensin receptors,
 myometrial **296**
 anhydramnios 261, 262, 377
 anococcygeal body 480, 481
 anogenital examination, sexual assault
 victims 972–978
 anogenital injuries, sexual
 assault 977–978
 anonymity, gamete donors 994
 anorexia nervosa 547, 650
 anorgasmia 963–964
 antenatal care 47–56
 common symptoms in pregnancy 49
 documentation 55
 domestic violence 50–51
 female genital mutilation 51, **51**
 frequency and timing 55–56
 health promotion 336
 information provision 47–48
 lifestyle advice 48–49
 organization 54–56
 providers 55
 see also antenatal screening
 antenatal classes 47–48
 antenatal education 47–49
 antenatal screening 52–54
 chromosomal abnormalities 53–54, 59–69
 fetal complications 53–54
 fetal structural anomalies 54, 69
 first trimester 58–69
 late obstetric complications 69
 maternal complications 52–53
 newborn screening and 447–448
 non-invasive prenatal testing 65–68
 principles 58
 sexually transmitted infections 52, 911–912
 single gene disorders 69
 antepartum haemorrhage 342, 343
 anterior abdominal wall 477, 478
 anterior colporrhaphy 762, 776
 anti-androgens 642–643
 antibiotics
 abnormal uterine bleeding 913
 bacterial vaginosis in pregnancy 397, 916
 chlamydia infection 616, **616**, 916, 919
 gonorrhoea 917–918, 919
 pelvic inflammatory disease 616, **616**, 916
 preterm labour 409
 prophylactic
 abortion 600
 caesarean section 215
 endocarditis 94
 PPROM 402
 puerperal infections 437
 secondary postpartum haemorrhage 438
 anti-c antibodies 153, **154**, 248
 anticoagulation
 delivery planning 156–157
 postpartum obese women 215–216
 prosthetic heart valves in pregnancy 91–92
 venous thromboembolism in pregnancy 156–157
 anti-D antibodies 153, **154**, 248
 antidepressants
 breastfeeding and 184
 detrusor overactivity **781**, 782
 neonatal symptoms 183
 postpartum depression 180
 safety in pregnancy 183–184
 anti-D immunoglobulin
 after sensitizing events 52, 153
 induced abortion 600
 routine antenatal prophylaxis 52, 55–56, 153
 spontaneous miscarriage 565
 targeted prophylaxis 52, 153
 threatened miscarriage 565–566
 anti-E antibodies 153
 antiemetics, in pregnancy 49
 antiepileptic drugs (AEDs) 186–187, 188, 202
 antifibrinolytics, heavy menstrual bleeding 658
 antihistamines, nausea and vomiting of pregnancy 49
 antihypertensive therapy
 acute, in pregnancy 79
 chronic hypertension in pregnancy 77
 chronic kidney disease 135–136
 gestational hypertension 78
 postpartum 81
 anti-Kell antibodies 153, **154**, 249
 anti-Müllerian hormone (AMH)
 absent, heterosexual development 549
 follicular development 623
 serum 627–628, **634**
 assisted conception 704
 infertility 695
 prediction of menopause 674
 secondary amenorrhoea 635–636
 antimuscarinic drugs, detrusor overactivity **781**, 781–782
 antioxidants, in pregnancy 13
 antiphospholipid syndrome (APS)
 recurrent miscarriage 571
 secondary 192, 194
 antiplatelet agents, pre-eclampsia prophylaxis 77
 antipsychotics 186
 antenatal exposure 187
 breastfeeding and 188
 antiretroviral therapy (ART) 163
 anti-sperm antibodies 706
 antithrombin III (AT III), in pregnancy **10**
 antithymocyte globulin **141**
 antithyroid antibodies, recurrent miscarriage 571–572
 antithyroid drugs 124–125, 244

- anti-tumour necrosis factor (TNF)
 - agents 195–198
 - antral follicle count (AFC) 511
 - amenorrhoea 636
 - assisted conception 705
 - infertility 695, 696
 - anxiety
 - adverse effects of untreated
 - prenatal 178–179
 - postnatal, in obesity 216
 - anxiety disorders 180–183, 185
 - aorta, intra-abdominal 477, 478
 - aortic coarctation 88
 - aortic compression, postpartum
 - haemorrhage 344–345
 - aortic dissection 88
 - aortic pulse wave velocity (aPWV), in
 - pregnancy 7
 - aortic regurgitation 91
 - aortic stenosis
 - congenital 255–256
 - pregnancy 87–88
 - aortocaval compression, in
 - pregnancy 427
 - AP-1 transcription factor 392
 - aphthous ulcers, vulval 805
 - apoptosis, syncytiotrophoblast 23
 - APOSTEL III trial 407
 - appendectomy
 - ovarian cancer surgery 892
 - in pregnancy 203–204
 - Arabin cervical pessary 274
 - arginine vasopressin (AVP), in
 - pregnancy 11
 - ARIEL2 study 895
 - Aristotle 18
 - arrestins 297
 - arrhythmias
 - fetal 245–246, 265
 - pregnant women 93–94
 - arterial embolization, postpartum
 - haemorrhage 345
 - arterial function, in pregnancy 7
 - arterial thrombosis, oral contraceptive
 - users 947
 - arteriovenous malformations, heavy
 - menstrual bleeding 655
 - arthritis
 - gonococcal 917
 - inflammatory, pregnancy
 - in 194–198
 - sexually acquired reactive (Reiter's syndrome) 804, 915
 - artificial urinary sphincter 778
 - Asherman's syndrome *see* intrauterine adhesions
 - aspartate aminotransferase (AST)
 - 116, **117**
 - aspiration, maternal collapse **340**
 - aspirin
 - chronic kidney disease 131
 - pre-eclampsia prevention 44, 77
 - recurrent miscarriage 571, 572
 - thalassaemia 152–153
 - assisted reproduction 704–718
 - abbreviations **705**
 - chlamydia infection and
 - complications 717–718
 - ectopic pregnancy risk 590, 718
 - endometriosis 707, 738–739
 - ethical issues 992–996
 - funding 643, 993
 - important comorbidities
 - 706–707
 - indications 701
 - investigations 704–706
 - male factor infertility 699
 - methods 707–717
 - multiple pregnancy 269, 278, 717–718
 - premature ovarian
 - insufficiency 646
 - recurrent miscarriage 569–570
 - results 712, **712**
 - see also* fertility treatment; *in vitro* fertilization
 - ASTEC study 880, 881
 - asthenozoospermia 697
 - asthma 200
 - asymptomatic bacteriuria, antenatal
 - screening 52
 - asynclitism 354, 355, 361
 - forceps delivery 363
 - athletes, amenorrhoea 650–651
 - atopic dermatitis, vulval 553
 - atopic illness, breastfeeding and 440
 - atosiban, acute tocolysis 406, 406–407
 - atrial flutter (AF), fetal 245, 246
 - atrial septal defect (ASD) 87, 256
 - atrioventricular (AV) block,
 - fetal 246
 - complete 193, 246
 - atrioventricular septal defect 256
 - attention deficit hyperactivity disorder (ADHD) 449
 - atypical glandular cells (AGC) 863, 866–867
 - atypical placental site nodules
 - 575, 578
 - augmentation index (AIx), normal
 - pregnancy 7
 - autism spectrum disorders (ASD)
 - prenatal antidepressant
 - exposure 184
 - preterm survivors 390, 449
 - autoimmune diseases
 - diabetes association 105
 - hepatitis 123
 - rheumatic, pregnancy in 191–199
 - thyroid 124–125
 - vulval bullous 805
 - autonomic neuropathy, diabetic 105
 - autonomy, patient 999–1001, 1002, 1005–1006
 - average for gestational age (AGA) 31
 - Avon Longitudinal Study of Parents and Children (ALSPAC) 459
 - axillary hair 544
 - azathioprine **141**, 193, **197**
 - azithromycin
 - abnormal uterine bleeding 913
 - chlamydia infection 916, 919
 - gonorrhoea 918, 919
 - Mycoplasma genitalium* 919
 - azoospermia 693, 697, 699
 - ICSI 713–714
 - surgical sperm retrieval 717
- b**
- Baby-Friendly Initiative 443
 - bacille Calmette–Guérin (BCG)
 - vaccine 453
 - backache, in pregnancy 49
 - bacteraemic shock, maternal
 - collapse **340**
 - bacterial infections
 - childhood vulvovaginitis 553
 - pelvic inflammatory disease
 - 612–613
 - vagina 811–812, 813
 - bacterial vaginosis (BV) 811–812
 - pelvic inflammatory disease
 - risk 612
 - post-abortion infection 600
 - preterm labour risk 394, 396–397
 - recurrent 920–921
 - therapy in pregnancy 397, 916
 - treatment 921
 - Baden–Walker Halfway Scoring System 757, **758**
 - bagel sign, ectopic pregnancy 513, 513, 591
 - balanced translocations,
 - parental 569–570
 - ballet dancers 651
 - balloon catheter, postpartum
 - haemorrhage 345

- bariatric delivery rooms 213
- bariatric surgery
 - polycystic ovary syndrome 641
 - pre-conception counselling 41–42, 209
 - pregnancy after 211
- Barker hypothesis *see* fetal programming
- Bartholin's abscesses 813, 917
- Bartholin's cysts 809, 813
- Bartholin's gland carcinoma 809, **839**
- Bartholin's glands 479, 480
- basal body temperature (BBT)
 - family planning 951
 - gestational age determination 308
- basal cell carcinoma, vulva **839**, 848
- basal metabolic rate, in pregnancy 12
- basal plate, placental 19, 20, 21
- base deficit, fetal 373, **374**
- basic life support 339
- basiliximab **141**
- Basson's model of cyclical sexual response 956
- Bax proteins 623
- Bayesian inference 471
- bazedoxifene (BZA) 679
- Bcl-2 827
- Beckwith–Wiedemann syndrome (BWS) 222–223, 260
- bed rest, multiple pregnancy 273
- behavioural disorders, preterm survivors 390, 449
- Behçet's syndrome
 - pregnancy 199
 - vulval 806–807, 807
- benzathine penicillin, syphilis 168, 928
- benzodiazepines 185
- bereavement, stillbirth 418–419
- best interests 970, 991, 1005–1006
- β_2 -adrenoceptor (ADRB2) **296**, 297
- β_2 -sympathomimetics
 - acute tocolysis 405
 - mechanism of action 297
 - multiple pregnancy 273, 274
- betamethasone, antenatal therapy 407, 408
- bethanechol 784–785
- Bethesda system
 - glandular cervical lesions 863, **863**
 - squamous cervical lesions 862
- bevacizumab
 - ovarian cancer 893–895
 - recurrent ovarian cancer 896, 897, 898
- bias 462–463, 1011
- bicarbonate, plasma, in pregnancy 8, 8
- Bierer forceps 604, 604
- bile acids, serum **117**, 121
- bilirubin, serum 116, **117**
- Billings method 951
- biochemical pregnancy loss 559, **560**, 568, **569**
- bio-identical hormones 679
- biologics, in pregnancy 195–198
- biomarkers
 - endometriosis 731, 732
 - ovarian cancer 887
 - see also* vaginal biomarkers
- biometry, fetal
 - growth assessment 32–33, 33, 223
 - growth charts 34, 35
 - multiple pregnancy 272
 - third trimester 234, 234
- biophysical profile, fetal 227, 237
- post-term pregnancy **314**, 316
- biopsy
 - cervical cancer 868–869
 - choriocarcinoma 579, 579
 - hysteroscopic 528
 - sentinel node *see* sentinel lymph node biopsy
 - ultrasound-guided 501, 502
 - vulva 797, 840
- biopsychosocial model, sexual dysfunction 959, 960
- biparietal diameter (BPD) 34, 35, 234, 234
- bipolar disorder 185, 186
- bipolar electrosurgery 521
 - advanced 520, 521
 - hysteroscopic equipment 522–523, 523
 - laparoscopic equipment 526
- bipolar resectoscope 523, 523, 533
- birth injury
 - inducing labour to prevent 332
 - infants of diabetic mothers 109
 - instrumental vaginal delivery 364
 - legal aspects 1006
 - post-term pregnancy 312
- birthweight
 - accuracy of prenatal estimates 33
 - cut-offs to classify newborns 31
 - estimated fetal weight vs. 34, 34
 - infants of diabetic mothers 109
 - risks of post-term pregnancy and 312–313
 - see also* estimated fetal weight; fetal size
- Bishop score, Calder modification 326–327, **327**
- bladder
 - anatomy 483, 483
 - diverticula 772
 - exstrophy 495
 - injury, caesarean section 367
 - trabeculation 772
 - wall thickness 769
- bladder diary 767, 768
- bladder neck suspension
 - procedures 777
- bladder problems *see* lower urinary tract disorders
- bladder retraining 779–780, 783
- blastocyst
 - endometrial interactions 629
 - transfer, IVF 710, 711
 - trophoblast differentiation 20, 20
 - see also* embryo
- bleeding disorders
 - heavy menstrual bleeding 655
 - inherited, pregnancy 157–159
- blob sign, ectopic pregnancy 591, 591
- Blood, Diane 993
- blood group, antenatal
 - determination 52
- blood loss, miscarriage 565
- blood pressure (BP)
 - chronic kidney disease 134, 135–136
 - dialysis patients 138
 - labour and delivery 86
 - measurement in pregnancy 53, 75
 - normal pregnancy 6–7, 7, 7
 - postnatal monitoring 81
 - postpartum changes **434**
 - targets in kidney disease 131
 - thresholds in pregnancy 74, 78
 - see also* hypertension
- blood salvage, obstetric
 - haemorrhage 346
- blood transfusion
 - chronic kidney disease 138
 - intrauterine *see* intrauterine transfusion
 - major obstetric haemorrhage 155, 344
 - sickle cell disorders 152
 - thalassaemia 152
- blood volume
 - labour and delivery 86
 - normal pregnancy 85, 147, **148**

- blues, postpartum 179, 438
- B-Lynch brace suture 345, 345
- BMI *see* body mass index
- body awareness training 960
- body-identical hormones 679
- body mass index (BMI)
 - assisted conception and 707
 - duration of gestation and 309
 - measurement 632–633
 - miscarriage risk and 568
 - obesity cut-offs **208**
 - onset of puberty and 543
 - pre-conception advice 41
 - prolapse risk and 756
 - see also* obesity
- body weight *see* weight
- bonding, mother–infant 435
- bone mineral density (BMD)
 - depot medroxyprogesterone acetate users 945
 - measurement 636, 675
 - premature ovarian insufficiency 646–647
 - weight-related amenorrhoea 650
- bone morphogenetic proteins (BMPs), follicular development 623, 624, **624**
- boric acid 922
- bosentan 89
- botulinum toxin
 - chronic pelvic pain 749–750
 - detrusor overactivity **781**, 782
- Bourne, Aleck 988
- bouton de régles* 925
- bowel obstruction
 - neonates 456
 - ovarian cancer 898
- bowel surgery, endometriosis 735
- bowel symptoms *see* gastrointestinal symptoms
- brace suture, B-Lynch 345, 345
- brachial plexus injury, neonatal 454
- brachytherapy
 - cervical cancer 872
 - endometrial cancer 881
 - vaginal cancer 851
- Bradford Hill criteria 461, **462**
- bradycardia, fetal 246, 375
- bradykinin, myometrial effects **296**, 297
- brain
 - congenital malformations 255, 257–258
 - sparing, compromised fetus 222, 225
- brain injury, preterm infants 451
- brain tumours
 - amenorrhoea 549, 649
 - metastatic, gestational trophoblastic tumours 581, 584
 - precocious puberty 545
 - see also* pituitary tumours
- Brandt–Andrews manoeuvre 301
- BRCA mutation carriers
 - ovarian cancer management 895
 - ovarian cancer risk 885
 - prophylactic oophorectomy 889
- BRCA mutation testing 891, 899
- BRCAness phenomenon 885
- breast
 - development at puberty 544
 - lactating 441, 441
- breast cancer
 - breastfeeding and 440
 - combined oral contraceptive pill and 947
 - HRT and 681, 682
 - polycystic ovary syndrome 640–641
 - pregnancy and 44, 204
- breastfeeding 438–441, 456–457
 - advantages 438–441
 - chickenpox 175
 - diabetic mothers 110
 - disease-modifying antirheumatic drugs (DMARDs) 195, **196–197**
 - drug safety 438, **456**, 456–457
 - HIV transmission 162
 - kidney transplant recipients 142
 - management 442–443, **443**
 - obesity and 216, 440–441
 - psychotropic medication 184, 188
 - trends in UK 441, **441**
 - see also* lactation
- breast milk
 - anti-infective properties 439
 - ejection reflex 441–442, 442
 - nutritional aspects 438–439, **439**
 - production 441, 442
 - volumes 442
- breathing problems, maternal collapse 341
- breathlessness, in pregnancy 200
- breech presentation 354–358
 - antenatal management 355–356
 - entrapment of aftercoming head 357–358
 - first twin 277
 - mode of delivery 356
 - preterm delivery 356, 357–358, 410
 - types 354–355, 355
 - vaginal delivery 356–357, 357, 358
- Brenner tumours **886**
- British Committee for Standards in Haematology 148
- British Pregnancy Advisory Service (BPAS) 989–990
- bromocriptine
 - hyperprolactinaemia 647–649, 648, **649**
 - lactation suppression 418, 443
 - peripartum cardiomyopathy 93
- bronchopulmonary dysplasia 450, 451
- Brown, Louise 992
- brow presentation 358
- Bruce, Fiona 990
- bruising, sexual assault 977
- bullous drug eruptions 804–805
- bullous pemphigoid 805
- bupropion 962
- Burch colposuspension 776, 776, 779
- burn injuries, sexual assault 977
- Burns–Marshall method 357
- buserelin 708
- C**
- Ca²⁺-ATPases 292, 294
- CA-125, serum
 - adnexal masses 506, 507
 - endometriosis 731, 732
 - ovarian cancer 887, 888, 889
- cabergoline
 - hyperprolactinaemia 647–649, **649**
 - lactation suppression 418, 443
- caesarean scar pregnancy 590, 592
- caesarean section (CS) 365–368
 - anaesthesia 426–427
 - breech presentation 356
 - classification of urgency 365
 - complications 367–368
 - delivery of deeply impacted head 367–368, 368
 - diabetes 109, 110
 - ethical and legal issues 991–992
 - failed induction 285, 330
 - genital herpes 173–174
 - HIV infection 163
 - indications 365
 - induction of labour and post-term pregnancy 317, 318–319, **331**
 - term pregnancy 332
 - kidney transplant recipients 142

- lower uterine segment (LUS)
365–366, 366
at maternal request 332, 1005
multiple pregnancy 277,
278–279
obesity 213, 214, 215, 366
omphalocele 260
peri-mortem (PMCS) 341, 367, 428
predicting likelihood 233
preterm infants 410
previous
fetal blood sampling 382
induction of labour 326, 333
post-term pregnancy 320
scar assessment 233
rates 365
rheumatoid arthritis 194
shoulder presentation 359
sterilization at time of 949
surgical wound infection 437
upper uterine segment
(UUS) 366–367
CAESAR trial 366
caffeine intake, pregnancy 40
calcineurin inhibitors
safety in pregnancy 141, **141**
topical, vulval disease 800, 802
calcineurin–NFAT signalling
cascade 288
calcitonin 14
calcitonin gene-related peptide **296**
calcium
dietary intake 677
homeostasis, myometrial cells 293
intracellular ($[Ca^{2+}]_i$)
myometrial contraction
291, 292, 292–293
myometrial stores 293–294
metabolism in pregnancy 14
supplements, pre-eclampsia
prophylaxis 44, 77
urinary excretion in pregnancy 11
calcium channel blockers,
tocolysis 293, 407
calcium channels
store-operated (SOC) 292, 294
T-type 292, 293
voltage-operated L-type (VOC)
292, 292–293, 294
calcium gluconate, magnesium
toxicity 80
Calder modification of Bishop
score 326–327, **327**
caldesmon 293
calmodulin 291–292
cameras, endoscopic 520
candidiasis
childhood vulvovaginitis 553
neonatal 453
recurrent vulvo-vaginal (RVVC)
921–922
vaginal 812–813
candour, duty of 338
capacity (mental capacity)
assessment 970
to consent to abortion 598–599,
990–991
pregnant women 992
sexual assault victims 969–970
capillary haemangiomas, vulval 809
capsular decidua 25, 25
carbamazepine 187, 202
carbimazole 124–125
carbohydrate metabolism, in
pregnancy 12, 12–13
carbon dioxide (CO_2)
insufflation, laparoscopy 525
placental transfer 8
tension (P_{CO_2}), in pregnancy
8, 8, 8
carboplatin, ovarian cancer
893–895, 896
carcinosarcoma, ovarian **886**
cardiac arrest
peri-mortem caesarean section 341,
367
in pregnancy 94, 341, 427
cardiac disease *see* heart disease
cardiac output
exercise in pregnancy **9**
labour and delivery 86
normal pregnancy 6, 7
postpartum changes 434, **434**
cardinal ligaments 482–483
cardiogenic shock, maternal
collapse **340**
cardiomyopathy
hypertrophic (HCM) 92–93
peripartum 44, 93
cardiopulmonary resuscitation (CPR)
maternal collapse 339, 339, 341
in pregnancy 341, **427**, 427–428
cardiorespiratory distress,
neonatal 455
cardiotocography (CTG)
antenatal 54
external cephalic version 356
fetal growth restriction
227, 228
post-term pregnancy **314**,
314–315
reduced fetal movements 235
computerized analysis 383
intrapartum 381
on admission 380
induction of labour 330
intermittent auscultation vs.
380, **380**
interpretation 378–380, **379**
preterm labour 410
cardiovascular disease
adults with low birthweight 222
diabetes 105
epidemiological studies 459
HRT-related risks 680–681
physiological effects of
pregnancy 85–86
polycystic ovary syndrome
639–640
postmenopausal women 674
pre-conception counselling
44, 45
pre-eclampsia-related risk 82
premature ovarian
insufficiency 647
progestogen-only contraception
users 944
screening, postmenopause 675
SLE 194
cardiovascular system
effects of labour and
delivery 86
fetal anomalies 255–257
postpartum changes 434, **434**
pregnancy-related changes 6, 6–7,
7, 7, 85–86
CARE study 758
Carnett test 745
CARPREG score 87
case–control studies 461–463
catecholamines
during labour 423
maternal prenatal stress 178
myometrial effects **296**, 297
normal pregnancy 14
CATmaker 1012
Catt, Sarah 988
caudal regression 106
cavernous haemangiomas,
vulval 809
CCR5 $\Delta 32$ gene deletion 915
cediranib 896
ceftriaxone
gonorrhoea 917–918, 919
pelvic inflammatory disease **616**
cell salvage, obstetric
haemorrhage 346
centiles 470, 471

- central nervous system
 - anomalies 257–258
- Centre for Evidence-Based Medicine 1010, 1012
- Centre for Reviews and Dissemination (CRD) 1009
- cephalhaematoma 364
- cephalopelvic disproportion 359–360
- cerebral aneurysms 203
- cerebral circulation, in pregnancy 11
- cerebral haemorrhage *see* intracranial haemorrhage
- cerebral palsy 454
 - hypoxic–ischaemic encephalopathy 373–374
- legal aspects 1006
- magnesium sulfate tocolysis
 - and 409
- multiple pregnancy 269
- post-term pregnancy 312
- PPROM and 402
- preterm infants 389–390, 449
- see also* neurodevelopmental outcome
- cerebral vascular disease 203
- cerebral vein thrombosis 203
- cerebroplacental ratio (CPR) **222**, 225–226, 237
- certolizumab 195
- cervical cancer 867–875
 - clinical presentation 868
 - diagnosis 868–869
 - epidemiology 858, 859, 860, 868
 - follow-up 873
 - future prospects 874
 - heavy menstrual bleeding 654–655
 - HRT and 682
 - natural history 861, 862
 - oral contraceptive pill and 947
 - palliation 873–874
 - pathological subtypes 868, **868**
 - pregnancy 873
 - prognostic factors 874
 - psychological impact 874
 - recurrence 873
 - risk factors 858–862
 - spread 870, **870**
 - staging 869, **869**
 - survival 874, 874
 - treatment 870–873
 - stage Ia 870–871
 - stage Ib2 872
 - stage Ib–IIa 870, 871–872
 - stage IIb–IV 870, 872–873
 - vulval cancer risk 837–838
- cervical cancer screening **863**, 863–864
 - abortion patients 600
 - benefits 858
- cervical cap, contraceptive 950
- cervical cerclage 396, 398–399
 - emergency rescue 399
 - multiple pregnancy 273
 - recurrent miscarriage 570
 - technique 399
- cervical competence 393
- cervical cytology 863
 - after CIN treatment 866
 - glandular lesions 863, **863**
 - squamous lesions 862, **862**
- cervical dilatation
 - osmotic dilators 604
 - phases in normal labour 299, 299
 - rate, active phase of labour **299**
 - surgical abortion 603–604, 604
 - surgical management of miscarriage 564
- cervical ectopy (erosion) 817, 817, 818
- cervical glandular intraepithelial neoplasia (cGIN) 863
- cervical glandular lesions
 - classification 863, **863**
 - management 866–867
- cervical incompetence (weakness) 393
 - after surgical abortion 605
 - cervical cerclage 398–399
 - recurrent miscarriage 570
- cervical intraepithelial neoplasia (CIN)
 - classification **862**, 862–863
 - glandular lesions 863, **863**
 - natural history 861, 862
 - pregnancy 867
 - preterm labour risk 393
 - risk factors 861–862
 - squamous lesions 862, **862**
 - treatment 864–866, **865**
 - ablative methods 865–866
 - complications 866
 - excisional methods 865
 - follow-up 866
 - vaginal intraepithelial neoplasia and 814, 814
- cervical length measurement
 - cervical cerclage and 398, 399
 - PPROM 403
 - predicting success of induction 233, 327
 - preterm labour prediction 395, 395–396, 396
 - multiple pregnancy 273
- serial measurement 396
- third trimester 231–232, 232
- symptomatic preterm labour 404–405
- cervical metaplasia 817, 817–818, 818
- cervical mucus
 - barrier function 611
 - method, family planning 951
- cervical priming
 - miscarriage 564
 - pre-abortion 602
- cervical ripening
 - assessment 326–327, **327**
 - methods of induction 327–329, **328**
 - outpatient setting 330
 - physiology 289, 391
- cervical squamous lesions,
 - classification 862, **862**
- cervical stenosis 646, 866
- cervicitis
 - acute necrotic herpetic 923, 924
 - chlamydial 818, 913, 913
 - chronic 818
 - Mycoplasma genitalium* 918
- cervix
 - anatomy 482, 482
 - benign lesions 817–819
 - function, and preterm labour 393
 - malignant disease *see* cervical cancer
 - premalignant disease 858–867
 - squamocolumnar junction 817, 817, 861
 - tears, surgical abortion 605
 - transformation zone 817–818, 861
- cetrorelix 709
- checkpoint inhibitors, ovarian cancer 899
- chemoradiation, cervical cancer 872–873
- chemotherapy
 - cervical cancer 872–873
 - endometrial cancer 881
 - gestational trophoblast tumours 578, 580–585
 - intraperitoneal 894–895
 - ovarian cancer 893–895, 896–897
 - pregnancy 160, 204
 - vaginal cancer 852
 - vulval cancer 848
- Chester v Afshar* [2004] 1000–1001
- chest X-ray (CXR)
 - in pregnancy 86, 205, **205**
 - pulmonary embolism 156
 - respiratory disorders 200

- chickenpox *see* varicella
- chignon 364
- childbirth
- ethical issues 991–992
 - fear of 182
 - prolapse aetiology 755
 - stress incontinence and 774
 - see also* delivery; intrapartum care; labour
- children
- gynaecological disorders 552–556
 - law on sexual activity with 967
 - termination of pregnancy 990–991
- child sexual abuse
- clinical presentation 553, 554
 - laws 967
 - sexual dysfunction and 958
- child sexual exploitation 971, 981
- child welfare provision, fertility treatment 702, 992–993
- CHIPS (Control of Hypertension in Pregnancy Study) 78
- chlamydia antibody titres (CAT) 696–697, 915
- chlamydia infection 912–916
- abnormal uterine bleeding 655, 913
 - antimicrobial therapy 616, **616**, 916, 919
 - arthritis and 915
 - assisted reproduction failure 915
 - cervicitis 818, 913, 913
 - clinical spectrum 913–916
 - diagnostic tests 614–615, 910–911
 - ectopic pregnancy risk 590, 915
 - epidemiology 907–909, 912
 - natural history 912–913
 - neonatal 453, 916
 - pathology 615–616, 912
 - pelvic inflammatory disease 612, 615–616, 914–915
 - periappendicitis and perihepatitis 913–914
 - post-abortion 600
 - pregnancy 915–916
 - prophylaxis 916
 - screening 618, 696–697, 912
 - test of cure (TOC) 916
 - treatment 916, 919
 - tubal factor infertility 617, 914–915
- Chlamydia trachomatis see* chlamydia infection
- cholecystectomy 203–204
- cholestasis, obstetric *see* intrahepatic cholestasis of pregnancy
- cholesterol, serum 13, 636
- cholestyramine 195
- chorioadenoma destruens 578–579
- chorioamnionitis
- diagnosis 403
 - initiating labour 288, 393–394
 - PPROM 402–403
 - pre-labour rupture of membranes 331
 - preterm labour 393–394
- choriocarcinoma 575, 579, 586
- clinical presentation 438, 579
 - diagnosis 579, 579
 - management 582–584, 583
 - see also* gestational trophoblast neoplasms
- chorion 20, 22
- chorion frondosum 23
- chorionicity 269–270
- chorionic mesoderm 25, 25
- chorionic plate 19, 20
- chorionic villus sampling (CVS) 63–65, 66–67
- congenital adrenal hyperplasia 245
 - multiple pregnancy 64, 271
- chorion laeve *see* fetal membranes
- chromosomal abnormalities
- cystic hygroma 262
 - first-trimester screening 59–69
 - combined programmes 60–62
 - confirmatory tests 63–65, 67
 - diabetes 107
 - non-invasive prenatal testing 65–69
 - screen-positive results 62–63 - infertile men 717
 - maternal age and risk 43, **43**
 - miscarriage 560, 569–570
 - multiple pregnancy 270–271
 - nuchal translucency 60
 - premature ovarian insufficiency 646
 - see also* aneuploidies; Down's syndrome
- chronic kidney disease (CKD) 129, 130–138
- antenatal care 133–136
 - classification 130–131, **131**
 - fetal surveillance 136
 - implications of pregnancy 130–133, **132, 133**
 - long-term effects of pregnancy 136–137
 - postpartum follow-up 142
- pre-pregnancy counselling 45, 129–130
- secondary amenorrhoea 650
- specific causes 134, **135**
- temporary dialysis in pregnancy 133
- timing of delivery 136
- chronic lung disease of prematurity 389, 450, 451
- chronic pelvic pain (CPP) 744–750
- after hysteroscopic sterilization 749
 - after pelvic inflammatory disease 617
 - classification of causes **745**
 - clinical history 744–745
 - definition 744
 - endometriosis 729–730
 - examination 745–746
 - investigations 746
 - management 746–747
 - myofascial pain 749–750
 - pelvic congestion syndrome 748
 - ultrasound imaging 509, 510
- CIN *see* cervical intraepithelial neoplasia
- circulatory problems, maternal collapse 341–342
- cirrhosis, pregnancy in 123
- cisplatin
- gestational trophoblastic tumours 584
 - ovarian cancer 893, 894
- citalopram 184
- clam cystoplasty 783, 783
- clear cell adenocarcinoma, vagina 816, 853
- clear cell ovarian carcinoma 725, **886**, 892
- cleft lip and palate 262
- termination for 989, 1002
- clindamycin
- bacterial vaginosis 397, 812, 921
 - pelvic inflammatory disease **616**
- clinical practice guidelines 1009, 1010, **1010**
- Clinical Risk Index for Babies (CRIB) scoring system 228
- clitoris 479, 480, 957
- clobetasol propionate 799, 802
- clomifene citrate (Clomid)
- ovulation disorders 699
 - ovulation induction 707
- polycystic ovary syndrome 643
- unexplained subfertility 698

- clomipramine 184
- Clostridium* infections,
 - post-abortion 600
- clotrimazole 812–813, 922
- clozapine 188
- coagulation system
 - normal pregnancy 9, **10**, 10, 147
 - postpartum changes 434, **434**
- coagulopathies
 - heavy menstrual bleeding 655, 656
 - major obstetric haemorrhage 155
- coarctation of aorta 88
- coccygeus muscle 481
- Cochrane Library 1009
- Cockroft–Gault formula 131
- COC pill *see* combined oral contraceptive pill
- co-cyprindiol 946
- coelomic metaplasia theory,
 - endometriosis 723
- cognitive behavioural therapy (CBT)
 - peripartum depression and anxiety 181, 185
 - premenstrual syndrome 667
 - sexual dysfunction 960, 962
- cognitive function
 - effects of HRT 681
 - postmenopause 674
 - preterm survivors 449
- cohort studies 459, 461
- cold coagulation, CIN 865
- cold knife conization
 - cervical cancer 868, 870
 - CIN 865
- collapse, obstetric patient
 - 339–342, **340**
 - airway problems 341
 - basic life support 339
 - breathing problems 341
 - cardiac arrest 341
 - circulatory problems 341–342
 - obstetric causes 346–347
- colon cancer, oral contraceptive pill
 - and 947
- colour power angiography (CPA)
 - 26, 27
- colpocleisis 762–763
- colposcopy
 - cervical ectopy 817, 817
 - cervical lesions 864
 - indications 863–864
 - pregnancy 867
 - vaginal intraepithelial neoplasia 815, 815
- colposuspension 776, 776, 779
- Columbus, Realdus 18
- combined hormonal contraception
 - 945–948
 - contraindications 946, **946**
 - drug interactions 947–948
 - mode of action 945–946
 - obesity 208
 - oral *see* combined oral contraceptive pill
 - practical prescribing 947
 - risks 946–947
 - side effects 946
 - transdermal 945
 - vaginal ring 945
- combined oral contraceptive (COC)
 - pill 945–948
 - bacterial vaginosis and 921
 - contraindications 946, **946**
 - drug interactions 947–948
 - endometriosis 735, 736, 739
 - heavy menstrual bleeding 555, 658, 661
 - missed pills 945–946
 - non-contraceptive benefits 951
 - obesity 208
 - polycystic ovary syndrome 641, 642
 - practical prescribing 947
 - premature ovarian insufficiency 676
 - premenstrual syndrome 669
 - risks 946–947
 - sexually transmitted infection rates and 908, 908
- combined spinal–epidural
 - analgesia 424, **425**
- communication
 - after perinatal death 417, 447
 - neonatal care 445–446
 - obstetric team 337
 - patient/family 338
- complement (C3, C4) 192, **193**
- complementary therapies
 - chronic pelvic pain 747
 - endometriosis 737
 - menopause 684
 - premenstrual syndrome 667
 - see also* acupuncture; herbal remedies
- complete androgen insensitivity syndrome 489–490
- computed tomography (CT)
 - adnexal masses 507
 - cervical cancer 869
 - endometrial cancer 879
 - hyperprolactinaemia 647, 649
- ovarian cancer 891
- pelvic inflammatory disease 510, 615
- in pregnancy 205, **205**
- urogram 769
- uterine pathology 503
- computed tomography pulmonary angiography (CTPA) 156, 205, **205**
- conception rates
 - factors influencing 702, **702**
 - IVF cycles 643
 - polycystic ovary syndrome 643, 643
- condoms, male and female 950
- condylomata acuminata *see* genital warts
- condylomata lata 927
- confidence intervals 467
- confounding 462
- congenital abnormalities 455–456
 - antiepileptic drugs and 187, 202
 - diabetic pregnancy 101, 103, 106
 - post-term pregnancy 311
 - psychotropic medications and 183, 186, 187
 - see also* fetal anomalies
- congenital adrenal hyperplasia (CAH) 244–245, 490
 - delayed puberty 549
 - late onset 544, 545, 633
- congenital heart block 193, 246
- congenital heart disease (CHD) 255–257
 - acyanotic 87–88
 - complete atrioventricular block 246
 - cyanotic 88–89
 - infants of diabetic mothers 106
 - inheritance 87
 - neonatal care 455
 - nuchal translucency 62
 - postoperative 88–89
 - pregnancy in women with 85, 87–89
 - risk factors 255
- congenital pulmonary airway malformation (CPAM) 263–264
- conization
 - cervical cancer 868, 870
 - CIN 865
 - in pregnancy 873
- conjunctivitis, neonatal 453
- connective tissue diseases, in pregnancy 198–199
- connexin 43 (GJA1) 298

- conscientious objection, abortion 598
- consent
- abortion 598–599, 990–991
 - caesarean section 991–992
 - fertility treatment 993–994
 - sexual assault victims 969–970, 972
- constipation, pregnancy-related 49
- consultants, hospital 1004–1005
- contingency tables 467, **472**
- continuity of care 435
- continuous glucose monitoring (CGM) 104, 107
- contraception 939–951
- bacterial vaginosis recurrence and 921
 - barrier methods 950
 - choice of method 940
 - combined hormonal 945–948
 - effectiveness 939, **940**
 - emergency *see* emergency contraception
 - fertility awareness methods 950–951
 - intrauterine methods 940–943
 - kidney transplant recipients 142
 - lactational amenorrhoea method 951
 - legality of post-implantation methods 990
 - long-acting reversible (LARC) 939
 - medical eligibility 939–940, **940**
 - non-contraceptive benefits 951
 - obesity 207–208, 209, 948
 - post-abortion 600
 - pre-pregnancy advice 39
 - progestogen-only 943–945
 - protection against pelvic infection 619
 - systemic lupus erythematosus 192
- controlled cord traction 301
- convulsions *see* seizures
- copper-bearing intrauterine devices (Cu-IUD) 940–943
- emergency contraception 948
 - see also* intrauterine contraceptive devices
- cordocentesis
- fetal thrombocytopenia 247
 - red cell alloimmunization 250, 250
- cord prolapse 350, 350–351, 376
- cornual pregnancy 590, 591–592
- coronary artery disease
- diabetic women 105
 - HRT-related risk 680
 - polycystic ovary syndrome 639–640
 - pregnancy 92
- coronavirus respiratory infections 201
- coroners 418
- corpus callosum, agenesis 257
- corpus luteum 628, 630, 630, 820
- cysts 505, 505, 820
 - regression 630, 630
- correlation 470–471
- correlation coefficient 471
- corticosteroids
- asthma 200
 - congenital adrenal hyperplasia 245
 - fetal lung maturation
 - diabetic pregnancy 108, 408
 - multiple pregnancy 274
 - preterm labour 407–408
 - fetal/neonatal alloimmune thrombocytopenia 247–248
 - immune thrombocytopenic purpura 151
 - kidney disease **141**
 - lichen planus 802
 - lichen sclerosus 799
 - pregnancy 14
 - replacement therapy 125, 126
 - rheumatic diseases in pregnancy 192, **196**
 - scleroderma renal crisis and 198
- corticotrophin releasing hormone (CRH)
- initiation of labour 287, 309, 391–392
 - prenatal stress and 178
- cortisol
- biosynthesis 497
 - normal pregnancy 14
 - prenatal stress 178
 - urinary/serum 633, **634**
- counselling
- gestational trophoblast neoplasia 585–586
 - infertility 701–702
 - Mayer-Rokitansky-Küster-Hauser syndrome 491, 550
 - miscarriage 566
 - pelvic organ prolapse 758–759
 - pre-conception *see* pre-conception counselling
 - premature ovarian insufficiency 646, 676
 - sexual dysfunction 959–960
 - sterilization 950
 - XY females 550
- couples relationship psychotherapy 955, 960
- cow's milk **439**, 440
- CPR *see* cardiopulmonary resuscitation
- craniopharyngioma 549, 648
- C-reactive protein (CRP), chorioamnionitis 403
- creatinine, serum (S_{cr})
- chronic kidney disease 130, 131, 132, **132**
 - kidney transplant recipients 139, **139**
 - normal pregnancy 11, 130
- creatinine clearance, in pregnancy 11, 130
- Créde manoeuvre 301
- Critical Appraisal Skills Programme (CASP) 1012, **1013**
- critical care, obstetric patients 427–428, **428**
- Crohn's disease, vulval 806, 806
- cross-sectional studies 460
- crown–rump length (CRL)
- gestational age assessment 32, 53, 307–308, 317
 - miscarriage diagnosis 512, 562, 563, 563
- cryoprecipitate, obstetric haemorrhage 155, 344
- cryopreservation
- eggs 716
 - embryo 705, 714–715
 - ovarian tissue 646
- cryotherapy
- CIN 865
 - genital warts 926
- CT *see* computed tomography
- CTG *see* cardiotocography
- culdoscopy 535
- culdotomy, laparoscopic specimen retrieval 526
- cumulus oophorus 625
- Cushing's disease 633
- Cushing's syndrome 126, 633
- cyanosis
- congenital heart disease 88–89
 - neonatal congenital heart disease 455
 - pregnant women with heart disease 86–87
- cyclic ADP-ribose (cADPR) 293–294
- cyclic AMP (cAMP) 295, **296**, 297
- cyclic GMP (cGMP) 295
- cyclooxygenase-1 (COX-1) 400
- cyclooxygenase-2 (COX-2; PTGS2)
- initiation of labour 288, 289, 290
 - regulation of myometrial expression 295

cyclooxygenase-2 (COX-2) inhibitors
 prevention of preterm labour 400
 rheumatic diseases in pregnancy **196**
 cyclophosphamide
 gestational trophoblastic tumours **582, 582–583**
 in pregnancy 193, **197**
 cyclosporin 141, **141, 197**
 cyproterone acetate 642, **678, 946**
 cystic fibrosis
 meconium ileus/peritonitis 259
 newborn screening **448**
 pregnancy in 201–202
 pre-ICSI screening 713–714
 cystic hygroma 262
 cystitis, interstitial *see* interstitial cystitis
 cystocele 755, 772
 cystometry 768–769, 770–771
 cystoscopy, fetal 262
 cytogenetic abnormalities, uterine fibroids 827
 cytogenetic tests 64
 cytokines, onset of labour 288, 289, 391
 cytomegalovirus (CMV) 169–171
 congenital infection 170, 171, 176
 vertical transmission 170
 cytroreductive surgery *see* debulking surgery
 cytotrophoblast 20, 20, 21, 22
 cell turnover 24
 extravillous 22
 syncytial fusion 23–24
 villous 23

d

daclizumab **141**
 Daily Record of Severity of Problems (DRSP) 664, 665
 Daisy Network 676
 danazol 668, 737
 Dandy–Walker malformation 257
 Danish Osteoporosis Prevention Study (DOPS) 680
 darifenacin **781, 782**
 Database of Abstracts of Reviews of Effects (DARE) 1009
 da Vinci[®] surgical system 525
 DAX1 gene 485
 D-dimers 156
 deafness, congenital 996
 debulking surgery

endometrial cancer 880
 ovarian cancer 892, 897–898
 decidua
 capsular 25, 25
 initiation of labour 287–288
 postpartum necrosis 433
 deciduitis 288
 deep vein thrombosis (DVT)
 diagnosis 155–156
 in pregnancy 155–157
 defecation, obstructed 756
 deflexion, fetal head 354
 dehydroepiandrosterone (DHEA) 287, 680
 dehydroepiandrosterone sulfate (DHEAS) 633, **634**
 DeLee incision 366
 delivery 301
 anticoagulated women 91–92, 156–157
 breech presentation 356–358, 357, 358
 cardiovascular adaptations 86
 clinical assistance at 301
 diabetes 109–110
 emergencies 347–351
 growth-restricted fetus 227–228
 isolated controlled hypertension 79
 neonatal care planning and 446
 obesity 212–215
 placenta and fetal membranes 301
 pre-eclampsia 79
 preterm infants 410
 twins and multiple pregnancies 277–278
see also childbirth; labour
 dementia 674, 681
 denominator (fetal presenting part) 354
 11-deoxycorticosterone 14
 Depoprovera[®] 943–944
 depot medroxyprogesterone acetate (DMPA)
 contraception 943, 943–944
 heavy menstrual bleeding 658
 menstrual suppression in adolescents 555
 non-contraceptive benefits 951
 obesity 208
 recurrent vulvo-vaginal candidiasis 922
 side effects 944–945
 depression
 adverse effects of untreated prenatal 178–179
 antenatal and postnatal screening 179

neurotransmitter function 667
 non-pharmacological treatments 185
 postpartum *see* postpartum depression
 in pregnancy 179, 183
see also antidepressants
 dermatitis, vulval 802–803
 dermoid cysts, ovarian 505, 505, 819, 820
 descriptive statistics 468–471
 DESKTOP trial 897
 desmopressin **781, 782, 784**
 desvenlafaxine succinate 684
 detrusor muscles 483
 detrusor overactivity 767, 779–784
 clinical symptoms 779
 drug therapy 780–782, **781**
 investigations 769, 772, 780
 neurogenic 772, 779
 neuromodulation 782–783
 NICE guidelines 783–784
 surgery 783
 treatment 779–784, **780**
 developing countries, sexually transmitted infections 911–912
 developmental outcome *see* neurodevelopmental outcome
 dexamethasone
 antenatal therapy 407, 408
 congenital adrenal hyperplasia 245
 gestational trophoblast neoplasms 583
 dexamethasone suppression test 633
 diabetes insipidus 125
 diabetes mellitus 97–111
 antenatal care **106, 106–109**
 antenatal corticosteroids 108, 408
 classification 97–99, **98**
 complications screening 104–105
 delivery planning 109
 diagnosis 99–100, **100, 637**
 fetal/neonatal adverse effects **102, 106, 110–111**
 genital warts 926, 926
 gestational *see* gestational diabetes
 glycaemic control 97, 100–104
 intrapartum care 109–110
 kidney transplant recipients 142
 long-term effects on child **102, 111**
 mitochondrial **98**
 monogenetic (maturity-onset, of the young) **98**
 non-diabetic comorbidities 105–106

- polycystic ovary syndrome
 - 637, 640
- postpartum care **106**, 110
- pre-conception care 44,
 - 101–102, **103**
- pre-gestational 97–98
- pregnancy outcomes 97, 98,
 - 100–101, *101*, **102**
- recurrent miscarriage 571
- secondary **98**
- thalassaemia 152
- diabetes mellitus type 1 (type 1 DM) **98**
 - antenatal care 107, 108
 - autoimmune diseases 105
 - diabetic complications 104, 105
 - diagnosis 99
 - postpartum care 110
 - pre-conception care 103–104
 - pregnancy outcomes 97, 100, *101*, 111
 - timing and mode of delivery 109
- diabetes mellitus type 2 (type 2 DM) **98**
 - antenatal care 107, 108
 - diabetic complications 104
 - diagnosis 99
 - gestational diabetes predicting 110
 - metabolic risk factors 105–106
 - postpartum care 110
 - pre-conception care 104
 - pregnancy outcomes 97, 100, *101*, 111
 - timing and mode of delivery 109
- diabetic ketoacidosis (DKA)
 - 105, 107
- diabetic macrovascular disease 105
- diabetic nephropathy 104–105, **135**
 - kidney transplantation 142
- diabetic neuropathy 105
- diabetic obstetric antenatal clinics 106
- diabetic retinopathy 104
- diacylglycerol (DAG) 292,
 - 295, **296**
- diagnostic test accuracy studies 1009,
 - 1011–1012, **1013**
- dialysis 137–138
 - antenatal care 137–138
 - pregnancy outcomes 137
 - temporary 133
- diamorphine 424
- Dianette, polycystic ovary syndrome 642
- diaphragm, contraceptive 950
- diaphragmatic hernia, congenital
 - 263, 455
- diarrhoea, breastfed infants 439
- diathermy *see* electrosurgery
- diazepam, eclampsia 80
- dichorionic pregnancy 269, 270
 - fetal growth restriction 272
 - invasive prenatal diagnosis 271
- dietary advice
 - antenatal 48
 - endometriosis 733
 - maternal obesity 210
 - pre-conception 39–40, **40**
- dietary supplements
 - after bariatric surgery 209
 - dialysis patients 138
 - maternal obesity 210
 - pregnancy 40, 48
- diethylstilbestrol (DES)
 - ectopic pregnancy 590
 - preterm labour 393
 - vaginal lesions 816, 853
- DiGeorge's syndrome 257
- DIGITAT (Disproportionate Intrauterine Growth Intervention Study at Term) 228
- digoxin
 - fetal tachycardia 246
 - pre-abortion feticide 604, 607
- dihydrotestosterone **634**
- 1,25-dihydroxyvitamin D 14
- Dilapan-S 604
- dilatation and curettage 564
- dilatation and evacuation (D&E)
 - 603–605
 - complications 605
 - procedure 604–605
- dilatation and extraction (D&X) 603
- dimethyl sulfoxide (DMSO) 787
- dinoprostone
 - induction in obesity 213
 - induction of labour **328**, 329
 - see also* prostaglandin E₂
- Diogenes of Apollonia 18
- dioxin 724
- 2,3-diphosphoglycerate (2,3,-DPG) 8
- discipline, professional 1004
- disease-modifying antirheumatic drugs (DMARDs) 194, 195,
 - 196–197**
- disorders of sexual development (DSD) 488–492, **489**
 - 46XX **489**, 490–492
 - 46XY 488–490, **489**
 - primary amenorrhoea 548
 - see also* sex chromosome disorders
- disseminated intravascular coagulation (DIC) 417
- dizygotic twins 270
- DMPA *see* depot medroxyprogesterone acetate
- DNA
 - cell free (cfDNA), maternal plasma 65
 - fetal fraction 68
 - see also* non-invasive prenatal testing
- documentation
 - antenatal care 55
 - endoscopic surgery 521–522
 - neonatal care 446
 - obstetric emergencies 338
- domestic violence
 - antenatal care 50–51
 - enquiring about 50, 909
 - health effects 968
 - honour-based crimes 980
 - perinatal mortality 417
 - sexual abuse 980
- donor insemination 701, 717
- dopamine, sexual function 955
- dopamine agonists, hyperprolactinaemia
 - 125, 647–649, **649**
- Doppler ultrasound 499
 - endometrial polyps 502, 502
 - fetal growth restriction 223, 224, 225–227, 226, 227
 - intrapartum fetal heart rate monitoring 380
 - multiple pregnancy 272
 - placental assessment 26, 27
 - post-term pregnancy 316
 - pre-eclampsia screening 76
 - red cell alloimmunization 249, 249
 - third-trimester fetal assessment 236, 236–237, 237
 - timing of delivery and 228
 - uterine tumours 503, 503
 - vasa praevia 232–233
- douching, vaginal 611–612, 921
- doula 423
- Down's syndrome
 - antenatal screening 53–54, 59–69
 - confirmatory tests 63–65
 - diabetes 107
 - first-trimester combined 60–62
 - multiple pregnancy 61, 270–271
 - non-invasive prenatal testing 54, 65–67
 - questions and misconceptions 62
 - screen-positive results 62–63
 - special conditions 61–62
 - uptake and ethics 60

- Down's syndrome (*cont'd*)
 clinical features 59
 duodenal atresia 259
 incidence 59
 maternal age and risk 43
 risk estimation 60
 ultrasound markers 61
 doxorubicin hydrochloride,
 pegylated liposomal
 (PLDH) 896, 897
 doxycycline
 chlamydia infection 916, 919
 pelvic inflammatory disease 616
 pre-abortion prophylaxis 600
 preterm birth prevention 916
 syphilis 928
 DRD4 dopamine receptor gene 955
 drospirenone
 HRT 678, 679
 polycystic ovary syndrome 642
 premenstrual syndrome 669
 drug use, recreational
 antenatal advice 48
 neonatal effects 454–455
 dual-energy X-ray absorptiometry
 (DEXA) 675
 ductus arteriosus
 maintaining patency 256
 NSAID-induced constriction 400
 ductus venosus (DV) 226–227
 Doppler waveforms 61, 226–227,
 227, 228
 Dührssen incisions 358
 duloxetine 775, 781
 duodenal atresia 259, 456
 Dworkin, Ronald 988
 dyschezia, menstrual 730
 dysfunctional uterine bleeding
 (DUB) 653
 dysmenorrhoea
 chronic pelvic pain 744–745
 endometriosis 729–730, 737
 primary 555
 dyspareunia 730, 745, 964–965
 dysrhythmias *see* arrhythmias
 dystocia, post-term pregnancy 312
- e**
 early fetal demise 560
 early pregnancy
 complications 559
 endometrial development 628–630
 ultrasound imaging 512–514,
 562, 562
 viability assessment 512
 early pregnancy units 559
 early term pregnancy 307
 eating disorders 650
 ECG *see* electrocardiogram
 echocardiography
 fetal 255
 in pregnancy 86
 eclampsia 74
 management 80, 346, 346
 maternal collapse 340
 postnatal presentation 81
 ectopic pregnancy (EP) 589–594
 assisted reproduction and
 590, 718
 chlamydia and 590, 915
 diagnosis 591, 591–592, 592
 intrauterine insemination 708
 IUCD users 590, 942
 kidney transplant
 recipients 138–139
 M4 prediction model 513–514
 management 592–594, 593
 non-tubal 590, 591–592
 pelvic inflammatory disease
 and 589–590, 617–618
 risk factors 589–590
 tubal 590, 591, 591, 592–594
 types 590
 ultrasound 512–513, 513, 591,
 591–592, 592
 eczema, vulval 802–803
 Edinburgh Postnatal Depression Scale
 (EPDS) 179, 180
 effective renal plasma flow (ERPF), in
 pregnancy 10, 10
 eflornithine 642
 eggs *see* oocytes
 Ehlers–Danlos syndrome (EDS) 199
 eicosanoids, myometrial
 effects 296
 Eisenmenger's syndrome 89
 ejaculatory disorders 693, 699
 electrical stimulation, urinary
 incontinence 775
 electrocardiogram (ECG)
 fetal 382–383
 in pregnancy 86
 pulmonary embolism 156
 electroconvulsive therapy (ECT) 185
 electrolysis, for hirsutism 642
 electromyography 773
 electronic fetal monitoring
 (EFM) 380, 380, 381, 383
 see also cardiotocography
 electrosurgery (diathermy)
 bipolar *see* bipolar electrosurgery
 CIN lesions 865
 endoscopic 520–521
 hysteroscopic equipment
 522–523, 523
 laparoscopic 526
 monopolar 521, 526
 ELITE (Early versus Late Intervention
 Trial with Estradiol) 680
 EMA/CO chemotherapy
 complications 583, 585
 gestational trophoblastic
 tumours 582, 582,
 582–583, 584
 salvage of failures 584
 embolic transport theory,
 endometriosis 723–724
 embryo
 biopsy 716
 consent to storage/use 994
 cryopreservation 705, 714–715
 early stage 710–711
 heart activity 512, 513, 563, 593
 histiotrophic nutrition 6, 22
 sex selection 996
 see also blastocyst; crown–rump
 length
 embryo transfer 710–711
 frozen 712, 712, 714–715
 numbers 269, 278, 710, 717–718
 see also in vitro fertilization
 emergencies, obstetric 336–351
 collapse 339–342, 342, 346–347
 communication and team
 working 337
 documentation 338
 duty of candour 338
 emergency delivery 347–351
 haemorrhage *see* obstetric
 haemorrhage
 minimizing adverse consequences
 337–339
 minimizing risk 336–337
 training 338–339
 triage 336
 emergency contraception (EC)
 948–949
 impact of obesity 208, 948
 rape victims 978
 starting contraception
 after 949
 emotional intimacy, sexual
 response 955, 956
 emotional support
 infertility 701–702
 postnatal 435
 empty (gestation) sac 560,
 562–563, 569

- empty sella syndrome 548–549
- endocarditis, infective, in
 - pregnancy 94
- endocervical polyps 654, 659, 818, 818
- endocrine disorders
 - fetal 243–245
 - pregnancy 124–126
 - recurrent miscarriage 571
 - secondary amenorrhoea 650
 - sexual dysfunction 961, 962
- endocrine system
 - normal pregnancy 13–15
 - onset of labour 391–392
- endodermal sinus tumours,
 - vagina 853
- endoglin (sEng) 74
- endometrial ablation/resection 659
 - adenomyosis 824
 - complications 533
 - hysteroscopic 531
 - premenstrual syndrome 668
 - uterine fibroids 831
- endometrial cancer 876–882
 - aetiology 876–878, **877**
 - chemotherapy 881
 - clinical presentation 878
 - heavy menstrual bleeding 654–655
 - histological subtypes **878**, 878–879
 - HRT and 682
 - imaging 504, 879
 - incidence 876, 877
 - management 879–881
 - oral contraceptive pill and 947
 - polycystic ovary syndrome 640
 - protection from *see* endometrial protection
 - radiotherapy 880–881
 - relapsed 881
 - staging 879, **879**
 - surgery 879–880
 - types 878, **878**
- endometrial dysfunction
 - endometriosis 730
 - heavy menstrual bleeding 655
 - recurrent miscarriage 572
- endometrial glands, embryo
 - nutrition 6, 22
- endometrial hyperplasia
 - heavy menstrual bleeding 654–655
 - malignancy risk 878
 - polycystic ovary syndrome 640
- endometrial polyps 824–826
 - diagnosis 825, 825
 - heavy menstrual bleeding 654
 - infertility 700
 - treatment 530, 659, 825
 - ultrasound 502, 502, 504
- endometrial protection
 - postmenopause 678, **678**
 - premenstrual syndrome 668, 669
- endometrial sampling (biopsy)
 - 656, 878
- endometrial thickness, ultrasound
 - measurement 500, 504, 640
- endometrioid ovarian carcinoma 725, **886**
- endometriomas (cystic ovarian endometriosis) 725, 725, 819
 - imaging 505–506, 506
 - infertility 696, 696
 - laparoscopic surgery
 - fertility benefits 737–738, 738
 - pain relief 734, 736
 - low-invasive diagnosis 731, 732
 - pre-IVF treatment 707, 739
 - treatment 701
- endometriosis 723–740
 - aetiology 723–724
 - classification systems 726–729, 727–729
 - clinical examination 695, 731
 - comorbidities 724–725
 - complementary therapy 737
 - deep 726, 726
 - classification 726–729, 728
 - low-invasive diagnosis 731, 732
 - surgical treatment 735, 738
 - diagnosis 730–732
 - HRT 682, 724
 - infertility 692, 701, 730
 - assisted conception 738–739
 - emerging therapies 740
 - medical therapy 739
 - pre-IVF treatment 707, 739, 739
 - surgical treatment 737–738, 738
 - low-invasive diagnostic tests 731–732
 - low-value care concept 731
 - medical treatment 736–737
 - emerging 737
 - empirical 733–734
 - fertility benefits 739
 - prior to IVF 739, 739
 - natural history 724–725
 - networks of expertise 732
 - ovarian cancer and 725, **886**, 888
 - ovarian cystic *see* endometriomas
 - peritoneal (typical) 725, 725
 - peritoneal pocket lesions 726
 - phenotypes at laparoscopy 725, 725–726
 - prevalence 724
 - subtle or atypical 726
 - surgical treatment
 - fertility benefits 737–738, 738
 - pain relief 734–736, 735
 - prior to IVF 707, 739
 - symptoms 729–730
 - treatment 701, 732–740
 - aims 733
 - decision-making 732, 733
 - fertility 737–740
 - symptomatic 733–737
 - ultrasound imaging 510
 - vaginal 814
- Endometriosis Fertility Index (EFI) 726, 729, 729
- Endometriosis Health Profile-30 (EHP-30) 730
- Endometriosis Phenome and Biobanking Harmonisation Project (EPHect) 740
- endometritis
 - chlamydial 913
 - Mycoplasma genitalium* 918
 - pelvic inflammatory disease 615
 - post-abortion 618
 - postpartum 438
- endometrium 482
 - angiogenesis 629
 - early pregnancy 629–630
 - histological assessment 656
 - menstrual cycle changes 628–629, 629
 - postpartum regeneration 433, 434
 - sonohysterography 500–501, 501
- endoscopic surgery 519–537
 - training 536–537
 - see also* hysteroscopy; laparoscopy
- endothelial function, in pregnancy 15
- endothelin, myometrial signalling **296**
- end-stage renal failure (ESRF)
 - kidney transplant recipients **139**
 - pregnancy-related risk **132**, 133, **133**, 136–137
 - see also* dialysis
- energy requirements, in
 - pregnancy 12–13
- Entonox, labour analgesia 424
- Enzian classification, deep
 - endometriosis 726–729, 728
- e-PAQ 757
- EP/EMA chemotherapy 584
- Epi-CKD formula 131
- EPICure studies 389, 446, 449, 450, 1006

- epidemiology
 - definition 459
 - descriptive studies 460
 - observational studies 460
 - perinatal 459–464
 - study designs 460, 460–464
- epidermal growth factor (EGF) 289, 290, 827
- epidermal growth factor receptor (EGFR) 289, 290
- epidermoid cysts, vulval 809, 809
- epidermolysis bullosa 804
- epidural anaesthesia/analgesia
 - breech presentation 356
 - cephalopelvic disproportion 360
 - inherited bleeding disorders 159
 - instrumental vaginal delivery 361
 - labour 424–426
 - low dose (mobile) 424, 425, **425**
 - obesity 213, 214
 - pre-eclampsia 80
 - pyrexia in labour and 375–376
 - twin delivery 278
 - urinary retention after 437
- epigenetics 223
- epilepsy 202
- episiotomy 368–369
- epithelial ovarian cancer (EOC) 884–899
 - see also* ovarian cancer
- epithelioid trophoblastic tumour (ETT) 575, 579–580
 - management 584–585
- Epstein–Barr virus (EBV)
 - infection 805
- Erb's palsy 454
- erythema infectiosum 171
- erythema multiforme 804–805
- erythrocyte sedimentation rate (ESR) 9, 192, **193**
- erythromycin 402, 919
- erythropoietin
 - changes in pregnancy 9, 14
 - recombinant human 138
- Essure® system
 - female sterilization 531, 532, 949
 - tubal factor infertility 700
- estimated fetal weight (EFW)
 - defining growth restriction 221, **222**
 - discordancy, twin pregnancy 272
 - reference charts 34, 34
 - ultrasound biometry 33, 223, 234, 234
 - see also* fetal size
- estradiol
 - endometrial effects 628–629
 - hormone replacement therapy 677
 - ovarian cycle 624, 626, 628
 - precocious puberty 545
 - pubertal growth 544
 - routes of administration 677
 - serum **634**, 635, 709
 - transdermal 669, 677
 - vaginal 677–678
- estrogens *see* oestrogens
- estrone **634**
- etanercept 195
- ethics 987–997
 - abortion 987–991
 - fertility treatment 992–996
 - obligations of doctors 1000
 - patient autonomy 999–1001
 - pregnancy and childbirth 991–992
- ethinylestradiol 661, 945
- ethnic/racial differences
 - age at puberty 543
 - hirsutism 633
 - polycystic ovary syndrome 639
 - post-term pregnancy 309
 - preterm delivery 388
 - stillbirth 415
 - uterine fibroids 826–827
- etoposide
 - gestational trophoblastic tumours **582**, 582–583, 584
 - ovarian cancer 897
 - see also* EMA/CO chemotherapy
- EuroQoL instrument 745
- Evans, Natallie 994
- Every Newborn Action Plan 420
- evidence-based medicine (EBM) 1008–1014
 - applying the evidence 1012–1013
 - critical appraisal 1010–1012, **1013**
 - evaluating performance 1013–1014
 - framing structured questions 1008, **1009**
 - searching the literature 1009–1010, *1010*
 - steps 1009
- exenteration
 - cervical cancer 873
 - endometrial cancer 881
 - vaginal cancer 852, 853
- exercise
 - antenatal advice 48–49
 - obese pregnant women 211
 - postmenopause 677
 - response in pregnancy 9, **9**
- exercise-related
 - amenorrhoea 547–548, 650–651
- exomphalos 259–260, 456
- expanded carrier screening (ECS) 69
- external cephalic version (ECV) 355–356
 - second twin 278
- external genitalia
 - anatomy 478–479, 479, 480
 - development 486–487, 487
- extracorporeal membrane oxygenation (ECMO) 455
- extravillous trophoblast *see* trophoblast, extravillous
- extremely low birthweight 387
- extremely preterm infants 387
 - survival and morbidity 389, 389–390, **390**
- eye infections, neonatal 453
- f**
- face presentation 358–359, 359
- factor VII
 - in pregnancy 9, 10, 147
 - recombinant activated 346
- factor VIII, in pregnancy 9, 10, 147
- factor X, in pregnancy 9, 10, 147
- Faculty of Sexual and Reproductive Healthcare (FSRH) 940, 941, 942, 947
- faecal incontinence,
 - postpartum 437–438
- fallopian cancer, staging **890**
- fallopian tubes
 - anatomy 482, 483
 - development 486
 - ectopic pregnancy 590, 591, 592–594
 - premalignant lesions 888
 - see also* tubal disease; tubal patency testing
- Fallop's tetralogy 88, 256–257
- false negative 466, 467
- false positive 466, 467, 1012
- famciclovir 925
- familial recurrent hydatidiform mole (FRHM) syndrome 576, 577
- family, preterm babies 390, 450
- Family Planning Association 599
- FASTER trial 76–77, 308, 317
- fat metabolism, in pregnancy 13
- fatty acid oxidation disorders 118, 119
- fear of childbirth 182
- female genital mutilation (FGM) 981–982

- obstetric implications 51
- WHO classification **51, 982**
- female same-sex relationships 957
 - attitudes towards 954
 - fertility treatment 691, 693, 701
- Female Sexual Function Index (FSFI) 962
- female sterilization *see* sterilization, female
- femur length (FL), fetal
 - growth curve 35
 - measurement 32–33, 33, 234, 234
- Ferriman–Gallway score 641, 642
- ferritin, serum
 - antenatal screening 52
 - iron deficiency 9, 148, 149
- fertility
 - breastfeeding and 440
 - chemotherapy-treated molar pregnancy 585
 - dialysis patients 137
 - kidney transplant recipients 138
 - maternal age and 42–43, **43**
 - obesity 208–209
 - see also* infertility
- fertility awareness methods (FAM), family planning 950–951
- fertility-sparing surgery
 - cervical cancer 870, 871–872
 - endometrial cancer 880
 - ovarian cancer 892
- fertility treatment 698–702
 - consent 993–994
 - endometriosis 707, 738–739, 740
 - ethical issues 992–996
 - funding 702, 993
 - gamete donation 994–995
 - obesity 208
 - regulating access to 992–993
 - unlicensed 995–996
 - welfare of the child 702, 992–993
 - see also* assisted reproduction
- fesoterodine **781, 782**
- fetal acidemia 373
 - fetal and neonatal consequences 373–374
 - fetal blood sampling **381, 381–382, 382**
 - fetal heart rate patterns **379**
 - paired umbilical cord samples 373, **374**
- fetal alcohol syndrome 41, 48
- fetal anaemia 248–251
 - hydrops 265
 - one monochorionic twin 276
- parvovirus B19 infection 171, 172, 251, 252
- red cell alloimmunization 248–251
- fetal and neonatal alloimmune thrombocytopenia (FNAIT) 154–155, 247–248
 - diagnosis **154**
 - management 247–248
- fetal anomalies 254–265
 - abdominal wall defects 259–261
 - antenatal screening 54, 254
 - diabetes 108
 - first trimester 69
 - multiple pregnancy 270–271
 - cardiovascular system 255–257
 - central nervous system 257–258
 - gastrointestinal tract 259
 - genitourinary tract 261–262
 - head and neck 262
 - obesity-related risk 212
 - prevalence 254
 - skeletal system 262–263
 - termination for 989, 1002, 1003
 - thoracic 263–264
 - timing and development 254–255
 - see also* congenital abnormalities
- fetal assessment, third trimester 231–238
- fetal attitude 298
- fetal blood sampling (FBS) 378, 381–382
 - dilemmas 382
 - interpretation **381, 381–382, 382**
- fetal compromise
 - brain sparing 222, 225
 - caesarean section 365
 - discordant, multiple pregnancy 275
 - fetal blood sampling 381–382
 - fetal heart rate patterns 378, 378–380, **379**
 - instrumental vaginal delivery 360, 364
 - intrauterine resuscitation 426, **426**
 - pathophysiology 372–373
 - prediction of risk 376–377
 - see also* fetal acidemia; fetal hypoxia
- fetal fibronectin test
 - post-term pregnancy 309
 - prediction of preterm labour 397
 - symptomatic preterm labour 404–405, **405**
- fetal fraction 68
- fetal growth 31–36
 - assessment 54, 223–225, 233–235
 - causes 223–224
 - diabetes 108, 109
- methods 31–33
- multiple pregnancy 272
- obesity 212
- international standards 34–36, 35, 223
- maternal diabetes **102, 106, 109**
- regulation 222–223
- standards or references 34, 233–234
- fetal growth restriction (FGR) 221–228
 - chronic hypertension and 77
 - chronic kidney disease 133, **133**
 - consequences 221–222
 - definition 221, **222**
 - diabetes 109
 - early onset **222, 233, 236**
 - kidney transplant recipients **139, 142**
 - late onset **222, 233, 234–235**
 - monitoring 225–227
 - multiple pregnancy 272–273
 - neonatal problems 451
 - placental pathophysiology 24–25
 - prediction **224, 224–225, 233–237**
 - rheumatoid arthritis 194
 - screening 54, 223
 - small for gestational age (SGA) vs. 34
 - stillbirth risk 221, 233, 416
 - systemic lupus erythematosus 192
 - Takayasu's arteritis 199
 - timing of delivery 227–228
 - ultrasound assessment 26
 - see also* small for gestational age
- fetal head *see* head, fetal
- fetal heart
 - antenatal auscultation 54
 - development 255
 - intrapartum auscultation 378, 380, **380**
- fetal heart rate (FHR) 378–380
 - abnormalities, induced labour 328, 330, 382
 - aneuploidies 63
 - baseline 378, **379, 379–380**
 - baseline variability 378, **379, 380**
 - classification systems 378–380, **379**
 - decelerations
 - cord compression 375, 375
 - interpretation 378, 378, **379**
 - irregular 245
 - short-term variability (STV) 227

- fetal heart rate (FHR) monitoring,
 - intrapartum 301, 378–381
- abnormal labour 376
- computerized analysis 383
- fetal blood sampling and 382
- interpretation 378–380, **379**
- obesity 214
- preterm labour 410
- techniques 380–381
- see also* cardiotocography
- fetal hydrops *see* hydrops fetalis
- fetal hypoxia
 - clinical signs in labour 377
 - diagnosis 376–383
 - fetal and neonatal
 - consequences 373–374
 - fetal heart rate patterns 378, 378–380, **379**
 - maternal infections 375–376
 - metabolic acidemia 373, **374**
 - pathophysiology 372–373
 - prediction of risk 233–237, 376–377
 - uterine contraction-related 374–375
 - see also* fetal compromise
- fetal lie 298
- fetal loss
 - intrauterine transfusion 250
 - invasive prenatal diagnosis 64, 271
 - multiple pregnancy 269, 270
 - obesity 212
 - by week of gestation 560
 - see also* intrauterine fetal death; miscarriage; stillbirth
- fetal macrosomia *see* macrosomia, fetal
- fetal membranes (chorion laeve) 25–26
- characteristics 26
- delivery 301
- development 23, 24, 25
- layers 25, 25
- visible, cervical cerclage and 398
- fetal monitoring in labour 377–383
 - admission cardiotocography 380
 - cardiotocography 381
 - computerized cardiotocograph analysis 383
 - fetal blood sampling 381–382
 - fetal ECG 382–383
 - fetal heart rate 378–381
 - future prospects 383
 - identifying high-risk fetus 376–377
 - intermittent auscultation 380
 - preterm labour 410
- fetal movement counting 54, 234–235
 - post-term pregnancy 313–314, **314**
- Fetal Pillow® 368, 368
- fetal position 298, 354
 - intrapartum diagnosis 361
 - see also* malposition, fetal
- fetal presentation 298, 354
- fetal presenting part, levels 354, 355
- fetal programming (Barker hypothesis)
 - fetal growth restriction 221
 - maternal hyperglycaemia 100, 101
 - maternal obesity 207, 216–217
 - prenatal stress 179
 - see also* long-term health consequences
- fetal sex
 - diagnosis 159, 270
 - sex-selective termination 990
- fetal size
 - effects on course of labour 298
 - estimation 32–33, 33, 54
 - see also* birthweight; estimated fetal weight
- fetal structural anomalies *see* fetal anomalies
- fetal therapy (including surgery)
 - anaesthesia 427
 - chronic feto-fetal
 - transfusion 275–276
 - complete atrioventricular block 246
 - congenital pulmonary airway
 - malformation 264
 - diaphragmatic hernia 263
 - ethical issues 991
 - hypoplastic left heart syndrome 256
 - hypothyroidism 244
 - lower urinary tract obstruction 262
 - myelomeningocele 258
 - tachycardia 246
 - twin anaemia polycythaemia
 - sequence 276
 - see also* intrauterine transfusion
- fetal varicella syndrome (FVS) 174
- fetal viability
 - confirmation 53
 - limits 387
- feticide, pre-abortion 604, 607
- fetishism 958
- feto-fetal transfusion, acute 274–275
- feto-fetal transfusion syndrome (FFTS),
 - chronic 275, 275–276
- fetomaternal haemorrhage (FMH) 153, 565
- fetoscopic endoluminal tracheal occlusion (FETO) 263
- fetoscopic laser ablation, inter-twin communicating vessels 275
- fetus
 - cardinal movements 299, 300
 - factors influencing course of
 - labour 298
 - measurement *see* biometry, fetal
 - medical conditions 243–251
 - patienthood 991
 - personhood 987–988, 1003
 - physiology 372–374
 - responses to labour 374–376
 - signals for parturition 285–287
 - tumours 264
- FGR *see* fetal growth restriction
- fibrinogen
 - major obstetric haemorrhage 155
 - normal pregnancy 9, 10
- fibrinoid
 - fibrin-type 20, 23
 - matrix-type 20, 25
- fibrinolysis
 - postpartum changes 434, **434**
 - pregnancy and labour 9, **10**
- fibroblast growth factor 827
- fibroids, uterine *see* uterine fibroids
- fibromas, ovarian 820, 820
- fibronectin
 - fetal *see* fetal fibronectin test
 - normal pregnancy **10**
- fifth disease 171
- FIGO *see* International Federation of Gynecology and Obstetrics
- Filshie clips 949
- fistulae 785, 814
- Fitz-Hugh–Curtis syndrome 510, 614, 914, 914
- fixed drug eruptions 804
- flecainide 94, 246
- Flt-1, soluble *see* sFlt-1
- fluconazole 812–813, 922
- flucytosine 922
- fluid management
 - maternal collapse 341–342
 - postpartum haemorrhage 344
 - pre-eclampsia 80
- fluid overload, operative
 - hysteroscopy 533
- fluorescence *in situ* hybridization (FISH) 64
- 5-fluorouracil 816, 848
- fluoxetine 184, 668
- fms-like tyrosine kinase-1, soluble
 - see* sFlt-1
- focal segmental glomerular sclerosis (FSGS) **135**

- folate
 deficiency 149
 fortification of foods 40, 48
 in normal pregnancy 9, 147
 Foley catheter, extra-amniotic 329
 folic acid supplements 149
 antenatal care 48
 antiepileptic-treated women 187, 202
 haemoglobinopathies 152
 obesity 209–210
 pre-conception care 40, 698
 folinic acid
 EMA/CO regimen **582**
 gestational trophoblastic tumours **581, 581, 581–582**
 follicles, ovarian
 antral stage 624, 625
 development 623–628, 625
 endocrine control 624–627, 626, 627
 fetus 488, 488
 Kallmann's syndrome 624, 626
 paracrine control 623–624, **624**
 threshold concept 626–627, 628
 dominant 626–627, 628
 natural attrition 623
 persistent, progestogen-only pill users 944
 preovulatory 624, 625
 primordial 623–624, 625
 ultrasound imaging 511
 see also antral follicle count
 follicle-stimulating hormone (FSH)
 follicular development 624, 626, 626–627, 627
 intrauterine insemination 707, 708
 molecular structure 624, 625
 onset of puberty 543
 serum **634**
 infertility 695
 menopause 674, 675
 premature ovarian insufficiency 635, 676
 threshold concept 626–627, 628
 follicular cysts 505, 944
 folliculogenesis 623–628
 fontanelles, during labour 361
 Fontan operation, pregnancy after 88–89
 foods, to avoid in pregnancy **40, 48**
 Foods Standards Agency 40, 48
 footling breech 354–355, 355
 forced marriage 980
 forceps
 laparoscopic grasping 525, 525
 obstetric 361–362
 disposable plastic 364, 365
 pre-abortion cervical dilation 603–604, 604
 forceps delivery 361–363
 breech presentation 357
 complications 364, 438
 indications 361
 non-rotational 362, 362
 preterm infants 410
 rotational 362–363
 Fordyce spots 796, 797
 foreign bodies, vaginal 554
 forensic history-taking 970–971, **971**
 forensic medical examination 971–978, **972**
 forensic samples 978
 forest plot 463, 463–464, 1011, **1011**
 fornices, vaginal 481
 Framingham Heart Study 459
 Fraser criteria 599
 free androgen index 633, **634**
 freezing *see* cryopreservation
 frequency, urinary 786–787
 causes **786**
 diurnal 786
 pelvic organ prolapse 756
 frequency–volume charts 767, 768
 fresh frozen plasma (FFP), obstetric haemorrhage 155, 344
 Frøen–Codac 2009 classification system 415
 FSH *see* follicle-stimulating hormone
 full term pregnancy 307
 fundal height *see* symphysis–fundal height
 fungal infections
 vaginal 812–813
 vulvovaginitis in children 553
Fusobacterium 393
g
 GABA (γ -aminobutyric acid), premenstrual syndrome and 667
 gabapentin
 chronic pelvic pain 747
 menopausal symptoms 684
 safety in pregnancy 187
 galactorrhoea 633, 647
 galactosaemia 548
 gallstones 116
 gamete intrafallopian transfer (GIFT) 714
 gametes
 donation 994–995
 posthumous use 993
 see also oocytes; sperm
 gamma-glutamyl transpeptidase (GGT), serum 116, **117**
 ganirelix 709
 gap junction proteins, myometrial 298
Gardnerella vaginalis 394, 920
 gastrointestinal symptoms
 ectopic pregnancy 589
 medical abortion 606
 pelvic organ prolapse 756
 gastrointestinal system
 congenital anomalies 259, 455–456
 normal pregnancy 11–12
 gastroparesis, diabetic 105
 gastroschisis 260–261, 456
 gemeprost 565, 602
 gender identity 957
 gender transition surgery 957
 general anaesthesia
 caesarean section 426
 obesity 213
 pre-eclampsia 80
 rheumatoid arthritis 194
 generalized anxiety disorder 180–181
 General Medical Council (GMC) 999, 1001, 1004, 1005
 genetic counselling,
 pre-conception 43
 genital herpes 922–925
 pregnancy 172–174, 923–924
 recurrent, perimenopausal women 924–925
 severe primary 923
 symptomless 922, 923
 genital tract
 abnormalities,
 amenorrhoea 645–646
 anatomy 477–484
 atrophy, postmenopause 672–673
 congenital anomalies 490–495, 511
 development 485–488
 developmental disorders 488–496
 epithelium 477–478
 injuries, sexual assault 977–978
 genital tract infections
 ectopic pregnancy risk 590
 post-abortion 600
 preterm labour 393–394
 puerperal 436–437
 genital warts 925–926
 effects of HPV vaccination 925
 in pregnancy 926
 treatment 926

- genitopelvic pain/penetration disorder 964–965
- genitourinary syndrome of menopause (GSM) 673
- genomic imprinting 223
- gentamicin 94, **616**
- germ cells 487–488
- gestation, normal duration 31–32
- gestational age
 - abortion methods and 601, 601
 - defining post-term pregnancy 307
 - estimation 31–32
 - accuracy 32, 307–308, 316–317
 - clinical assessment 32
 - diabetes 106
 - pre-abortion 599–600
 - ultrasound 32, 53, 512
 - perinatal mortality and 310–312, **311**
- gestational diabetes (GDM)
 - 97–98
 - diagnosis 99–100, **100**
 - intrapartum insulin therapy 110
 - long-term effects on child 111
 - management 110
 - maternal age and risk 43, **43**
 - obesity and 211
 - pregnancy outcomes 97, 99
 - previous history 107
 - risk factors 99–100, **100**
 - screening 53, 99–100, **100**
 - stillbirth risk 416–417
 - timing of delivery 109
- gestational hypertension 74, 75, 78
- gestational trophoblast neoplasms (GTNs) 575–586
 - classification 575
 - high-risk disease 582–583, 583
 - incidence 575
 - low-risk disease 580–582
 - first-line chemotherapy **581, 581**, 581–582
 - second-line chemotherapy 582, **582, 582**
- malignant 578–580
- premalignant 576–578
- prognostic scoring 580, **580**
- psychological issues 585–586
- relapse risk 585
- risk factors 575–576, **576**
- treatment 580–585
 - long-term toxicity 585
 - salvage of failures 584
 - subsequent fertility 585
- ultra-high-risk disease 583–584
- see also* molar pregnancy
- gestation sac 512
 - ectopic pregnancy 591, 592
 - empty **560, 562–563, 569**
 - extrauterine 513, 513
- gestrinone 737
- GFR *see* glomerular filtration rate
- Gillick competence 599, 990
- GJA1 (gap junction protein) 298
- glibenclamide (glyburide) 107, 110
- glomerular filtration rate (GFR)
 - chronic kidney disease 130, 131
 - estimated (eGFR) 130–131, **131**
 - kidney transplant recipients 140
 - normal pregnancy 10, 10, 130
- glomerulonephritis, chronic **135**
- glucagonoma syndrome 807
- glucocorticoids *see* corticosteroids
- glucose
 - excretion in pregnancy 11
 - monitoring
 - continuous (CGM) 104, 107
 - home blood (HBGM) 107
 - placental transfer 222
 - plasma/blood
 - antenatal targets 107, 110
 - diabetes diagnosis 99, **100**
 - labour and delivery 109
 - normal pregnancy 12, 12
 - see also* hyperglycaemia
- glutaric aciduria type 1 **448**
- glycaemic control 97, 100–104
 - antenatal 107–108, 110
 - benefits of good 100–101, 103
 - pre-conception targets 44, 103–104
- glycosuria, normal pregnancy 11
- GnRH *see* gonadotrophin-releasing hormone
- GOG score, cervical cancer 872
- GOG studies, ovarian cancer 893, 894–895, 898
- goitre, fetal 243, 244
- gonadal agenesis 548
- gonadal dysgenesis 548
 - pure 496, 548
- gonadotrophin-releasing hormone (GnRH) 543
 - inherited deficiency 547
 - menstrual cycle 624–626, 628
 - ovulation induction 649
 - pulsatile secretion 624–626, 628
- gonadotrophin-releasing hormone (GnRH) agonists
 - chronic pelvic pain 746
 - endometriosis 701, 736, 739, 739
 - frozen embryo cycles 715
 - heavy menstrual bleeding 658
 - IVF protocols 708, 709
 - precocious puberty 545
 - premenstrual syndrome 664–666, 668–669
 - uterine fibroids 828
- gonadotrophin-releasing hormone (GnRH) antagonists
 - endometriosis 737
 - IVF protocols 709
- gonadotrophins
 - follicular development 624, 626
 - molecular structure 624, 625
 - polycystic ovary syndrome 643
 - serum **634, 635**
- gonads
 - development 487–488
 - disorders of development 488–489
- gonococcal infection, disseminated 917
- gonococcal ophthalmia, neonatal 453, 917
- gonorrhoea 916–918
 - antimicrobial therapy 616, **616**
 - diagnosis 614–615, 910–911
 - epidemiology 908, 908–909, 916–917
 - pathology 615
 - pelvic inflammatory disease 612
 - pregnancy 917
 - test of cure (TOC) 918
 - treatment 917–918, 919
 - untreated or untreatable 918
 - vaginitis 813
 - see also* *Neisseria gonorrhoeae*
- goserelin 708, 746
- GPPSU gene **624**
- G protein-coupled receptors (GPCRs)
 - desensitization 297
 - uterine contraction 292, 293, 294–295, **296**
 - uterine relaxation 295–296, **296**
- G-protein receptor kinases (GRK) **296, 297**
- Grade Working Group 1010
- Grading of Recommendations Assessment, Development and Evaluation (GRADE) system 1012
- granulation tissue, vaginal 760–761
- granulosa cell layer 624, 625
- Graves' disease
 - fetal hyperthyroidism 243–244
 - pregnancy in 124–125
- grief response, stillbirth 418–419

groin lymph nodes *see* inguinofemoral lymph nodes
 group B *Streptococcus*, neonatal sepsis 453

growth

fetal *see* fetal growth
 preterm survivors 450
 pubertal 544
 growth differentiation factor-9 (GDF-9) 623, **624**
 growth hormone 544, 550–551
 G-spot 957
 guidelines, clinical practice 1009, 1010, **1010**
 Guillain–Barré syndrome 175
 gynaecological malignancy
 kidney transplant recipients 142
 ultrasound-guided biopsy 501, 502
 gynaecology
 ambulatory 519–537
 role of imaging 499–514
 Gynecologic Oncology Group *see* GOG

h

HABITS study 682
 haemangiomas, vulval 809
 haematocolpos 493, 494, 494, 546
 management 493, 550
 haematocrit
 fetal anaemia 250
 normal pregnancy 147, **148**
 haematological changes, pregnancy 9, 147, **148**
 haematological malignancies 159–160
 haematological problems 147–160
 haematometra 493, 546
 haematosalpinx 493
 haemodialysis *see* dialysis
 haemoglobin, glycosylated (HbA_{1c})
 antenatal assessment 107
 diagnosis of diabetes 99
 pre-conception targets 44, 103–104
 pregnancy outcomes and 101, 103
 haemoglobin (Hb) concentration
 defining anaemia 148
 heavy menstrual bleeding 555
 pregnancy 9, 52
 haemoglobinopathies 52, 151–153
 haemolytic disease of fetus and newborn (HDFN) 248–251
 antenatal screening 52
 management 248, 250–251
 prevention 153–154, **154**
 sensitizing events **153**
 haemomonochorial placentation 18, 19

haemoperitoneum, ectopic
 pregnancy 593, 593
 haemophilias 159
 haemorrhage
 CIN treatment 866
 hysteroscopic surgery 533
 intra-abdominal *see* intra-abdominal bleeding
 obstetric *see* obstetric haemorrhage
 ovarian cysts 509, 821
 haemorrhoids, pregnancy-related 49
 haemotrophic nutrition 22–23
 haemoxidase (HO)-1 74
 Hailey–Hailey disease 804
 hair loss, puerperium 435
 handicap criterion, abortion 989, 1002–1003
 Hart's line 796, 796
 Hassan's technique 524
 HbA_{1c} *see* haemoglobin, glycosylated
 hCG *see* human chorionic gonadotrophin
 head
 congenital anomalies 262
 fetal
 compression during labour 375
 delivery of deeply impacted 367–368, 368
 entrapment of aftercoming 357–358
 intrapartum examination 361
 measurement 32–33, 33
 vertex 354
 headache 202–203
 head circumference, fetal
 growth curve 35
 measurement 32–33, 33, 234, 234
 Health Technology Assessment (HTA) Database 1009
 hearing, newborn screening 448
 hearing impairment, preterm infants 449
 heart, fetal *see* fetal heart
 heart block, congenital 193, 246
 heartburn, pregnancy-related 49
 heart disease
 congenital *see* congenital heart disease
 endocarditis prophylaxis 94
 investigations in pregnancy 86
 ischaemic *see* coronary artery disease
 physiological effects of pregnancy 85–86
 pre-conception counselling 44, 45
 in pregnancy 85–94

rheumatic 89–91
 valvular 87–88, 89–91
 heart failure
 neonatal 455
 in pregnancy 93
 heart murmurs
 newborn infants 455
 pregnant women 86
 heart rate
 fetal *see* fetal heart rate
 normal pregnancy 6, 7, 7
 postpartum changes **434**
 heart sounds, in pregnancy 86
 heart valves, mechanical 91–92
 heat shock protein-60 (HSP) antibodies, anti-chlamydial 915
 heavy menstrual bleeding (HMB)
 653–661
 adenomyosis 654, 823
 adolescents 554–555
 aetiology 653–655, 654
 chlamydia infection 913
 clinical evaluation 655–657, **656**
 definition 653
 iatrogenic 655
 management 657, 657–661
 prevalence and impact 653
 severe acute 661
 HELLP syndrome 80–81, 119–120
 classification systems **120**
 defined 74
 diagnosis **117**, 118, 119
 liver rupture and infarction 120–121
 lupus nephritis 134
 overlap syndromes 117–118, 119
 pathophysiology 118
 heparin
 interstitial cystitis 787
 prosthetic heart valves 91
 pulmonary embolism 157
 recurrent miscarriage 571
 venous thromboembolism 156
 see also low molecular weight heparin
 hepatic encephalopathy 119
 hepatitis B
 chronic infection 164
 diagnosis 164
 neonatal infection 164
 post-exposure prophylaxis 978
 pregnancy 122, 163–165
 prevalence **162**, 163
 screening 52, 161, 704–705
 transmission 163–164
 vaccination 164

- hepatitis B immunoglobulin (HBIG) 164
- hepatitis C
 - lichen planus and 800
 - pregnancy 122–123
 - screening 51, 704–705
- hepatitis E 123
- herbal remedies
 - chronic pelvic pain 747
 - menopausal symptoms 684
 - sexual dysfunction 962
- hereditary non-polyposis colorectal carcinoma 876–877, 885
- hermaphrodite, true 549
- herpes simplex virus (HSV)
 - clinical features 173
 - congenital infection 172, 173
 - diagnosis 173
 - disseminated, in pregnancy 924, 924
 - epidemiology 907–908
 - genital infection *see* genital herpes
 - infection in pregnancy 172–174, 923–924
 - neonatal infection 172, 173
 - type 1 (HSV-1) 172, 922, 923
 - type 2 (HSV-2) 172, 922, 923
- herpesviruses 172
- HFEA *see* Human Fertilisation and Embryology Authority
- hidradenitis suppurativa 804, 804
- hidradenoma papilliferum 809
- high-density lipoprotein (HDL)
 - cholesterol, in pregnancy 13
- high-grade serous ovarian cancer (HGSOC) 884, 885, **886**
 - PARP inhibitor therapy 895
 - pattern of spread 890
 - precursor lesions 888
- high-intensity focused ultrasound (HIFU), uterine
 - fibroids 831–832
- hirsutism 633
 - adolescents 555–556, **556**
 - Ferriman–Gallwey score 641, 642
 - management 641–643
- histamine, myometrial effects 296, **296**
- histiotrophic nutrition 6, 22
- HIV *see* human immunodeficiency virus
- HLA
 - pelvic inflammatory disease risk and 611
 - trophoblastic expression 5
- hMG *see* human menopausal gonadotrophins
- holoprosencephaly 257–258
- home, early medical abortion 606, 989–990
- home birth
 - post-term pregnancy and 319
 - right to choose 999–1000
- home blood glucose monitoring (HBGM) 107
- homocystinuria **448**
- homologous recombination (HR) 895
- honour-based violence 980
- hormone replacement therapy (HRT) 677–682
 - alternatives to 682–684
 - androgens 679–680
 - benefit–risk balance 680–681
 - bio(body)-identical 679
 - contraindications 681–682
 - duration 682
 - endometriosis 682, 724
 - future research 684–685
 - isolated GnRH deficiency 550
 - monitoring 675
 - oestrogens 677–678
 - official guidelines 682
 - ovarian cancer and 681, 682, 885
 - premature ovarian insufficiency 646, 647, 676
 - premenstrual syndrome 668, 669
 - progestogens/progesterone 678–679
- hospital-acquired infections 215
- hospital discharge, postnatal 435
- hot flushes 672
- HPV *see* human papillomaviruses
- HRT *see* hormone replacement therapy
- HSV *see* herpes simplex virus
- human chorionic gonadotrophin (hCG) 13, 14
 - accuracy of measurement 580
 - early pregnancy maintenance 630
 - ectopic pregnancy 592–593
 - follicular development 624
 - gestational trophoblast tumours 580
 - indications for chemotherapy 578, **578**
 - low-risk disease 581, 581–582, 582
 - prognostic scoring **580**
- IVF protocols 709, 711–712
- molecular structure 624, 625
- pre-eclampsia risk and 77
- ratio, pregnancy of unknown location 513
- recurrent miscarriage 572
- β -human chorionic gonadotrophin (β -hCG)
 - free (fb-hCG), Down's syndrome screening 60–61
 - miscarriage 563
 - post-abortion testing 607
 - pregnancy of unknown location 513, 563
- human epididymis 4 (HE4) 887
- Human Fertilisation and Embryology Act 1990 992, 994
- Human Fertilisation and Embryology Authority (HFEA)
 - Code of Practice 993, 994
 - embryo sex selection 996
 - export of gametes 993
 - licensing of clinics 992, 995
 - number of embryos transferred 710, 717
 - reporting to 712
- human immunodeficiency virus (HIV)
 - antenatal screening 52, 161, 162
 - assisted conception screening 704–705
 - with associated nephropathy (HIVAN) **135**
 - depot medroxyprogesterone acetate and 944
 - management in pregnancy 162–163
 - maternal infection 162–163
 - mother-to-child transmission 162
 - neonatal post-exposure prophylaxis 163
 - pelvic inflammatory disease and 618
 - post-exposure prophylaxis 978
 - prevalence 162, **162**
 - sexually transmitted infections and 908, 908
- human menopausal gonadotrophins (hMG) 704
 - hypogonadotrophic hypogonadism 649
 - Kallmann's syndrome 624, 626
 - ovulation induction 699
- human papillomaviruses (HPV)
 - cervical cancer risk 858–861, 862
 - cervical intraepithelial neoplasia and 861
 - DNA testing 863, 864, 866
 - epidemiology 907–908
 - genital warts 925
 - oncogenic subtypes 858

- preterm labour risk 393
- vaccination
 - cervical cancer prevention 867, 874
 - genital warts and 925, 926, 926
 - vaginal intraepithelial neoplasia and 814
 - vulval cancer and 838
- human platelet antigens (HPA) 154, 247
- Hunter, John 704
- Huntington's disease 996, 1002
- hydatidiform mole *see* molar pregnancy
- hydralazine 79
- hydrops fetalis 264–265
 - fetal arrhythmias 245–246, 265
 - intrauterine transfusion 250
 - non-immune 251, 264
 - parvovirus B19 infection 171, 172, 251
 - red cell alloimmunization 249, 249
- hydrosalpinges 510
 - assisted conception and 706
 - hysteroscopic occlusion 531–532
 - treatment options 700
- hydroxychloroquine (HCQ) 134, 192, 193, **196**
- 21-hydroxylase deficiency 490
- 17-hydroxyprogesterone **634**
- 17 α -hydroxyprogesterone caproate 400, 490
- 11 β -hydroxysteroid dehydrogenase 14, 178
- hymen 479
 - imperforate 493, 493–494, 546, 550
 - myth of the intact 977–978
- hyperaldosteronism, primary 126
- hyperandrogenism (androgen excess)
 - adolescents 556
 - congenital adrenal hyperplasia 244–245, 490
 - infertility 696
 - management 641–643
 - polycystic ovary syndrome 637, 639, 641–643
 - secondary amenorrhoea 633
- hypercalcaemia 126
- hyperemesis gravidarum 49, 117, **117**
 - multiple pregnancy 272
- hyperglycaemia
 - fetal complications 106
 - maternal collapse **340**
 - pathophysiological effects 100–101, *101*
 - pregnancy outcomes 99, 100–101, *101*, **102**
 - see also* glycaemic control
- Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study 99
- hyperinsulinaemia
 - fetal/neonatal effects **102**, 106, 109
 - polycystic ovary syndrome 637, 639–640
 - see also* insulin resistance
- hyperlipidaemia
 - normal pregnancy 13
 - obesity 417
 - polycystic ovary syndrome 636
 - postmenopausal women 674
- hyperparathyroidism 126
- hyperpigmentation, vulval 807–808
- hyperprolactinaemia
 - amenorrhoea 548, 633, 634–635, 647
 - management 647–649, **649**
 - polycystic ovary syndrome 635, 647
- hypertension
 - acute treatment in pregnancy 79
 - antenatal screening 53, 75
 - chronic
 - pre-conception care 45
 - in pregnancy 74, 77
 - chronic kidney disease 132, 133, 135–136
 - delivery in isolated controlled 79
 - gestational 74, 75, 78
 - HRT 681
 - kidney transplant recipients 142
 - mild 74
 - moderate 74
 - obesity-related 211
 - postpartum 81
 - severe 74
 - see also* blood pressure
- hypertensive disorders of pregnancy 73–82
 - antenatal management 77–81
 - antenatal screening 53, 75
 - diabetes 108
 - chronic kidney disease 135
 - definitions 74–75
 - multiple pregnancy 272
 - obesity-related risk 211
 - postnatal management 81–82
 - risk assessment 75–77
 - thrombocytopenia 150
 - see also* pre-eclampsia
- hyperthyroidism
 - amenorrhoea 634
 - fetal/neonatal 125, 243–244
 - pregnancy in 124–125
- hypertrophic cardiomyopathy (HCM)
 - neonatal 110–111
 - pregnancy in 92–93
- hyperventilation, normal pregnancy 8, 8
- HYPITAT study 78
- hypoglycaemia
 - diabetic pregnancy 105, 108
 - maternal collapse **340**
 - neonatal 110, 451–452
 - unawareness 105
- hypogonadotrophic hypogonadism 692
 - diagnosis 695
 - follicular development 624, 626
 - kisspeptin deficiency 626
 - management 649, 699
 - primary amenorrhoea 547, 550
 - secondary amenorrhoea **635**, 636
- hypophosphataemia 138
- hypopigmentation, vulval 808
- hypopituitarism 125, 692, 699
- hypoplastic left heart syndrome (HLHS) 255–256
- hypoplastic right heart syndrome 256
- hypotension, obstetric
 - haemorrhage 342
- hypothalamic amenorrhoea 626, **635**, 649, 692
 - treatment 699
- hypothalamic–pituitary–adrenal (HPA) axis 178
- hypothalamic–pituitary–gonadal axis 543, 626, 627
- hypothalamus, pregnancy 14
- hypothermia
 - hypoxic–ischaemic encephalopathy 374, 454
 - preterm infants 450
- hypothyroidism
 - amenorrhoea 634
 - congenital/fetal 244, **448**
 - pregnancy in 124
- hypoxia, fetal *see* fetal hypoxia
- hypoxia-inducible factor (HIF)-1 13
- hypoxic–ischaemic encephalopathy (HIE) 373–374, 453–454
- hysterectomy
 - abdominal 661
 - cervical cancer 870
 - CIN 865
 - complications 661
 - endometrial cancer 879, 881
 - endometriosis 735–736
 - gender transition 957
 - heavy menstrual bleeding 660–661

- hysterectomy (*cont'd*)
 laparoscopic 660–661
 premenstrual syndrome 668
 radical
 cervical cancer 871
 Piver–Rutledge classification 871, **871**
 Querleu–Morrow classification 871, **872**
 uterine fibroids 830
 vaginal 661
 vaginal intraepithelial neoplasia after 814, 814, 815
 hysterosalpingo-contrast sonography 501
 assisted conception 705
 infertility 511, 696
 hysterosalpingo-foam sonography 501, **501**
 hysterosalpingography (HSG) 501
 assisted conception 705
 infertility 696
 lipiodol, in endometriosis 740
 secondary amenorrhoea 636, 636
 hysteroscopes 522
 hysteroscopy 519–524, 527–534
 best practice in ambulatory 529–530
 diagnostic 527–530
 complications 529
 contraindications **528**
 indications **528**
 infertility 697, 705–706
 technique 527–528, 528, 529
 endometrial polyps 825
 equipment 520–524
 heavy menstrual bleeding 656
 no touch vaginoscopic 527, 528
 operative 530–534
 ambulatory 532–533, **533**
 bipolar electrodes 522–523, 523
 clinical applications 530–532
 complications 533, **533**
 indications **530**
 infertility 531, 700
 mechanical instruments 522
 resectoscopes 523, 523
 tissue removal systems 524, 524
 sterilization 531, 532, 949
 theatre set-up 526–527, 527
 uterine distension 522
 hysterotomy, resuscitative 367
- i**
- ICON studies 893, 894, 896
 ICSI *see* intracytoplasmic sperm injection
- IgA, in breast milk 439, 439
 IgA nephropathy 134, **135**
 iliococcygeus muscle 481
 Ilingworth, Ronald 1006
- imaging
 endometriosis 731, 732
 groin node assessment **842**
 gynaecological 499–514
 pelvic inflammatory disease 615
 pregnancy 205
 urinary tract 769, 773
 see also computed tomography; magnetic resonance imaging; ultrasound
- imipramine **781**, 782
 imiquimod cream 816, 926
 immigrants, stillbirths 415, 417
 immune thrombocytopenic purpura (ITP) 150–151, **151**
 immunologic surveillance defects theory, endometriosis 723
- immunology
 normal pregnancy 5–6
 obesity 215
 recurrent miscarriage 571–572
- immunosuppressive therapy
 autoimmune liver disease 123
 breastfeeding 142
 contraception and 142
 gynaecological malignancy 142
 neonatal effects 142, **142**
 renal disease 140–141, **141**
 rheumatic diseases 193, **197**
- impaired fasting glycaemia **637**
 impaired glucose tolerance **637**
- implantation
 endometrial interactions 629
 placental development 20, 20–21
- implants, contraceptive 943
 incidence 464–465
 incision injuries, sexual assault 977
 indometacin 400, 406
 induced abortion *see* termination of pregnancy
- induction of labour 326–329
 advanced maternal age 332
 anticoagulated women 156–157
 complications 330
 contraindications 326
 definition 326
 diabetes 109
 failure 285, 330
 fetal macrosomia 238, 332
 indications 326, **327**
 intrauterine fetal death 332–333, 417–418
- at maternal request 331–332
 methods 327–329, **328**
 monitoring 330
 obesity 212–213
 outpatient setting 330
 post-term pregnancy **314**, **317–319**, 320, 331, **331**
 PPROM 402
 predicting success 233, 238, 326–327
 pre-eclampsia 333
 pre-labour membrane rupture 331
 previous caesarean section 326, 333
 risks and benefits 331–333
 shoulder dystocia prevention 332
- infant feeding 438–441
 UK trends 441, **441**
 see also breastfeeding
- infanticide 186
- infant mortality rate
 post-term pregnancy **311**, 311–312
 preterm infants 389, 389, 448–449
- infections
 acute pelvic 611–619
 breastfed babies 439
 childhood vulvovaginitis 553
 congenital 548
 genital tract *see* genital tract infections
 intrapartum, fetal hypoxia 375–376
 neonatal 452–453
- in pregnancy 161–177
 activating onset of labour 288
 antenatal screening 52, 161
 kidney transplant recipients 142
 obesity and 215
 preterm labour 393–394
 prevalence 161, **162**
 respiratory tract 200–201
 stillbirth risk **416**
- puerperal **436**, 436–437
 obesity and 215
 sexually transmitted *see* sexually transmitted infections
- vagina 811–813
 vulval ulceration with 805
 see also sepsis/septicaemia
- infectious tubulointerstitial disease **135**
- inferior epigastric vessels 477
 inferior vena cava 477, 478
 infertility (subfertility) 691–703
 aetiology 691–693, **692**
 counselling and support 701–702

- definition 691
- endometriosis *see under*
 - endometriosis
- funding of treatment 702
- history and examination 693–695
- information provision 697–698
- investigations 695–697
- male factor *see* male factor infertility
- management 693–702
- ovulatory disorders 691–692
- pelvic inflammatory
 - disease 617–618
- peritoneal disease 692, 701
- polycystic ovary syndrome
 - 643–644, 692
- prevalence 691
- prognosis 702
- sexual dysfunction and 958
- treatment of cause 698–701
- tubal factor *see* tubal disease
- ultrasound 511, 511, 696, 696
- unexplained 691, **692**, 698
- uterine factors 692–693, 700–701
- see also* assisted reproduction; fertility
- inflammatory arthritides 194–198
- inflammatory bowel disease
 - pregnancy 204
 - vulval involvement 806, 806
- inflammatory response
 - menstruation 630
 - onset of parturition 287–288, 391
 - preterm labour 393
- infliximab 195
- influenza 201
- information provision, antenatal
 - 47–48
- infundibulopelvic ligament 483
- inguinofemoral lymphadenectomy
 - complications 847, **847**
 - en bloc dissection 845,
 - 845–846, 846
 - laterality 845
 - sentinel node biopsy vs. 842, **843**
 - separate groin incisions 845,
 - 845–846
 - vaginal cancer 852
 - vulval cancer 845, 845–847, 846
- inguinofemoral (groin) lymph nodes
 - assessment 841, **842**
 - management of involved **846**,
 - 846–847, 848
 - sentinel node biopsy 841–842, 843
 - vulval cancer involvement **844**,
 - 844–845
- inhibin-A, pre-eclampsia and 77
- inhibin B
 - menstrual cycle regulation 626, 627
 - serum **634**, 635
- injuries *see* traumatic injuries
- inositol 1,4,5-trisphosphate
 - (InsP₃) 292, 294, 295, **296**
- inositol 1,4,5-trisphosphate receptors
 - (ITPR) 292, 293, 294
- instrumental vaginal delivery
 - (IVD) 360–365
 - assessment and
 - preparation 360–361
 - choice of instruments 361–364
 - complications 364, 438
 - episiotomy 369
 - new developments 364, 365
 - preterm infants 410
 - sequential 364
 - trial of 364
- insufflators, laparoscopic 525
- insulin-like growth factor-1
 - (IGF-1) **624**, 827
- insulin-like growth factor-2
 - (IGF-2) 222
- insulin-like growth factor-binding
 - protein 1 (IGFBP-1), vaginal
 - fluid 327, 402, 404–405
- insulin-like growth factor receptors
 - (IGF-R) 222
- insulin resistance
 - amenorrhoea 633, 636
 - diabetic pregnancy 108
 - normal pregnancy 12, 12–13
 - polycystic ovary syndrome
 - 639–640
 - postmenopausal women 674
 - see also* hyperinsulinaemia
- insulin-sensitizing agents, polycystic
 - ovary syndrome 644–645
- insulin treatment
 - antenatal 107, 108
 - labour and delivery 109–110
 - postpartum 110
- intensive care, obstetric patients
 - 428, **428**
- INTERGROWTH study 34–36,
 - 35, 223
- interleukin-1 (IL-1) 287, 289, 290
- interleukin-6 (IL-6), serum 732
- intermenstrual bleeding (IMB)
 - chlamydia infection 913
 - investigations 656, 657
 - malignant disease 654–655, 878
 - pelvic inflammatory disease 613
- internal cephalic version, second
 - twin 278
- internal iliac vein, transvenous
 - occlusion 748, 748–749
- International Association of Diabetes
 - and Pregnancy Study Groups
 - (IADPSG) 99, **100**
- International Federation of Gynecology
 - and Obstetrics (FIGO)
 - cervical cancer staging 869, **869**
 - endometrial cancer staging
 - 879, **879**
 - fetal blood sampling 381, **382**
 - fetal monitoring in labour
 - 378–379, **379**, 380
 - gestational trophoblast
 - neoplasm prognostic
 - score 580, **580**
 - ovarian cancer staging 889, **890**
 - PALM-COEIN system 502,
 - 653–655, 654
 - uterine fibroid classification
 - 826, 826
 - vulval cancer staging 841, **841**
- international normalized ratio (INR), in
 - pregnancy 91
- International Ovarian Tumour Analysis
 - (IOTA)
 - ADNEX model 507, 508
 - Simple Rules **506**, 506–507
- International Society for Premenstrual
 - Disorders
 - 663–664
- International Society for Sexual
 - Medicine (ISSM) 962
- interstitial cystitis 745, 787–788,
 - 788**, 788
- interstitial pregnancy 590, 591, 592
- interventional radiology
 - postpartum haemorrhage 345
 - see also* uterine artery embolization
- intervillous space 21–22, 22
- intimate partner violence *see* domestic
 - violence
- intra-abdominal bleeding
 - ectopic pregnancy 593, 593
 - ultrasound imaging 500
- intracranial haemorrhage (ICH)
 - fetal/neonatal alloimmune
 - thrombocytopenia
 - 247–248
 - obstetric patients 203, **340**
- intracytoplasmic sperm injection
 - (ICSI) 713–714
 - indications 699, 701, 706, 713
 - technique 713, 713
- intrahepatic cholestasis of pregnancy
 - (ICP) **117**, 121, 121–122

- intrapartum care 300–301
 - diabetes 109–110
 - emergency deliveries 347–351
 - fetal monitoring 377–383
 - multiple pregnancy 277–278
 - obesity 213–215
 - organization 336
 - preterm labour 409–410
 - see also* delivery; labour
 - intrapartum fetal death 373
 - intraperitoneal chemotherapy, ovarian cancer 894–895
 - intrauterine adhesions (Asherman's syndrome)
 - after curettage for miscarriage 564
 - diagnosis 636, 636
 - hysteroscopic adhesiolysis 531
 - infertility 693, 700
 - management 645–646
 - recurrent miscarriage 570
 - intrauterine contraceptive devices (IUC; IUCD) 940–943
 - contraindications 941
 - ectopic pregnancy risk 590, 942
 - efficacy 941
 - emergency contraception 948
 - insertion after abortion 600
 - kidney transplant recipients 142
 - mechanism of action 941
 - obesity 208
 - pelvic inflammatory disease 613, 618, 942
 - post-insertion instructions 943
 - risks 941–942
 - side effects 942
 - timing of insertion 942–943
 - see also* levonorgestrel-releasing intrauterine system
 - intrauterine fetal death
 - diagnosis 417
 - management 332–333, 417–418
 - obesity and 212
 - one twin 275
 - post-term pregnancy 310–311, **311**
 - see also* fetal loss; stillbirth
 - intrauterine growth restriction (IUGR)
 - see* fetal growth restriction
 - intrauterine insemination (IUI) 707–708
 - endometriosis 738–739
 - indications 701, 708
 - investigations 705, 706
 - intrauterine pressure, measurement in labour 298
 - intrauterine resuscitation, fetus 426, **426**
 - intrauterine transfusion (IUT)
 - one monochorionic twin 276
 - parvovirus B19 infection 172, 251
 - red cell alloimmunization 250, 250
 - intravenous immunoglobulin (IVIG)
 - fetal/neonatal alloimmune thrombocytopenia 247
 - in pregnancy 151, **197**
 - recurrent miscarriage 571
 - intraventricular haemorrhage
 - antenatal corticosteroids and 407, 408, **408**
 - preterm infants 451
 - invasive mole 578–579
 - in vitro* fertilization (IVF) 704, 708–716
 - agonist trigger 709
 - complications 717–718
 - conception rates 643
 - ectopic pregnancy risk 590, 718
 - egg donation 715–716
 - embryo transfer 710–711
 - endometriosis 701, 739
 - ethical issues 992–995
 - frozen embryo replacement cycles 712, **712**, 714–715
 - hCG injection 709
 - indications 701, 708
 - intracytoplasmic sperm injection 713–714
 - investigations 704–706
 - latest trends 713
 - luteal phase support 711–712
 - monitoring 709
 - multiple pregnancy risk 269, 278, 710, 717–718
 - obesity 208
 - oocyte retrieval 709–710
 - pathologies affecting outcome 706–707
 - pregnancy test 712
 - protocols 708–709
 - results 712, **712**
 - tubal disease 700
 - iodine staining, vaginal intraepithelial neoplasia 815, *815*
 - IOTA *see* International Ovarian Tumour Analysis
 - iron
 - absorption 148, **149**
 - chelation therapy 153
 - dietary intake 148, **149**
 - intramuscular 149
 - intravenous 149
 - oral preparations 149, **149**
 - requirements in pregnancy 147, 148
 - serum, normal pregnancy 9
 - supplementation
 - iron deficiency 148, 149
 - routine antenatal 5, 48
 - iron deficiency anaemia
 - heavy menstrual bleeding 555
 - pregnancy 9, 148–149, **149**
 - irrigation pump, laparoscopic 525
 - irritable bowel syndrome (IBS) 745
 - irritant eczema, vulval 802
 - ischaemic heart disease *see* coronary artery disease
 - isoproterenol 297
 - isovaleric acidemia **448**
 - itraconazole 812–813
 - IUC; IUCD *see* intrauterine contraceptive devices
 - IVF *see in vitro* fertilization
- j**
- Japanese Gynecologic Oncology Group study 893–894
 - Jarisch–Herxheimer reaction 168, 928
 - jaundice, neonatal 452
 - Jaydess® intrauterine system 941
 - Jepson, Joanna 989
 - Joel–Cohen technique 365
 - Johnston, Howard 994
 - Jordan v Whitehouse* [1981] 1006
 - josamycin 919
 - junior hospital doctors 1004
 - juvenile recurrent respiratory papillomatosis 926
- k**
- KAL1* gene 624
 - Kallmann's syndrome
 - amenorrhoea 547, 636
 - follicular development 624, 626
 - Kaplan–Meier plots 464–465, 465
 - karyotyping
 - amenorrhoea 636
 - neonatal care planning 446
 - prenatal diagnosis 64
 - recurrent miscarriage 569
 - Kell alloimmunization 248, 250–251
 - KHD3CL* gene 577
 - kidney
 - congenital anomalies 261, 495
 - donors, pregnancy 142
 - hormones in pregnancy 14–15
 - multicystic dysplastic 261
 - normal pregnancy 10, 130
 - solitary and pelvic **135**

- kidney disease *see* chronic kidney disease; renal disease
- kidney transplant recipients 138–143
antenatal care 139–142, **140**
graft function in pregnancy 140
graft rejection in pregnancy 140
neonatal problems 142, **142**
postpartum care 142–143
pregnancy outcomes 138–139, **139**
pre-pregnancy counselling 139, **139**
- Kielland's forceps 362–363
- killer immunoglobulin-like receptors (KIRs) 5
- kisspeptin **624**, 624–626, 627
- c-*Kit* deficiency **624**
- Kit ligand deficiency **624**
- Kiwi OmniCup® 361, 363
- Kleihauer test 565, 566
- Korotkoff sounds 75
- Kronos Early Estrogen Prevention Study (KEEPS) 680
- I**
- La antibodies 193, 246
- labetalol 78, 79
- labial adhesions, children 554
- labia majora 478, 479
- labia minora 478–479, 479
- labour 285–301
active phase 299
ambulation in 425
analgesia 423–426
non-regional 423–424
obesity 213
regional 424–426
augmentation 329–330
breech delivery 356
brow presentation 358
cephalopelvic disproportion 360
obesity 213
cardinal movements 299, 300
cardiovascular adaptations 86
fetal monitoring 377–383
fetal responses
abnormal labour 375–376
normal labour 374–375
first stage 299
duration **299**
phases 299, 299
induction *see* induction of labour
latent phase 299, **299**
management 300–301
breech presentation 356
diabetes 109–110
multiple pregnancy 277–278
obesity 213–215
see also intrapartum care
mechanics 298–299
pain 423
passage 298–299, 359
passenger 298, 359–360
physiological mechanisms 285–298, 286, 290, 391–392
endogenous mediators 288–289, 391–392
fetal signals 285–287
inflammatory responses 287–288, 391
uterine contractility 290–295, 291, 292
uterine relaxation 295–298
powers 298, 360
preterm *see* preterm labour
progress
cephalopelvic disproportion 360
obese women 214
predicting failure 237–238
regional analgesia and 424–425
prolonged, fetal effects 376
second stage 299, 299
duration **299**
stages 299, **299**
third stage 299
duration **299**
hypertensive disorders 79
management 301
see also delivery
laceration injuries, sexual assault 977
lactate, fetal blood 381
lactation
drug safety 438
ovulation suppression 434
physiology 441, 441–442, 442
suppression 418, 443
see also breastfeeding
lactational amenorrhoea 434, 440, 951
lactic acid and glycerol gel, intravaginal 921
lactobacilli
intravaginal therapy 921
vaginal 394, 811
Lactobacillus iners 394
lactoferrin 439
laminaria 604
lamotrigine
breastfeeding and 188
hormonal contraception and 948
safety in pregnancy 187, 202
laparo-endoscopic single-site surgery (LESS) 525
laparoscopes 524
laparoscopic surgery 536
complications 536, **537**
ectopic pregnancy 593, 593–594
endometriosis 734–735, 735, 737–738, 738
hysterectomy 660–661
infertility 700, 701
instruments 525, 525–526
ovarian diathermy 644
prolapse 761
robotic 525
specimen retrieval 526
sutures 526
laparoscopic uterosacral nerve ablation (LUNA) 734, 746
laparoscopy 519–522, 534–536
anatomical aspects 477, 478
chronic pelvic pain 746
classification of procedures **536**
diagnostic 534–536
contraindications **534**
endometriosis 731
indications **534**
infertility 696, 705–706
outcomes and complications 535–536
pelvic inflammatory disease 615
technique 534–535, 535
equipment 520–522, 524–526
experimental minimally invasive 526
operative *see* laparoscopic surgery
theatre set-up 527, 527
trocars and cannulae 524–525
large for gestational age (LGA) 31
large loop excision of transformation zone (LLETZ) 865, 868
cervical cerclage after 399
pregnancy 873
preterm labour after 393
laser conization 865
laser therapy/surgery 521
CIN 865–866
hirsutism 642
vaginal intraepithelial neoplasia 815–816
vulvovaginal atrophy 678
last menstrual period (LMP)
gestational age estimation 32, 307–308, 317
miscarriage 561
prior to abortion 600
late term pregnancy 307
latex hypersensitivity 809–810
leadership, obstetric emergencies 337
leflunomide 195, **196**

- left lateral position, pregnancy 86, 94
- legal aspects 999–1006
 - abortion **598**, 598–599, 988–990, 1001–1004
 - autonomy 999–1001
 - capacity and consent 599, 969–970
 - cerebral palsy 1006
 - postgraduate training 1004–1006
 - professional discipline 1004
 - sexual assault and rape 967
- legal proceedings
 - giving evidence in court 981
 - statements for the courts 980–981
- leiomyomata, uterine *see* uterine fibroids
- leiomyosarcoma
 - uterine *see* uterine leiomyosarcoma
 - vagina 852
- leptin 12, 13, 543
- lesbianism *see* female same-sex relationships
- letrozole 643
- leukaemia 159–160
- leuprorelin 708
- levator ani muscles 481, 481, 756
- levels of fetal presenting part 354, 355
- levetiracetam 202
- levonorgestrel (LNG)
 - emergency contraception 948
 - endometrial protection in HRT **678**
 - impact of obesity 208, 948
- levonorgestrel-releasing intrauterine system (LNG-IUS) 940–943
 - adenomyosis 824
 - contraceptive efficacy 941
 - endometriosis 736–737
 - heavy menstrual bleeding 658
 - hormone replacement therapy **678**, 679
 - mechanism of action 941
 - menstrual suppression in
 - adolescents 555
 - non-contraceptive benefits 951
 - premenstrual syndrome 669–670
 - risks 941–942
 - side effects 942
 - timing of insertion 942–943
 - uterine fibroids 830
 - see also* Mirena® intrauterine system
- Levosert® intrauterine system 941
- LH *see* luteinizing hormone
- LIBERATE study 682
- libido *see* sexual desire
- lichen planus 800, 800–802, 801
- lichen sclerosus 798–800
 - children 553
 - clinical features 798–799, 798–799
 - histology 799, 799
 - malignancy and 799, 799, 837, 838, 849
- lichen simplex, vulva 802–803, 803
- lifestyle advice
 - antenatal 48–49
 - endometriosis 733
 - gestational diabetes 110
 - infertility 698, 699
 - menopause 676–677
 - obesity 209, 210–211, 217
 - pelvic organ prolapse 759
 - polycystic ovary syndrome 641, 643
 - pre-conception 39–42
- LigaSure™ system 520, 526
- Liggins, Sir Graham 407
- light sources, endoscopic 520
- likelihood ratio (LR) 60, 467, 1012
- LIMIT trial 217
- LION trial 893
- lipids, in pregnancy 13
- lipiodol 740
- liquor volume *see* amniotic fluid volume
- listeriosis (*Listeria monocytogenes*) 48, 453
- literature
 - critical appraisal 1010–1012, **1013**
 - searching 1009–1010, 1010
- lithium 186, 187, 188
- liver
 - changes in pregnancy 116
 - imaging in pregnancy 116
 - infarction 121
 - rupture 120–121
 - subcapsular haemorrhage 81, 120
- liver disease 116–123
 - diagnosis in pregnancy 116, **117**
 - fatty acid oxidation pathways 118
 - incidental to pregnancy 122–123
 - pregnancy-related 116–122, **117**
 - secondary amenorrhoea 650
- liver function tests
 - acute fatty liver of pregnancy 118, 119, **119**
 - HELLP syndrome 119, **120**
 - intrahepatic cholestasis of pregnancy 121
 - normal pregnancy 116, **117**
- liver metastases, gestational trophoblastic tumours 584
- liver transplantation 123
- LNG *see* levonorgestrel
- local anaesthesia
 - surgical abortion 603
 - vulval biopsy 797
- lochia 434
- long-acting reversible contraception (LARC) 939
- long-chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) 118
- long-term health consequences
 - breastfeeding 440
 - low birthweight 221–222, 449–450
 - maternal diabetes **102**, 111
 - maternal obesity 216–217
 - see also* fetal programming
- loop electrosurgical excisional procedure (LEEP) 865
- lorazepam 185
- Løvset manoeuvre 357, 358
- low birthweight (LBW) 31
 - antidepressants and 183
 - definition 387
 - long-term consequences 221–222, 449–450
 - prenatal depression 178
- low-density lipoprotein (LDL) cholesterol, in pregnancy 13
- lower urinary tract disorders 785–788
 - after cervical cancer surgery 871
 - chronic pelvic pain 745
 - pelvic organ prolapse 756, 758
 - see also* urinary incontinence
- lower urinary tract obstruction, congenital 261–262
- low molecular weight heparin (LMWH)
 - postpartum obese women 216
 - postpartum period 157, **158**
 - in pregnancy 91, 156–157, **158**
 - recurrent miscarriage 571
 - secondary antiphospholipid syndrome 194
- lung development 263
- lung metastases, gestational trophoblastic tumours 581, 583, 583
- lung volumes, in pregnancy 8, 8
- lupus, neonatal cutaneous 194
- lupus anticoagulant 194
- lupus nephritis **135**
 - flares in pregnancy 134, 192, 193, **193**
 - pregnancy outcomes 134
 - treatment in pregnancy 140–141, 193
- luteal phase support, IVF 711–712

- luteinizing hormone (LH)
 - follicular development 624, 626, 627
 - molecular structure 624, 625
 - onset of puberty 543
 - precocious puberty 545
 - serum **634**, 635, 695
 - surge 628
- Lyell's syndrome 805
- lymphangiectasia 810
- lymphangioma 262
- lymph node disease
 - cervical cancer 870, **870**
 - endometrial cancer 879, **879**
 - vulval cancer **844**, **844–845**
- lymph node dissection
 - cervical cancer 871, **872**
 - endometrial cancer 879–880
 - ovarian cancer 892–893
 - vaginal cancer 852
 - vulval cancer 845, 845–847, **846**, **846**
 - see also* inguinofemoral lymphadenectomy; pelvic lymphadenectomy
- lymphocyst, after vulval surgery 847
- lymphocytic hypophysitis 125
- lymphoedema
 - acute 809–810
 - after cancer surgery 847, 871
 - chronic 810
- lymphoma 159–160
- lymphovascular space invasion (LVSI), cervical cancer 870
- Lynch type II syndrome 876–877, 885
- m**
- M4 model, ectopic pregnancy
 - prediction 513–514
- macrophages, decidual 287
- macrosomia, fetal
 - cephalopelvic disproportion 359
 - induction of labour 238, 332
 - management of delivery 238
 - maternal diabetes 109
 - maternal obesity 215
 - prediction 237–238
- magnesium sulfate (MgSO₄)
 - cerebral palsy prophylaxis 409
 - eclampsia 80, 346
 - tocolysis 293, 408–409
- magnetic resonance imaging (MRI)
 - adenomyosis 504, 823–824
 - adnexal masses 507
 - cervical cancer 869, 873, 874
 - early pregnancy 512
 - endometrial cancer 504, 879
 - endometriosis 732
 - heavy menstrual bleeding 656
 - hyperprolactinaemia 647, 648, 649
 - liver disease 116
 - ovarian cancer 891
 - pelvic inflammatory disease 510, 615
 - pelvic organ prolapse 758
 - postmenopausal bleeding 504
 - uterine fibroids 503, 828
 - uterine leiomyosarcoma 503, 828
- Magpie trial 80
- male factor infertility
 - aetiology 693
 - ICSI 713–714
 - investigations 697, 706
 - management 698–699
 - surgical sperm retrieval 717
- male sterilization 949–950
- malignant disease
 - combined hormonal contraception and 947
 - in pregnancy 159–160, 204–205
- malnutrition 650
- malposition, fetal 354, 359–360
 - instrumental delivery 361, 362–364
 - intrapartum diagnosis 361
 - manual rotation 364
- malpresentations, fetal 354–359
- mammography 675
- Mann–Whitney *U* test 470, 471
- maple syrup urine disease **448**
- Marfan syndrome 44, 88
- marriage, forced 980
- Marshall–Marchetti–Krantz procedure 776
- massively parallel sequencing (MPS) 65, 68
- Masters and Johnson model of sexual response 955
- maternal age
 - advanced, induction of labour 332
 - fertility and 42–43, **43**
 - miscarriage and 568
 - molar pregnancy risk and 575, **576**
 - pre-conception counselling 42–43
 - pregnancy outcomes and 43, **43**
 - stillbirth risk and 43, 415
 - trends 191
- maternal deaths
 - caesarean section 367
 - causes 427
 - coincidental 461
 - definitions 461
 - direct 461
 - ectopic pregnancy 589
 - epilepsy 202
 - heart disease 85, 89
 - indirect 461
 - late 461
 - malignant disease 204
 - medical conditions 191
 - obstetric haemorrhage 342
 - pre-eclampsia 73, 74, 80
 - puerperal sepsis **436**, 436–437
 - venous thromboembolism 155, **436**, **436**
- maternal medicine specialists 39
- maternal mortality rate 47, 461
- maternal mortality ratio (MMR) 461
- maternal physiology 5–15
- maternal request
 - caesarean section 332, 1005
 - induction of labour 331–332
- maternal serum screening
 - Down's syndrome 60–61
 - factors influencing 61–62
 - multiple pregnancy 61, 270
 - reliability of assay results 62
- maternities, total number of 461
- maternity care, early access 43–44
- Mauriceau–Smellie–Veit manoeuvre 357, 358
- Mayer–Rokitansky–Küster–Hauser (MRKH) syndrome 490–492
 - diagnosis 490, 490–491, 547
 - management 491, 491–492, 549–550
- McCune–Albright syndrome 545
- McDonald procedure 399
- McIndoe procedure 491–492
- mean 468–469, 471
- mean cell volume (MCV)
 - folate deficiency 149
 - in pregnancy 147, 148
- mean pulmonary artery pressure (MPAP) 7, 89
- measles, mumps and rubella (MMR) vaccine 165, 166
- mechanical heart valves 91–92
- Meckel's diverticulum 477
- meconium, failure to pass 456
- meconium aspiration
 - neonatal care 452
 - post-term pregnancy 312, 331, **331**
- meconium ileus 259
- meconium peritonitis 259
- meconium staining
 - clinical significance 377
 - induction at or before 40 weeks 318

- median 470, 471
- medical conditions
 - contraindicating pregnancy 44
 - fetal 243–251
 - pre-conception counselling 38, 39, 44–45
 - pregnant women 191–205
 - secondary amenorrhoea 649–650
 - stillbirth risk 416, **416**
- medications, pre-conception
 - counselling 42, 191
- medium-chain acyl dehydrogenase deficiency **448**
- Medline 1009
- medroxyprogesterone acetate (MPA)
 - challenge test 635
 - chronic pelvic pain 746
 - depot *see* depot
 - medroxyprogesterone acetate
 - heavy menstrual bleeding 661
 - HRT preparations **678**
 - polycystic ovary syndrome 641
- mefenamic acid, heavy menstrual bleeding 658
- megaloblastic anaemia 149–150
- melanocytic naevi, vulval 808
- melanoma, malignant
 - vagina 853
 - vulva **839**, 840, 848
- melanosis, vulval 807, 808
- membranes, fetal *see* fetal membranes
- membrane sweeping 320, 329
- Mendelson's syndrome, maternal
 - collapse **340**
- meningitis, neonatal 453
- menopause 672–685
 - diagnosis 674–675
 - future research 684–685
 - interventions 676–684
 - long-term consequences 673–674
 - monitoring 675
 - prediction 674
 - premature *see* premature ovarian insufficiency
 - recurrent genital herpes 924–925
 - sexual activity and 959
 - symptoms 672–673
 - see also* hormone replacement therapy
- menorrhagia *see* heavy menstrual bleeding
- menstrual cycle 623–631
 - anovulatory 655
 - endometrial development 628–630
 - menstrual phase 629, 629, 630–631, 631
 - ovarian cycle synchronization 627
 - proliferative phase 628–629, 629
 - secretory phase 629, 629, 631
- menstrual disorders
 - adolescents 554–555
 - infertility 694
 - IUCD users 942
 - polycystic ovary syndrome 637, 641
 - progestogen-only contraception 944
 - terminology 653
 - see also* abnormal uterine bleeding; amenorrhoea; dysmenorrhoea; heavy menstrual bleeding
- menstruation 630–631, 631
 - bacterial vaginosis and 920–921
 - postpartum resumption 434
 - premenstrual disorders with
 - absent 664
 - retrograde 723
 - suppression, adolescents 555
- mental capacity *see* capacity
- Mental Capacity Act 2005 599, 969–970, 991, 992
- The Mental Health Trust v DD* [2014] 992
- mental problems *see* psychiatric problems
- mental state assessment, sexual assault victims 972, **975–976**
- Mersilene tape sutures, cervical cerclage 399
- mesh grafts, prolapse repair 763
- mesonephric duct *see* Wolffian duct
- mesonephros 485–486, 486
- meta-analysis 463, 463–464, 1011, 1011
- metabolic acidemia, fetal *see* fetal acidemia
- metastatic tumours
 - placenta 204
 - vulva **839**
- metformin
 - assisted conception cycles 707
 - diabetic pregnancy 107, 108, 110
 - infertility 699
 - polycystic ovary syndrome 644–645
 - recurrent miscarriage 571
- methicillin-resistant *Staphylococcus aureus* (MRSA) 215
- methotrexate
 - ectopic pregnancy 593
 - gestational trophoblastic tumours **581**, 581, 581–582
 - intrathecal 581, 584
 - rheumatic disease in pregnancy 195, **196**
 - see also* EMA/CO chemotherapy
- methyl dopa 81
- metronidazole
 - bacterial vaginosis 397, 812, 921
 - pelvic inflammatory disease 616, **616**
 - secondary postpartum haemorrhage 438
 - trichomoniasis 812, 920
- metroplasty, hysteroscopic 531
- microbiological tests
 - children 553
 - pelvic inflammatory disease 614, 614–615
 - sexually transmitted infections 910–911
 - vulval disease 797–798
- microcephaly, Zika virus infection 175, 176
- microepididymal sperm aspiration (MESA) 717
- microscopy, on-site vaginal 910
- middle cerebral artery (MCA) Doppler fetal growth restriction 225, 237, 237
- monochorionic twins 276
- parvovirus infection 251
- post-term pregnancy 316
- red cell alloimmunization 249, 249, 251
- Middle East respiratory syndrome coronavirus (MERS-CoV) 201
- midstream urine sample 767
- mifepristone
 - cervical priming 602
 - induction of labour 329
 - intrauterine fetal death 333, 418
 - medical abortion 605–606
 - legal aspects 989–990
 - miscarriage management 565
 - ovulation inhibition 628
- migraine 202–203, 947
- milk ejection reflex 441–442, 442
- Mill, John Stuart 1000
- Million Women Study (MWS) 680
- mindfulness therapy, sexual dysfunction 960, 962
- mini-laparoscopy 525
- minimal access surgery (MAS), prolapse 761
- minute ventilation, in pregnancy 8, 9
- Mirena[®] intrauterine system 941
 - endometrial cancer prevention 876
 - kidney transplant recipients 590
 - premenstrual syndrome 669–670
 - see also* levonorgestrel-releasing intrauterine system

- miscarriage 559–566
 aetiology 559–561
 antidepressant therapy and 183
 classification 568, **569**
 complete **560, 562**
 definition 559
 diagnosis 561–564
 differential diagnosis 561–562, **562**
 first trimester 559, 560–561, **569**
 incomplete **560, 562**
 inevitable **560**
 invasive diagnostic testing and 64
 management 564–565
 missed **560**
 diagnosis **562**, 562–563
 management 564
 multifetal pregnancy reduction 278
 multiple pregnancy 270
 obesity-related risk 212
 psychology and counselling 566
 rates 559, 560
 recurrent *see* recurrent miscarriage
 rhesus status 565–566
 second trimester 559, 561, **569**
 threatened **560, 562**, 565–566
 ultrasound diagnosis 512, 562–563, 563
- misoprostol
 cervical priming 564, 602
 induction of labour **328**, 328–329
 intrauterine fetal death 333, 418
 obesity 213
 medical abortion 605–606
 legal aspects 989–990
 miscarriage management 565
 mitochondrial trifunctional protein (MTP) 118
 mitral regurgitation 91
 mitral stenosis 89–90, 90
 mitral valve prolapse 89
 mitral valvotomy, balloon 90
 mixed urinary incontinence 784
 MKRN-3 gene 544–545
 Modified Diet in Renal Disease (MDRD) 130–131
 MOET (Managing Obstetric Emergencies and Trauma) 338
 molar pregnancy 575, 576–578, 586
 complete 576, 577
 diagnosis 577, 577
 risk factors 575–576
 differential diagnosis 561–562
 familial recurrent 576, 577
 incidence 575
- invasive mole 578–579
 low-risk disease management 580–582
 first-line chemotherapy **581**, 581, 581–582
 second-line chemotherapy 582, **582**, 582
 partial 576, 576–577
 registration and surveillance 578
 risk factors 575–576, **576**
 twin pregnancy 577–578
 see also gestational trophoblast neoplasms
- molecular cytogenetic tests 64
 monoamniotic twins 277
 monochorionic twins 269
 complications 274–277
 fetal growth restriction 272–273
 invasive prenatal diagnosis 271
 selective termination of pregnancy 271
 ultrasound determination 269–270
 monopolar electrosurgery 521, 526
 monotocous ovulation 623–628
 monozygotic twins 269, 270
 Montevideo units 298
Montgomery v Lanarkshire Health Board [2015] 1001
 mood changes, IUCD users 942
 mood stabilizers
 antenatal exposure 186–187
 breastfeeding and 188
 mosaicism 64, 67, 68
 confined to placenta (CPM) 64, 65
 Down's syndrome 59
 Turner's syndrome 67
 MOSES (Multidisciplinary Obstetric Simulated Emergency Scenarios) 338–339
 mother–infant bonding 435
 moulding, fetal head 360–361
 moxifloxacin
 Mycoplasma genitalium 919
 pelvic inflammatory disease 616, **616**
- MRI *see* magnetic resonance imaging
 mTOR inhibitors, ovarian cancer 899
 mucinous cystadenomas, ovarian 820–821
 mucinous ovarian carcinoma 725, **886**
 mucous membrane pemphigoid 805
 Müllerian agenesis, 46XX 490–492
 Müllerian (paramesonephric) ducts 486, 486
- Müllerian inhibiting substance *see* anti-Müllerian hormone
 Müllerian tubercle 486, 486
 multicystic dysplastic kidney (MCDK) 261
 multiparous women
 duration of labour **299**
 post-term pregnancy **311**, 312–313
 multiple pregnancy 268–279
 assisted conception and 717–718
 chorionicity and zygosity 269–270
 clinics 279
 death of one baby 419
 Down's syndrome screening 61, 270–271
 fetal growth restriction 272–273
 fetal reduction 278
 higher order 278–279
 incidence 268–269
 intrauterine insemination 707–708
 invasive prenatal diagnosis 64, 271
 IVF-related 269, 278, 710
 labour and delivery 277–278
 maternal homeostatic responses 271–272
 miscarriage 270
 monochorionic twinning complications 274–277
 non-invasive prenatal testing 68, 271
 perinatal loss 269
 polycystic ovary syndrome 643, 644
 prenatal diagnosis 270–271
 preterm labour 273–274, 392–393, 399
 see also twin pregnancy
 multiplex testing, sexually transmitted infections 910–911
 muromonab-CD3 **141**
Mycobacterium tuberculosis
 pelvic inflammatory disease 613
 see also tuberculosis
 mycophenolate mofetil (MMF) 123, 140–141, **141**, **197**
 mycophenolic acid **141**
Mycoplasma genitalium 918–919
 pelvic inflammatory disease 612–613, 614, 918
 pregnancy 918–919
 treatment 616, 919
Mycoplasma hominis 393, 397, 918, 919
 myelomeningocele 258
 myeloproliferative disorders 159

myocardial infarction (MI)
 combined oral contraceptive
 users 947
 effects of HRT 680
 in pregnancy 92
 myofascial pain 749–750
 myomectomy 660, 830
 hysteroscopic 530–531
 infertility 700
 prior to assisted conception 706
 uterine artery embolization vs. 831
 myometrial contractility
 290–295, 292
 action potential
 generation 292–293
 calcium homeostasis 293
 electrophysiological
 mechanisms 294
 endogenous and exogenous factors
 affecting 297
 inhibitory mechanisms
 295–298
 intracellular calcium stores
 293–294
 receptor-regulated 294–295
 smooth muscle contraction
 290–292, 291
 myometrium 289
 anatomy 481–482
 pregnancy-related changes 293
 myosin 290–291, 291, 292, 293
 myosin light chain (MYL₂₀)
 290–291, 293
 myosin light chain kinase (MYLK)
 291–292, 293

n

Nabothian follicle 817–818, 818
 naevi, vulval 808
 nafarelin 708
 naloxone 455
 nasal bone (NB), absence 61, 62
 National Association for PMS
 (NAPS) 671
 National Clinical Assessment
 Service 1004
 National Institute for Health and Care
 Excellence (NICE)
 antenatal and postnatal mental
 health 188, **188**
 antenatal care 55
 detrusor overactivity 783–784
 diabetes in pregnancy 107
 Down's syndrome screening 53
 fertility treatment 695, 698, 993
 fetal blood sampling 381, **381**

fetal heart rate monitoring
 378–379, **379**
 gestational diabetes 99, **100**
 heavy menstrual bleeding 656
 hypertension in pregnancy 74, 75,
 77, 78
 induction of labour 328, 329
 intrapartum care 360, 377–378, 380
 iron supplementation in
 pregnancy 9
 labour analgesia 424
 menopause 672, 675, 678
 miscarriage 562–563, 564, 565
 ovarian cancer 895, 896
 stress incontinence 778–779
 National Surveys of Sexual Attitudes
 and Lifestyles (Natsal) 954
 natural killer (NK) cells
 decidual 5–6, 9
 recurrent miscarriage 572
 natural orifice transluminal endoscopic
 surgery (NOTES) 526
 nausea and vomiting, in pregnancy 49
 near-infrared spectroscopy, fetal 378
 near-patient testing, sexually
 transmitted infections 910–911
 neck, congenital anomalies 262
 necrolytic migratory erythema 807
 necrotizing enterocolitis 451
 needle excision of transformation zone
 (NETZ) 865, 868
 negative likelihood ratio 467
 negative predictive value (NPV) 58,
 467, 1012

Neisseria gonorrhoeae 917
 detection 614–615
 pelvic inflammatory disease 612
 screening, abortion patients 600
see also gonorrhoea
 neonatal adverse outcomes 448–450
 antenatal corticosteroids 407–408
 antenatal NSAIDs 400, 406
 diabetes **102**, 106, 110–111
 fetal hypoxia 373–374
 instrumental vaginal delivery 364
 obesity 215, 216
 post-term pregnancy 312–313
 effects of induction **314**, 318,
 331, **331**
 preterm birth 389, 389–391, **390**,
 448–450
 systemic lupus erythematosus
 193–194, 246
 tocolytic agents 406, 407
see also neurodevelopmental
 outcome

neonatal care 445–457
 anticipation of problems 445
 breastfeeding and 456–457
 categories 445
 common problems 450–456
 communication and
 planning 445–447
 compassionate and palliative 446
 managed clinical networks 447
 newborn screening 447–448, **448**
 organization of services 447
 neonatal death
 communication after 447
 fetal hypoxia 373
 maternal diabetes 100, *101*
 multiple pregnancy 273
 post-term pregnancy 310, **310**,
311, 311–312
 preterm infants 389, 389
 stillbirth vs. 414
 neonatal encephalopathy 453–454
 hypoxic–ischaemic 373–374,
 453–454
 post-term pregnancy 312
 neonatal herpes 172, 173
 neonatal intensive care 445, 447
 neonatal resuscitation 447
 guidelines 446
 obstetric anaesthetist's role 428
 plan for high-risk deliveries 446
 neonatal sepsis/septicaemia
 402–403, 452–453
 neonatal units (levels 1 and 2) 447
 neonates
 common problems 450–456
 frequently asked questions **456**
 screening programmes
 447–448, **448**
 transport 447
 vulval changes 797
 nerve entrapment 745
 nested case–control studies 462
 neural tube defects (NTDs) 40,
 48, 258
 neuraxial blockade *see* regional
 anaesthesia/analgesia
 neurodevelopmental outcome
 breastfed infants 440
 fetal growth restriction 221–222
 hypoxic–ischaemic encephalopathy
 373–374
 intrauterine death of one twin 275
 monochorionic twins 276
 postpartum depression 180
 post-term pregnancy 312
 prematurity 389–390, 449, 451

- prenatal antidepressant exposure 184
- prenatal depression and anxiety 178
- ventriculomegaly 258
- see also* cerebral palsy
- neurogenic collapse, obstetric patient **340**
- neurogenic detrusor overactivity 772, 779
- neurokinin B 626
- neurological conditions
 - complicating pre-eclampsia 81
 - neonatal 453–455
 - pregnancy 202–203
 - urinary incontinence 766
- neuromodulation, detrusor overactivity 782–783, 783
- neurotransmitters, premenstrual syndrome aetiology 667
- neutrophils, in pregnancy 9, 147
- Newborn Hearing Screening Programme (NHSP) 448
- New York Heart Association (NYHA) class, in pregnancy 86–87
- Nexplanon® 943
- NFAT 288, 290
- NF- κ B 289, 290, 392
- NHS Economic Evaluation Database (NHS EED) 1009
- NHS indemnity 1006
- NHS Litigation Authority 1006
- NHS Newborn and Infant Physical Examination (NIPE) 448
- NHS Newborn Blood Spot Screening Programme 448, **448**
- An NHS Trust v CS* [2016] 991
- NICE *see* National Institute for Health and Care Excellence
- nifedipine
 - hypertension in pregnancy 79
 - tocolysis 293, 407
- nimesulide 400
- NIPT *see* non-invasive prenatal testing
- niraparib 895, 896
- nitrazine testing 402
- nitric oxide
 - pregnant uterus 6, 7
 - uterine relaxation 295
- nivolumab 899
- NLRP7* gene 577
- nocturia 786
- nocturnal enuresis 766
- non-invasive prenatal testing (NIPT) 65–69
 - causes of positive 67
 - congenital adrenal hyperplasia 245
 - cost-effectiveness 66
 - diagnostic tests after 66–67
 - Down's syndrome 54, 65–67
 - failure rate 68
 - first-trimester ultrasound and 68
 - multiple pregnancy 68, 271
 - other chromosomal abnormalities 67–68
 - non-parametric tests 470
 - non-steroidal anti-inflammatory drugs (NSAIDs)
 - acute tocolysis 406
 - endometriosis 734, 736
 - heavy menstrual bleeding 658
 - preterm labour prevention 399–400
 - rheumatic diseases in pregnancy 192, **196**
 - noradrenaline 14, 423
 - norethindrone 661
 - norethisterone **678**
 - norgestrel 661, **678**
 - normal, defining 468
 - normal distribution 468, 468–469
 - Northern Ireland, access to abortion 598
 - nortriptyline 184
 - NSAIDs *see* non-steroidal anti-inflammatory drugs
 - nuchal translucency (NT)
 - 3.5 mm or above 62
 - congenital heart defects 62
 - Down's syndrome screening 60, **61**, 62
 - measurement **61**
 - other aneuploidies 63
 - questions and misconceptions 62
 - nucleic acid amplification tests (NAAT) 612, 614, 615, 910
 - null hypothesis 466
 - nulliparous women
 - duration of labour **299**
 - endometrial cancer risk 877–878
 - post-term pregnancy 309, **311**, 312–313
 - nutrition
 - dialysis patients 138
 - haemotrophic 22–23
 - histiotrophic 6, 22
 - onset of puberty and 543
 - nystatin 922
- O**
- obesity 207–217
 - abdominal 640
 - amenorrhoea with 633, 636
 - antenatal care 210–211
 - assisted conception and 707
 - breastfeeding and 216, 440–441
 - children of diabetic mothers 111
 - classification **208**
 - clinics 211
 - contraception 207–208, 209, 948
 - Cushing's syndrome 633
 - delivery issues 212–215
 - endometrial cancer risk 878
 - fertility and conception 208–209
 - fetal complications **41**, 212
 - infertility 698
 - interventions 217
 - long-term effects on child 216–217
 - management 641
 - maternal complications **41**, 210–211, 215
 - neonatal complications 215, 216
 - polycystic ovary syndrome 637, 639–640, 641
 - postnatal care 215–217
 - post-term pregnancy 309
 - pre-conception advice 41–42, 209–210
 - prolapse risk 756
 - stillbirth risk 212, 416–417
 - thromboembolism risk 436
 - type 2 diabetes 105–106
- observational studies 460, 1009, 1012, 1013
- obsessive compulsive disorder (OCD) 181–182
- obstetric anal sphincter injuries (OASI) 368, 369–370, 437–438
- obstetric emergencies *see* emergencies, obstetric
- obstetric haemorrhage 342–346
 - anticoagulated patients 91–92
 - concealed 342
 - major, haemostatic measures 155
 - management algorithms 343, 344
 - minimizing morbidity 342
 - preterm labour 394
- obstetric history, previous poor 45
- occipito-anterior (OA) position 354
 - instrumental delivery 361, 362–363
- occipitofrontal diameter, fetal 35
- occipito-posterior (OP) position 359–360
 - diagnosis 361
 - instrumental delivery 361, 362–363
 - manual rotation 364
- occipitotransverse (OT) position 354
 - forceps delivery 362
- odds ratio (OR) 467
- Odon device 364

- oedema, pregnancy 11
- OEIS complex 260
- oesophageal atresia 455
- oestrogens
 - combined hormonal
 - contraception 945
 - deficiency, symptoms 672–673
 - fetoplacental synthesis 13
 - follicular development **624**, 626
 - isolated GnRH deficiency 550
 - nervous system effects 667, 674
 - ovarian cycle 626, 627
 - premenstrual syndrome 669–670
 - replacement therapy 677–678
 - premenstrual syndrome
 - 668, 669
 - urinary incontinence 785
- secreting tumours 545
- uterine fibroids and 827
- vaginal
 - prolapse 760, 761
 - sexual dysfunction 964
 - vaginal intraepithelial neoplasia 816
 - vulvovaginal atrophy 677–678, 813
- see also* estradiol; hormone replacement therapy
- Offences Against the Person Act 1861 (OAPA) 598, 988
- ofloxacin
 - chlamydia infection 916, 919
 - pelvic inflammatory disease 616, **616**
- Ogilvie's syndrome 367
- olaparib 895, 896
- olfacto-genital syndrome *see* Kallmann's syndrome
- oligaemic collapse, obstetric patient **340**
- oligoasthenoteratozoospermia 697, 713
- oligohydramnios 235, 377
 - genitourinary tract anomalies 261–262
 - NSAID-induced 400
 - post-term pregnancy 315
- oligospermia 697, 699
- omphalocele 259–260
- oocytes
 - cryopreservation 646
 - developing follicles 625
 - developing ovary 488
 - donation 699–700, 715–716, 995
 - final maturation 628
 - freezing 716
 - posthumous use 993
 - quality in endometriosis 730
 - retrieval 709–710, 710
 - total numbers 488
 - transvaginal retrieval 705, 709–710, 718
- oophorectomy, bilateral
 - endometriosis 735–736
 - heavy menstrual bleeding 660
 - premenstrual syndrome 668
 - prophylactic 889
- ophthalmia neonatorum 453, 916, 917
- opioid analgesics, labour 424
- OPPTIMUM study 401
- ORACLE study 402, 409
- oral contraceptive pill
 - combined *see* combined oral contraceptive pill
 - contraceptive effectiveness 939, **940**
 - ovarian cancer risk and 884
 - progestogen-only (POP) 944
- oral glucose tolerance test (OGTT)
 - polycystic ovary syndrome 636, **637**
 - pregnancy 99–100, **100**
- oral hypoglycaemic agents 107, 110
- orgasm 957, 963
- orgasmic disorder 963–964
- orofacial clefts 262
- oseltamivir 201
- osmolality, plasma, in pregnancy 6, 8, 11
- osmotic dilators 604
- ospemifene 678
- osteoporosis
 - depot medroxyprogesterone acetate and 945
 - effects of HRT 681
 - exercise-related amenorrhoea 651
 - postmenopausal 673–674, 675
 - premature ovarian insufficiency 646–647
- ovarian autoantibodies 646
- ovarian cancer 884–899
 - aetiology 884–885
 - CA-125 tumour marker 887
 - clinical presentation 885–887
 - endometriosis and 725, **886**, 888
 - epidemiology 884
 - epithelial (EOC) 884–899
 - future prospects 899
 - genetics 876–877, 885
 - grading 889
 - histopathological diagnosis 891
- HRT and 681, 682, 885
- imaging 505
- oral contraceptive pill and 947
- patterns of spread 889–890
- polycystic ovary syndrome 641
- precursor lesions 887–888
- prognostic factors 891
- recurrent 895–899
 - bowel obstruction 898
 - chemotherapy 896–897
 - platinum refractory 896
 - platinum resistant 896, 897
 - platinum sensitive 896
 - radiotherapy 899
 - surgery 897–898
- risk-reducing surgery 889
- screening 888–889
- staging 889, **890**
- subclassification 885, **886**
- treatment 891–899
 - advanced disease 893–895
 - BRCA-positive patients 895
 - chemotherapy 893–895
 - decision-making 891
 - multidisciplinary 893
 - primary surgery 891–893
- ovarian cycle
 - follicular phase 623–628, 627
 - luteal phase 627, 628, 630
 - periovulatory phase 628
 - suppression, premenstrual syndrome 668–670
- ovarian cysts
 - accidents 509, 509, 821
 - benign 820–821
 - endometriotic *see* endometriomas
 - haemorrhage 509, 821
 - imaging 505–506
 - infertility 696, 696
 - rupture 509
 - torsion 509, 509, 821
- ovarian diathermy, polycystic ovary syndrome 644
- ovarian drilling, laparoscopic 706–707
- ovarian failure
 - infertility 692, 695
 - occult 646
 - premature *see* premature ovarian insufficiency
 - primary amenorrhoea 548
- ovarian follicles *see* follicles, ovarian
- ovarian fossa 483
- ovarian function
 - puberty 543
 - puerperium 434

- ovarian hyperstimulation syndrome (OHSS) 718
 - anti-Müllerian hormone (AMH)
 - testing 627, 704
 - intrauterine insemination 708
 - polycystic ovary syndrome 643–644, 644
 - prevention 709, 718
 - ovarian ligament 483
 - ovarian masses *see* adnexal masses
 - ovarian pregnancy 819
 - ovarian reserve, assessment
 - assisted conception 704
 - infertility 511, 695, 696
 - prediction of menopause 674
 - secondary amenorrhoea 635–636
 - see also* anti-Müllerian hormone; antral follicle count
 - ovarian teratomas, mature cystic 505, 505, 819, 820
 - ovarian torsion 509, 509
 - ovarian tumours
 - ADNEX model 507, 508
 - androgen-secreting 549, 633
 - benign 819–821
 - imaging 505, 505–507, 506
 - IOTA Simple Rules **506**, 506–507
 - risk of malignancy index (RMI) 506, 507
 - ovarian veins 483
 - transvenous occlusion 748, 748–749
 - ovaries
 - anatomy 483, 819
 - benign disorders 819–821
 - cryopreservation 646
 - development 485, 487–488, 488
 - endometriosis 819
 - enlargement 819
 - multicystic 638, 650
 - polycystic *see* polycystic ovaries
 - ultrasound 500, 705
 - overactive bladder (OAB) 779, 783–784
 - see also* detrusor overactivity
 - overflow urinary incontinence **784**, 784–785
 - ovotestes 488–489, 549
 - ovulation 628
 - lactational suppression 434, 440
 - monotocous 623–628
 - ovarian cancer risk and 884
 - post-abortion 600
 - postpartum 434
 - premenstrual syndrome and 666
 - ovulation induction 699–700
 - hypogonadotrophic hypogonadism 649
 - intrauterine insemination 707, 708
 - IVF protocols 708–709
 - Kallmann's syndrome 624, 626
 - polycystic ovary syndrome 643, 643–644
 - weight-related amenorrhoea 650
 - ovulatory disorders 691–692
 - heavy menstrual bleeding 655
 - management 699–700
 - oxidative stress
 - placental 24–25
 - in pregnancy 5, 13
 - oxybutynin 780, **781**
 - oxygen
 - consumption, in pregnancy **8**, 8–9
 - delivery, fetus during labour 374–375
 - placental villous development 24–25
 - tension (PO_2), in pregnancy **8**, **8**
 - oxygen therapy
 - maternal collapse 341
 - resuscitation of fetus 426
 - oxyhaemoglobin dissociation curve, in pregnancy 8
 - oxytocin (OXT)
 - augmentation of labour 329–330
 - cephalopelvic disproportion 360
 - challenge, post-term pregnancy **314**
 - initiation of labour 288–289, 290, 391–392
 - mechanisms of action 292, 294–295, **296**
 - milk ejection reflex 441, 442
 - obesity 213
 - sexual function 955
 - third-stage management 301
 - uterine hyperstimulation 376
 - oxytocin antagonists 406, 406–407
 - oxytocin receptors (OXTR) 288, 289, 290, 392
- p**
- packed cell volume, in pregnancy 9
 - paclitaxel
 - gestational trophoblast neoplasia 584
 - ovarian cancer 893–895, 896, 897
 - pad test, urinary incontinence 767
 - Paget's disease, vulva **839**
 - pain
 - assessment 745
 - definition 423
 - endometriosis 729–730
 - management 733–737
 - labour 423
 - management *see* analgesia
 - miscarriage 561
 - see also* abdominal pain; pelvic pain
 - painful bladder syndrome 787–788
 - Pajot's manoeuvre 362, 362
 - palliative care
 - cervical cancer 873–874
 - newborn baby 446
 - ovarian cancer 895–899
 - PALM-COEIN system 502, 653–655, 654
 - Palmer's point 478, 524, 535
 - pancreas, in pregnancy 15
 - panic disorder 181
 - papyraceous fetus 270
 - para-aortic lymph node disease, cervical cancer 870, **870**
 - para-aortic lymph node dissection
 - endometrial cancer 880
 - ovarian cancer 892–893
 - paramesonephric ducts *see* Müllerian ducts
 - paraovarian cysts 495
 - paraphimias 957–958
 - parathyroid disease 126
 - parathyroid glands, in pregnancy 14
 - parathyroid hormone (PTH) 14
 - parathyroid hormone-related protein (PTHrP) 14
 - parental chromosomal abnormalities 569–570
 - parental conflict hypothesis 223
 - parity
 - duration of labour and **299**
 - post-term pregnancy rate and 309
 - risks of post-term pregnancy **311**, **312–313**
 - stillbirth risk and 415
 - paroxetine 183, 184
 - PARP (poly (ADP-ribose) polymerase) inhibitors 895, 896, 899
 - partial androgen insensitivity syndrome 490
 - parturition 285–298, 286
 - parvovirus B19 infection 171–172, 251, 252
 - passage (in labour) 298–299, 359
 - passenger (in labour) 298, 359–360

- patch testing 798
- patent ductus arteriosus, pregnancy 87
- patient-controlled intravenous analgesia (PCA) 424
- Patient Health Questionnaire (PHQ-9) 179
- Patwardhan method 368
- PCO₂, in pregnancy 8, 8, 8
- PCOS *see* polycystic ovary syndrome
- Pearl Index 465, 939, 941
- PEARL studies 658–659
- Pearson correlation test 471
- pedicle artery sign 502, 502
- pegylated liposomal doxorubicin hydrochloride (PLDH) 896, 897
- pelvic congestion syndrome 748, 748–749
- pelvic diaphragm *see* levator ani muscles
- pelvic examination
 - infertility 695
 - labour 300
 - pelvic inflammatory disease 613
 - pelvic organ prolapse 757
- pelvic floor 479–481, 756
- pelvic floor distress inventories 757
- pelvic floor muscles 480–481, 481
- pelvic floor muscle training (PFMT) 759, 775
- pelvic infection, acute 611–619
- pelvic inflammatory disease (PID) 611–619
 - chlamydial 612, 615–616, 914–915
 - clinical presentation 613, 613–614
 - costs of treating 612
 - differential diagnosis 614, **614**
 - ectopic pregnancy risk 589–590, 617–618
 - HIV-infected women 618
 - incidence 611
 - investigations 614, 614–616
 - IUCD users 613, 618, 942
 - managing male partners 616–617, 617
 - microbiology **612**, 612–613
 - Mycoplasma genitalium* 612–613, 614, 918
 - post pelvic surgery 618
 - pregnancy 618
 - prevention 618–619
 - prognosis 617–618
 - risk factors 611–612
 - treatment **616**, 616–617, 916
 - ultrasound imaging 510, 510
- pelvic inlet 479, 480
- pelvic lymphadenectomy
 - cervical cancer 871
 - endometrial cancer 880
 - ovarian cancer 892–893
 - vaginal cancer 852
 - vulval cancer 846
- pelvic lymph node disease
 - cervical cancer **870**, 870–871
 - vulval cancer 844, 846, 848
- pelvic organ prolapse *see* prolapse, pelvic organ
- pelvic outlet 479, 480
- pelvic pain
 - endometriosis 729–730
 - management 733–737
 - imaging 509–511
 - infertility 694
 - integrated approach 909
 - see also* chronic pelvic pain
- pelvic surgery, postoperative infections 618
- pelvic vein incompetence 748, 748–749
- pelvimetry, clinical 299, 359
- pelvis
 - anthropoid 359
 - bony 298–299, 359
 - anatomy 479, 480
 - clinical anatomy 477–484, 756
 - contracted 359
 - organs 479, 481–484, 482
- pembrolizumab 899
- pemphigoid 805
- pemphigus, benign familial chronic 804
- pemphigus vulgaris 805
- pentalogy of Cantrell 259
- percutaneous coronary intervention (PCI), in pregnancy 92
- percutaneous epididymal sperm aspiration (PESA) 717
- percutaneous surgical systems 526
- periappendicitis, chlamydial 913–914
- perihepatitis, chlamydial *see* Fitz-Hugh–Curtis syndrome
- peri-mortem caesarean section (PMCS) 341, 367, 428
- perinatal death 461
- perinatal epidemiology 459–464
- perinatal morbidity
 - multiple pregnancy 269
 - post-term pregnancy 312, 318, 331, **331**
 - see also* neonatal adverse outcomes
- perinatal mortality
 - chronic kidney disease **133**
 - induction of labour and 332
 - kidney transplant recipients **139**
 - maternal diabetes 100, 101
 - monoamniotic twins 277
 - multiple pregnancy 269, 277
 - post-term pregnancy **310**, 310–312, **311**
 - effects of induction **314**, 318, 331, **331**
 - see also* neonatal death; stillbirth
- perineal body 480, 481
- perineal hygiene, children 553
- perineal lacerations 368–370, 438
 - classification 368
 - instrumental vaginal delivery 364
- perineal repair 301, 369
- peripartum cardiomyopathy 44, 93
- peripheral neuromodulation 782
- peritoneal adhesion index 747
- peritoneal cancer, FIGO staging **890**
- peritoneal dialysis 138
- peritoneal disease, infertility 692
- peritoneum 478
- periventricular leukomalacia 409, 451
- peroxisome proliferator-activated receptor γ (PPAR γ) 13
- persistent genital arousal disorder 963
- persistent pulmonary hypertension of newborn (PPHN) 183, 400
- PET-CT *see* positron emission tomography-computed tomography
- pethidine 424
- PETROC/OV21 study 894
- Pfannenstiel incision 365
- PGP-9.5, endometrial 731, 732
- pH
 - fetal blood 381
 - umbilical cord vessels 373, **374**
 - vaginal 811
 - venous, in pregnancy 8, 8
- phaeochromocytoma 126
- pharmacogenomics 685
- pharyngeal gonorrhoea 917, 918
- phenylketonuria, newborn screening **448**
- phenytoin 202
- phosphatidylinositol 4,5-bisphosphate (PIP₂) 292, 295
- phospholamban 294
- phospholipase C β (PLCB) 294–295, **296**
- phospholipase C δ (PLCD) **296**

- photographs, endoscopic surgery 521–522
- phototherapy, neonatal jaundice 452
- photothermolysis, hirsutism 642
- physiology, maternal 5–15
- physiotherapy, postnatal 435
- phytoestrogens 684
- PICOD approach to clinical questions 1008, **1009**
- pigmentation disorders, vulval 807–808
- Pinard stethoscope 380
- pituitary apoplexy 125
- pituitary disease
 - amenorrhoea 635, **635**, 647–649
 - ovulation disorders 692
 - pregnancy 125
- pituitary gland, in pregnancy 14
- pituitary tumours
 - amenorrhoea 549, 633, 635, 647–649
 - management 647–649, 648
 - pregnancy 125
- Piver–Rutledge classification of radical hysterectomy 871, **871**
- placenta 18–25
 - abembryonic pole 22, 22–23, 24
 - delivery 301
 - development 20, 20–23, 22
 - early villous stage 21
 - lacunar stage 20–21
 - onset of maternal blood flow 22–23
 - plugging of spiral arteries 21–22
 - prelacunar stage 20
 - discoidal shape 18, 19
 - dysfunction, stillbirth risk 416
 - embryonic pole 22, 23, 24
 - growth-restricted fetus 222
 - hormones 13–14
 - infarction 26
 - invasive, caesarean section 366
 - materno-fetal barrier 18, 19
 - materno-fetal interdigitations 18, 19
 - metastatic tumours 204
 - mosaicism confined to (CPM) 64, 65
 - pre-eclampsia pathogenesis 73–74
 - remnants, hysteroscopic removal 532
 - retention 301
 - structure 18–19, 19
 - term
 - macroscopic features 19–20
 - measurements 19
 - ultrasound assessment 26, 27, 232–233
 - vascular arrangement 18–19, 19
- placenta accreta
 - care bundle components 342
 - prediction of risk 233
- placental abruption 342
 - fetal monitoring in labour 376
 - preterm labour 394
- placental α -microglobulin-1 (PAMG-1) 402, 404–405
- placental growth factor (PGF) 6, 13
 - pre-eclampsia 73–74
 - SLE pregnancy 192
- placental site
 - atypical nodules 575, 578
 - postpartum changes 433, 434
- placental site trophoblast tumour (PSTT) 575, 579–580
 - management 584–585
- placental villi
 - development 21
 - floating 21
 - infarction 26
 - oxygen regulation of development 24–25
 - primary 21
 - secondary 21
 - structure 23–25
 - term placenta 20
 - tertiary 21
 - trophoblast turnover 24
 - villous stroma 24
 - villous trees 18, 19, 20, 21
- placenta percreta 233
- placenta praevia, identifying women at risk 232
- placentation
 - haemomonochorial 18, 19
 - invasive 18
- placentomes 19, 21
- plasma membrane Ca^{2+} -ATPases (PMCA) 292, 294
- plasma volume (PV)
 - normal pregnancy 6, 9, 147, **148**
 - postpartum changes **434**
- plasminogen activator inhibitor-1 (PAI-1) **10**
- plasminogen activator inhibitor-2 (PAI-2) **10**
- platelet alloimmunization 154, 247
- platelet counts
 - immune thrombocytopenic purpura 151, **151**
 - normal pregnancy 9, 147, 150
 - postpartum 434, **434**
- platelet transfusion
 - fetal *in utero* 247
 - obstetric haemorrhage 155, 344
- pleural effusions, congenital 264
- pneumomediastinum, maternal collapse **340**
- pneumonia 200–201
 - congenital neonatal 452
 - postnatal 437
- pneumothorax, maternal collapse **340**
- Po_2 , in pregnancy 8, **8**
- podophyllotoxin 926
- polycystic kidney disease 131, **135**
- polycystic ovaries (PCO) 819
 - assisted conception and 706–707
 - ultrasound features 511, *511*, 637–639, 638
- polycystic ovary syndrome (PCOS) 636–645
 - adolescence 556
 - clinical features 637, **637**, 695
 - definition 632, 637
 - diagnosis 632–636, **634**
 - genetics 639
 - health consequences 639–641
 - infertility 643–644, 692
 - management 641–645
 - obesity 208
 - pathophysiology 639
 - pre-pregnancy counselling 209
 - racial differences 639
 - recurrent miscarriage 571
 - younger women 640
- polycythaemia, one monochorionic twin 276
- polyhydramnios
 - gastrointestinal tract anomalies 259
 - monochorionic twins 275
- polymerase chain reaction (PCR) 910
- polypectomy
 - heavy menstrual bleeding 659
 - hysteroscopic 530
 - infertility 700
- poly(ADP-ribose) polymerase (PARP)
 - inhibitors 895, 896, 899
- polyps *see* endocervical polyps; endometrial polyps
- Pomeroy technique 949
- POP-Q classification system 757, 758
- POPS study 461
- portal hypertension 123
- PORTEC study 881
- position, fetal *see* fetal position
- positive likelihood ratio 467

- positive predictive value (PPV) 467
 - diagnostic test 1012
 - screening test 58, 67, **67**
- positron emission tomography-
 - computed tomography (PET-CT)
 - cervical cancer 869, 873, 874
 - ovarian cancer 891
- post-coital bleeding (PCB)
 - chlamydial infection 913
 - endometrial polyps 654
 - gonorrhoea 917
 - malignant disease 654–655, 868
 - pelvic inflammatory disease 613
- post-coital pain 745
- post-embolization syndrome 831
- posterior colporrhaphy 762
- posterior nerve stimulation 782
- posterior urethral valves 261–262
- postgraduate training 1004–1005
- postmenopausal bleeding
 - endometrial cancer 878
 - imaging 504
 - vaginal pessary users 760–761
- postmenopausal health 672–685
- post-mortem examination, stillborn baby 419
- postnatal period *see* puerperium
- postpartum blues 179, 438
- postpartum care
 - diabetes **106**, 110
 - hypertensive disorders of pregnancy 81–82
 - IUCD insertion 942–943
 - obesity 215–217
- postpartum depression 179–180
 - multiple pregnancy 272
 - obesity 216
- postpartum haemorrhage (PPH)
 - haemostatic measures 155
 - management of massive 344, 344–346
 - obesity 215
 - secondary 438
- postpartum psychosis 185–186
- post-term pregnancy 307–320
 - aetiology 308–309
 - antenatal testing 313–316
 - amniotic fluid volume 315
 - biophysical profile 316
 - cardiotocography 314–315
 - Doppler velocimetry 316
 - fetal movement counting 313–314
 - associated risks 310–313
 - definitions 307
 - epidemiology 309
 - home birth and 319
 - incidence 307–308
 - induction **314**, 317–319, 331
 - at 41 weeks 317
 - caesarean delivery rates 317, 318–319
 - clinical guidelines 320
 - at or before 40 weeks 317–318
 - perinatal outcomes 318, 331
 - women's views 319
 - management 313–320
 - clinical guidelines 320
 - clinical practice 320
 - membrane sweeping 320, 329
 - prevention 316–319
- post-traumatic stress disorder (PTSD) 182–183
- potassium (K⁺) channels, Ca²⁺-
 - activated 292, 294
- potassium chloride, pre-abortion
 - feticide 604, 607
- potassium permanganate soaks 803
- potassium retention, in pregnancy 11
- pouch of Douglas 478
- power, statistical 466, 467
- power morcellators, laparoscopic 526
- powers (in labour) 298, 360
- PPROM *see* preterm pre-labour rupture
 - of membranes
- PPROMT trial 403
- precocious puberty 544–545
- pre-conception counselling 38–45
 - access to maternity care 43–44
 - contraindications to pregnancy 44
 - diabetes 44, 101–102, **103**
 - general advice 39–42
 - genetic counselling 43
 - indications 39
 - kidney transplant recipients 139, **139**
 - maternal age-related 42–43
 - medications 42, 191
 - obesity 41–42, 209–210
 - poor obstetric history 45
 - providers 39
 - purpose 38
 - renal disease 45, 129–130
 - specific medical diseases 44–45
 - timing 39
- prediction testing 467–468
- prednisone/prednisolone
 - asthma 200
 - recurrent miscarriage 571
 - rheumatic diseases in pregnancy **196**
- pre-eclampsia 73–77, 78–82
 - adverse pregnancy outcomes 73, 78
 - anaesthetic issues 80
 - antenatal screening 53, 75–77
 - blood pressure measurement 75
 - caesarean section 427
 - cardiovascular disease risk 82
 - chronic kidney disease **133**, 135, 136–137
 - complications 80–81
 - definitions 74
 - delivery planning 79
 - fetal growth restriction and 225
 - fluid management 80
 - induction of labour 333
 - kidney transplant recipients **139**, 140, 142
 - liver involvement 80–81, 119–120
 - diagnosis **117**, 120
 - fatty acid oxidation disorders 118
 - overlap syndromes 117–118
 - rupture and infarction 120–121
 - management 78–81
 - maternal age and risk 43, **43**
 - mild 79
 - multiple pregnancy 272
 - obesity-related risk 211
 - pathophysiology 24–25, 73–74
 - postnatal management 81–82
 - proteinuria measurement 75
 - recurrence risk 44, 81
 - renal disease-related risk 132–133
 - risk assessment 75–77
 - risk factors 75–76, **76**
 - risk reduction 44, 77
 - severe 74, 79
 - stillbirth risk 78, 416
 - systemic lupus erythematosus 134, 192, **193**
 - vitamin D deficiency and 40
- pregnancy
 - after molar pregnancy 585
 - cardiovascular changes 6, 6–7, 7, 7, 85–86
 - cerebral circulation 11
 - cervical cancer in 873
 - cervical changes 817, 817
 - cervical pre-invasive disease 867
 - chlamydial infection 915–916
 - common symptoms 49
 - contraindications 44
 - drug safety **42**
 - early *see* early pregnancy
 - early term 307
 - endocrine system changes 13–15
 - energy requirements 12–13

- ethical issues 991–992
- exercise response 9, 9
- full term 307
- gastrointestinal changes 11–12
- genital herpes 172–174, 923–924
- genital warts 926
- gonorrhoea 917
- haematological changes 9
- health promotion 336
- heart disease 85–94
- hypertensive disorders *see*
 - hypertensive disorders of pregnancy
- immunology 5–6
- late term 307
- Mycoplasma genitalium* 918–919
- pelvic inflammatory disease 618
- physiological changes 5–15
- post-term 307–320
- renal function changes 10, 10–11
- respiratory changes 8, 8, 8–9
- sexually transmitted
 - infections 911–912
- syphilis 166–168, 911–912, 927–928
- teenage 39
- trichomoniasis 920
- unplanned 39, 597, 939
- uterine changes 6, 293
- vulval changes 797
- pregnancy-associated plasma protein A (PAPP-A)
 - Down's syndrome screening 60–61
 - fetal growth restriction 224
 - pre-eclampsia and 77
- pregnancy of unknown location (PUL) 512, **560**, 591
 - management 593
 - role of ultrasound 513–514
 - serum β -hCG 513, 563
 - see also* ectopic pregnancy
- pregnancy of unknown viability (PUV) **560**, 563
- pregnancy tests
 - IVF cycles 712
 - pelvic inflammatory disease 614
 - post-abortion 607
 - pregnancy viability and 512, 562
- PREGNANT trial 401
- pregnenolone sulfate 287
- pre-granulosa cells 487–488, 488
- pre-implantation genetic diagnosis (PGD) 716
 - ethical issues 996
 - recurrent miscarriage 569–570
- pre-implantation genetic screening 716–717
- pre-labour rupture of membranes 331
- premature ovarian insufficiency (POI) 675–676
 - BMP15* mutations 624
 - causes of spontaneous 676
 - investigations 635, 636, 646, 676
 - management 646–647, 676
 - registry 676
 - see also* hormone replacement therapy
- premenopausal bleeding
 - imaging 502, 502–504, 503
 - see also* abnormal uterine bleeding; intermenstrual bleeding
- premenstrual disorders (PMDs)
 - core 663–664
 - variant 664
- premenstrual dysphoric disorder (PMDD) 663, 667, 669
- premenstrual exacerbation of
 - underlying disorders 664
- premenstrual syndrome (PMS) 663–671
 - adolescence 555
 - aetiology 666–667
 - definitions 663
 - diagnosis 664–666, 665, 666, 670
 - symptoms and
 - classification 663–664
 - treatment 667–671, 670
- premenstrual tension (PMT) 663
- PREM scoring system 228
- prenatal diagnosis
 - chromosomal abnormalities 63–65, 66–67
 - multiple pregnancy 270–271
 - non-invasive *see* non-invasive prenatal testing
- pre-pregnancy counselling *see* pre-conception counselling
- prepubertal child, gynaecological disorders 552–554
- presacral neurectomy,
 - endometriosis 734
- preterm birth (PTB)
 - antidepressants and 183
 - breech presentation 356, 357–358, 410
 - causes 231
 - chlamydia and 915–916
 - chronic kidney disease 132–133, **133**, 136
 - definition 307, 387
 - effect on family 390, 450
 - gonorrhoea and 917
 - growth-restricted fetus 221, 227–228
 - incidence 387, 388
 - intrapartum care 409–410
 - kidney transplant recipients **139**, 142
 - management 409–410
 - multiple pregnancy 273
 - neonatal outcomes 389, 389–391, **390**, 448–450
 - obesity 208, 212
 - predicting 231–232, 404–405
 - prenatal depression 178
- preterm infants
 - childhood morbidity 449
 - definitions 387
 - neonatal death 449
 - neonatal morbidity 449, 450–452
 - neonatal outcomes 389–391, 448–450
 - survival 389, 389, **390**, 448–449
 - teenage and adult survivors 449–450
- preterm labour 387–410
 - causes 391, 392–394
 - decidual inflammation 288
 - epidemiology 387–388
 - intrapartum care 409–410
 - kidney transplant recipients 142
 - management 404–409
 - acute tocolysis 405–407
 - antenatal corticosteroids 407–408
 - antibiotics 409
 - magnesium sulfate 408–409
 - prediction of delivery risk 232, 404–405
 - multiple pregnancy 273–274, 392–393, 399
 - pharmacological targets 293, 297
 - prediction 394–397
 - algorithms 397
 - multiple pregnancy 273
 - third trimester 231–232
 - prevention 397–401
 - multiple pregnancy 273–274, 399
 - PPROM 403
 - in utero* transfer 404, 410
- preterm pre-labour rupture of membranes (PPROM) 401–403
 - Ehlers–Danlos syndrome 199
- prevalence 464–465

- primitive germ cells 487–488
- primordial germ cells 487
- pristinamycin 919
- professional discipline 1004
- progesterone
 - early pregnancy 630
 - fetoplacental synthesis 13
 - hormone replacement therapy **678**, 678–679
 - IVF protocols 711–712
 - menopause 678–679
 - menstrual cycle 630
 - miscarriage diagnosis 563–564
 - mood-altering effects 666, 667
 - onset of labour 287, 391–392
 - ovarian cycle 627, 628
 - physiological effects 6, 8, 15
 - preterm labour prevention 231, 273–274, 400–401
 - recurrent miscarriage 572
 - serum levels **634**, 695
 - uterine fibroids and 827
- progesterone receptor modulator-associated endometrial changes (PAEC) 659
- progestogen-only
 - contraception 943–945
 - implants 943
 - indications and contraindications 944
 - injectable 943, 943–944
 - oral 944
 - side effects 944–945
- progestogen-only pill (POP) 944
- progestogens
 - challenge testing 635
 - endometriosis 736
 - heavy menstrual bleeding 555, 658
 - hormone replacement therapy **678**, 678–679
 - polycystic ovary syndrome 641
 - premenstrual disorders and 664
 - premenstrual syndrome 669–670
 - side effects 678–679
- prolactin
 - milk production 441, 442
 - postpartum changes 434
 - pregnancy 14
 - serum 633, **634**, 634–635
 - see also* hyperprolactinaemia
- prolactinoma 125, 635, 647–649
- prolapse, pelvic organ (POP) 755–763
 - aetiology 755–756
 - anterior compartment 762
 - apical 761
 - classification 757, **758**, 758
 - clinical presentation 756–757
 - epidemiology 755
 - evaluation 757
 - investigations 758
 - management 758–763
 - posterior compartment 762
 - surgery 761–763, 776
 - vaginal pessaries 759, 759–761, 760
- prolonged pregnancy *see* post-term pregnancy
- PROMPT (PRactical Obstetric Multi-Professional Training) 339
- pronephros 485
- propafenone 94
- propiverine 780–781, **781**, 784
- propylthiouracil 124–125, 244
- prostacyclin
 - myometrial signalling **296**
 - normal pregnancy 14–15
 - pulmonary vascular disease 89
- prostaglandin D₂ 287, **296**
- prostaglandin E₁ (PGE₁) analogues
 - induction of labour 328, **328**
 - see also* gemeprost; misoprostol
- prostaglandin E₂ (PGE₂)
 - decidual release 287
 - induction of labour **328**, 328–329
 - myometrial signalling **296**
 - see also* dinoprostone
- prostaglandin E₂ receptors (PTGER2) **296**, **297**
- prostaglandin-endoperoxide synthase 2 *see* cyclooxygenase-2
- prostaglandin E synthase (PTGES) 289, 290
- prostaglandin F_{2α} 287, **296**
- prostaglandins
 - induction of labour 327, **328**, 328–329
 - complications 330
 - intrauterine fetal death 418
 - initiation of labour 287–288
 - mechanisms of myometrial effects 294–295, **296**, 297
 - menstruation 630–631
- prostaglandin synthetase inhibitors *see* non-steroidal anti-inflammatory drugs
- Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) study 888
- prosthetic heart valves 91–92
- protein, urinary excretion 11, 75, 130
- protein C, in pregnancy 9, **10**
- protein/creatinine ratio test 75
- protein kinase A (PRKA) 295, **296**
- protein kinase C (PKC; PRKC) 289, 290, 295, **296**
- protein S, in pregnancy 9, 147
- proteinuria
 - chronic kidney disease 134
 - kidney transplant recipients 140
 - lupus nephritis **193**
 - measurement in pregnancy 11, 75
 - obstetric outcomes and 132
 - pre-eclampsia 78
 - significant (gestational) 74, 75, 130
- prothrombotic factors, recurrent miscarriage 571
- PRROMEXIL study 402–403
- pruritus 121, 121
- psoriasis 803, 803–804
- psychiatric problems
 - after stillbirths 419
 - antenatal screening 53, 179
 - breastfeeding and 184, 188
 - chronic pelvic pain 744
 - effects of untreated prenatal 178–179
 - medication safety in pregnancy 183–184, 186–187
 - mothers of preterm infants 390
 - NICE recommendations 188, **188**
 - pre-conception counselling 39
 - pregnancy and puerperium 178–188, 438
 - premenstrual syndrome 663, 664
 - preterm survivors 390, 449
 - sexual dysfunction 962
- psychological aspects
 - cervical cancer 874
 - gestational trophoblast neoplasms 585–586
 - infertility 691
 - miscarriage 566
 - pelvic inflammatory disease 612
 - premature ovarian insufficiency 676
 - puerperium 433
 - sexual well-being 958–959
 - stillbirth 418–419
- psychosexual therapy 960
- psychotherapy 185, 960
- psychotic disorders, pregnancy and puerperium 185–186
- puberty 543–551
 - age at 543
 - constitutional delay 547, 550
 - control of onset 543
 - delayed 545–551
 - physical changes 544

- precocious 544–545
 - vulval changes 797
 - pubic hair, growth 544
 - PubMed 1009, 1010
 - pubocervical ligaments 482
 - pubococcygeus muscle 481
 - puborectalis muscle 480, 481
 - puerperal sepsis **436**, 436–437
 - puerperium 433–443
 - complications 436–438
 - early ambulation 435
 - hospital discharge policies 435
 - infant feeding 438–441
 - management 435
 - physiology 433–435
 - psychological adjustment 433
 - psychological disorders
 - 179–183, 438
 - routine observations 435
 - thromboprophylaxis 157, **158**, 436
 - see also* breastfeeding; lactation
 - pull technique, deeply impacted fetal head 367
 - pulmonary circulation, in pregnancy 7
 - pulmonary embolism (PE)
 - acute life-threatening/massive 157, **340**
 - diagnosis 156
 - in pregnancy 155–157
 - puerperium 436, **436**
 - pulmonary hypertension 44, 89
 - persistent, of newborn (PPHN) 183, 400
 - pulmonary hypoplasia
 - congenital abnormalities 263, 455
 - PPROM 401–402
 - pulmonary oedema
 - mitral stenosis 90
 - peripartum cardiomyopathy 93
 - susceptibility in pregnancy 85–86
 - pulmonary stenosis
 - congenital 256
 - pregnancy 87
 - pulmonary vascular disease 89
 - pulse oximetry, fetal 378, 381
 - push technique, deeply impacted fetal head 367
 - P*-value 465–466
 - pyelonephritis, chronic **135**
 - pyoderma gangrenosum 806
 - pyosalpinx 510
 - pyramidalis muscle 477
 - pyrexia
 - in labour 375–376
 - puerperal **436**, 436–437
 - pyridoxine 667
- q**
- quality of life, premature ovarian insufficiency 675–676
 - quality-of-life measures
 - chronic pelvic pain 745
 - endometriosis 729, 730
 - pelvic organ prolapse 757
 - quantitative-fluorescent polymerase chain reaction (QF-PCR) 64
 - Querleu–Morrow classification of radical hysterectomy 871, **872**
 - quinagolide **649**
- r**
- r* (correlation coefficient) 471
 - racial differences *see* ethnic/racial differences
 - radiation dose, in pregnancy 205, **205**
 - radiofrequency ablation, uterine fibroids 831
 - radiotherapy
 - cervical cancer 872–873
 - complications 848–849, 851
 - endometrial cancer 880–881
 - ovarian cancer 899
 - in pregnancy 204
 - vaginal cancer 851
 - for vaginal intraepithelial neoplasia 816
 - vaginal intraepithelial neoplasia after 814
 - vulval cancer 848
 - raloxifene 737, 761
 - randomized controlled trials (RCTs) 463
 - critical appraisal 1011, **1013**
 - grading of evidence 1012–1013
 - searching the literature 1009
 - range 469, 471
 - ranitidine 365
 - rape *see* sexual assault/rape
 - rationing, health resources 1000
 - receiver operating characteristic (ROC) curve 468, 468
 - ReCoDe classification of stillbirth 415, **415–416**
 - rectocele 755
 - rectovaginal fistula 814
 - rectum 484
 - rectus abdominis muscle 477, 478
 - recurrent miscarriage 568–572
 - anatomical factors 570
 - associated factors 568–572
 - definition **560**, 568
 - endocrine factors 571
 - endometrial factors 572
 - epidemiology 568
 - genetic factors 569–570
 - idiopathic 572
 - immunological factors 571–572
 - prothrombotic factors 571
- red cell alloimmunization 248–251
- antenatal screening 52
 - intrauterine transfusion 250
 - middle cerebral artery Doppler 249, 249
 - prevention of haemolytic disease 153–154, **154**
 - sensitizing events **153**
- red cell mass, in pregnancy 9, 147, **148**
- 5 α -reductase deficiency 489, 549
- reflux nephropathy 134, **135**
- regional anaesthesia/analgesia
- anticoagulated patients 156–157
 - caesarean section 426, 427
 - labour 424–426
 - contraindications **424**
 - indications 425, **426**
 - serious complications 425–426, **426**
 - techniques 424, **425**
 - obesity 213, 214, 425
 - see also* epidural anaesthesia/analgesia
- regurgitant valve disease 91
- Reiter's disease 804, 915
- relative risk (RR) 467
- relaxation therapy, sexual dysfunction 960
- relaxin 13–14
- Re MB (An Adult: Medical Treatment)* [1997] 991
- remifentanyl, patient-controlled analgesia 424
- renal agenesis 261, 495, 495
- renal biopsy 136
- renal disease 129–143
 - diabetic pregnancy 104–105
 - long-term effects of pregnancy 136–137
 - pre-eclampsia 81
 - pre-pregnancy counselling 45, 129–130
 - see also* chronic kidney disease
- renal function
- antenatal monitoring 134–135
 - classification 130–131, **131**
 - deterioration in pregnancy 132, **132**, 133, **133**
 - kidney transplant recipients 139, **139**, 140
 - normal pregnancy 10, 10, 130
 - obstetric outcomes and **132**, 132–133, **133**

- renin–angiotensin–aldosterone system, in pregnancy 6, 6, 11, 14
- reproductive tract *see* genital tract
- resectoscopes, hysteroscopic 523, 523
- resistant ovary syndrome 547, 646
- respiratory disorders
 - neonates 452
 - pre-conception counselling 44
 - pregnancy 199–202
 - preterm survivors 389, 450, 451
- respiratory distress, neonatal 452
- respiratory distress syndrome (RDS), neonatal 389, 450
 - antenatal corticosteroids and 407–408, **408**
- respiratory failure, postpartum 202
- respiratory infections, postnatal 437
- respiratory system
 - congenital abnormalities 455
 - normal pregnancy 8, 8, 8–9
- resuscitation
 - intrauterine fetal 426, **426**
 - neonatal 428, 446, 447
 - see also* cardiopulmonary resuscitation
- retained products of conception (RPOC)
 - after surgical abortion 605
 - evacuation in miscarriage 564–565
 - hysteroscopic removal 532
 - secondary postpartum
 - haemorrhage 438
- retinopathy of prematurity 390, 451
- retrieval bags, laparoscopic 526
- retrograde menstruation theory, endometriosis 723
- retropubic mid-urethral tape
 - procedures 776–777
- revalidation, professional 1004
- Revised American Society for Reproductive Medicine classification of endometriosis (r-ASRM) 726, 727
- rhabdomyosarcoma, vaginal 852
- rhesus alloimmunization 248–250
 - antenatal screening 52
 - intrauterine transfusion 250, 250
 - management algorithm 248
 - miscarriage 565–566
 - monitoring 249, 249
 - prevention of haemolytic disease 153–154, **154**
- rheumatic heart disease 89–91
- rheumatoid arthritis (RA) 194–198
 - medication in pregnancy **196–197**, 196–198
 - obstetric management 195
- RHO guanine nucleotide exchange factor (ARHGEF) **296**
- rhythm method, family planning 950
- ring pessary 759, 759
- risk management, obstetric 338
- risk of malignancy index (RMI) 506, 507
- ritodrine 297, 405
- rituximab 193, 195, 198
- Ro antibodies 193, 246
- Robertsonian translocations 59, 64
- robotic-assisted laparoscopic surgery 525
- robotic-assisted surgery, prolapse 761, 762
- ROCA (Risk of Ovarian Cancer Algorithm) score 887, 888
- rofecoxib 400
- Rokitansky nodule 505, 505
- ROLO study 217
- Rotterdam criteria, polycystic ovaries 511, *511*, 637
- round ligament 483
- Royal College of Anaesthetists 425, 426
- Royal College of Obstetricians and Gynaecologists (RCOG)
 - abortion 599, 1002–1003
 - antenatal care 47, 51, 54
 - miscarriage 562–563
 - post-term pregnancy 320
 - recurrent miscarriage 568
 - stillbirth follow-up 419
 - vulval cancer 844
- rubella 165–166
 - antenatal screening 52, 161
 - congenital 165, 166
 - diagnosis 165–166
 - immune status, infertility 695–696
 - management in pregnancy 166
 - susceptibility, prevalence **162**, 165
- rucaparib 895
- Russell–Silver syndrome (RSS) 222–223
- R v Bourne* [1938] 988, 1001
- ryanodine receptors (RYR) 293–294
- S**
- sacral neuromodulation 782–783, 783
- sacral radiculopathy, genital herpes 923
- sacroccygeal teratomas 264
- sacrocolpopexy 761
- sacro-iliac joint 479
- sacrospinous fixation 761
- sacrospinous ligament 479, 480
- sacrospinous ligament 480, 481
- safeguarding 978–980, 982
- salbutamol 405
- salpingectomy
 - ectopic pregnancy 593–594
 - endometrial cancer 881
 - with hysterectomy 660
 - prior to IVF 700, 706
 - prophylactic 889, 949
- salpingitis
 - acute 510, 615–616
 - acute herpetic 923
 - gonococcal 917
- salpingo-oophorectomy, prophylactic bilateral 889
- salpingotomy, ectopic pregnancy 593–594
- same-sex relationships, female *see* female same-sex relationships
- sample size 466
- sarcoendoplasmic reticulum Ca^{2+} -ATPases (SERCA) 292, 294
- sarcoma
 - uterine *see* uterine sarcoma
 - vagina 852
 - vulva 838, **839**
- sarcoma botryoides 852
- sarcopenia, postmenopausal 673–674
- sarcoplasmic reticulum (SR) 292, 293, 294
- Sayana® 943–944
- schizophrenia 185–186
- scleroderma (systemic sclerosis)
 - pregnancy and **135**, 198–199
 - renal crisis 198
- SCOPE study 461
- screening tests
 - evaluation 467–468
 - important parameters 58, 67, **67**
 - principles 58
- searching, literature 1009–1010, *1010*
- seborrhoeic eczema, vulval 802
- seborrhoeic keratoses, vulval 808
- secondary sexual characteristics
 - absent 545, **546**, 547–549
 - management 550–551
 - development 544
 - precocious 544, 545
- seizures
 - eclamptic 80, 346, 346
 - epileptic 202
 - neonatal 312, 454
- selective estrogen response modulators (SERMs) 679, 685
 - endometriosis 737
 - pelvic organ prolapse 761

- selective noradrenaline reuptake inhibitors (SNRIs) 684
- selective progesterone receptor modulators (SPRMs)
- heavy menstrual bleeding 658–659
 - uterine fibroids 828–830
- selective serotonin reuptake inhibitors (SSRIs)
- anxiety disorders 181, 182
 - chronic pelvic pain 746
 - menopausal symptoms 684
 - premenstrual syndrome 667, 668
 - safety in pregnancy 183, 184
- selenium, dietary intake 5
- semen
- abnormalities 693
 - analysis 694, 697, **697**, 706
- sensate focus-based sex therapy 960, 961
- sensitivity
- diagnostic test 1012
 - non-invasive prenatal testing 66, 67
 - predictive test 468
 - screening test 58
 - statistical test 466, 467
- sentinel lymph node biopsy
- cervical cancer 869
 - vulval cancer 841–842, **843**, 843
- sepsis/septicaemia
- neonatal 402–403, 452–453
 - obese pregnant women 215
 - puerperal **436**, 436–437
- septic abortion 618
- septicaemia, gonococcal 917
- SERCA (sarcoendoplasmic reticulum Ca^{2+} -ATPases) 292, 294
- seromucinous ovarian carcinoma **886**
- seronegative
- spondyloarthropathies 194
- serotonin **296**, 667
- serotonin–noradrenaline reuptake inhibitors (SNRIs) 181, 183, 775
- serous ovarian carcinoma
- high grade *see* high-grade serous ovarian cancer
 - low grade **886**
- serous ovarian cystadenoma 820
- serous tubal intraepithelial carcinoma (STIC) 888
- sertraline 184
- severe acute respiratory syndrome (SARS) 201
- sex
- changing attitudes
 - towards 954–955
 - determination 485
 - differentiation 485, 486, 487, 487–488
 - fetal *see* fetal sex
 - selection, embryo 996
 - selective abortion 990
- sex chromosome disorders **488**, **489**
- non-invasive prenatal testing 67–68
 - primary amenorrhoea 548
- sex hormone-binding globulin (SHBG) 208, 633, **634**
- sex therapy 960, 961
- sexual abuse, child *see* child sexual abuse
- sexual activity
- antenatal advice 48–49
 - effects of ageing 958
 - post-partum resumption 958
- sexual arousal disorder 962–963
- sexual assault/rape 967–981
- abortion on grounds of 988, 990
 - acute presentation 969–978
 - assessing urgent needs **969**
 - capacity and consent 969–970
 - domestic violence 980
 - examination 971–978, **972**, **973–975**
 - giving evidence in court 981
 - health effects 968, 981
 - history-taking 970–971, **971**
 - honour-based crimes 980
 - laws 967
 - mental health assessment 972, **975–976**
 - myths and stereotypes **981**
 - post-exposure prophylaxis 978
 - presentation 967–969
 - prevalence 967
 - safeguarding 978–980
 - statements 980–981
 - suicide risk assessment 972, **976**
 - vicarious trauma 981
- sexual assault referral centre (SARC) 969
- sexual desire (libido) 942, 955
- sexual desire disorder 961–962
- sexual diversity 957
- sexual dysfunction 954–965
- cervical cancer patients 874
 - diagnostic classification 957–958, 961
 - pelvic organ prolapse 757
 - physical factors 959
 - psychological factors 958–959
- psychological interventions 959–961
- self-help resources **961**
- sexual history 907, 909–910
- sexual interest arousal disorder 961
- sexually acquired reactive arthritis (SARA; Reiter's syndrome) 804, 915
- sexually transmitted infections (STIs) 907–928
- diagnosis 910–911
 - ectopic pregnancy risk 590
 - epidemiology 907–909, 908
 - integrated approach 909, 909–910
 - partner management 910
 - pelvic inflammatory disease 612–613
 - pregnancy 911–912
 - screening
 - antenatal 52, 911–912
 - before IUCD insertion 618, 942
 - pre-abortion 600
 - routine gynaecology 911
 - sexual assault victims 978
 - sexual history-taking 909–910
- sexual medicine 954
- Sexual Offences Act 2003 967
- sexual orientation 957
- sexual preference disorders 957–958
- sexual response
- anatomy and physiology 956, 956–957
 - models of sexual function 955, 955, 956
- sexual violence *see* sexual assault/rape
- sFlt-1 (soluble fms-like tyrosine kinase-1)
- normal pregnancy 13
 - pre-eclampsia 73–74
 - SLE pregnancy 192, **193**
- SGA *see* small for gestational age
- Sheehan's syndrome 649
- Shirodkar suture 399
- shock, neonatal 455
- short stature, primary amenorrhoea
 - with 548–549, 550
- short-term variability (STV) 227
- shoulder dystocia 347–350
- induction to prevent 332
 - instrumental vaginal delivery 360
 - management 348–350, 349
 - maternal diabetes 109
 - maternal obesity 215
 - post-term pregnancy 312
 - prediction 237–238

- shoulder presentation 359
- sickle cell disorders 151–152
 - antenatal screening 52
 - folic acid supplements 40, 152
 - newborn screening **448**
- single gene disorders, first-trimester screening 69
- single mothers 49
- single nucleotide polymorphisms (SNPs) 65
- single women, fertility treatment 691, 693, 701
- sinus tachycardia, in pregnancy 94
- sirolimus **141**
- Sister Joseph's nodule 887, 890
- Sjögren's syndrome 246
- skeletal dysplasias 262–263
- skewness 470, 471
- skin infections, neonatal 453
- skin tags, vulval 808–809
- SLE *see* systemic lupus erythematosus
- sleep apnoea 417
- sliding procedures, stress urinary incontinence 776–777
- small cell carcinoma, cervix 868
- small for gestational age (SGA) 31, 221
 - antenatal screening 54
 - assessment of cause 223–224
 - consequences 221–222
 - fetal biometry 32–33, 33, 234, 234
 - gestational age estimation 32
 - lupus nephritis 134
 - monitoring 225–227
 - neonatal problems 451
 - risk factors **224**, 224–225
 - risks of post-term pregnancy 313
 - standards or references 34
 - symphysis–fundal height 33, 54, 234
 - timing of delivery 227–228
 - see also* fetal growth restriction
- smoking
 - antenatal advice 48
 - assisted conception and 707
 - cervical cancer risk 862
 - ectopic pregnancy risk 590
 - fertility effects 698
 - genital warts and 926
 - pelvic inflammatory disease risk 612
 - pre-eclampsia risk and 74
 - pre-pregnancy advice 40–41
 - stillbirth risk 416
- social disadvantage
 - antenatal support and 49
 - stillbirth 413, 417
 - vulval cancer and 837
- Society of Obstetricians and Gynaecologists of Canada (SOGC)
 - post-term pregnancy guidance 320
 - pre-eclampsia risk reduction 77
- sodium pentosan polysulfate 787
- sodium retention, in pregnancy 11
- solifenacin 781, **781**
- sonohysterography 500–501, 501, 502
- Sopher forceps 604, 604
- sotalol 246
- SOX genes 485
- Spalding's sign 417
- specificity
 - diagnostic test 1012
 - non-invasive prenatal testing 66, 67, **67**
 - screening test 58
 - statistical test 466, 467
- spectinomycin 918
- sperm
 - donation 701, 717, 994–995
 - online 995–996
 - posthumous use 993
 - surgical retrieval 717
- spermicides 950
- spinal (intrathecal) anaesthesia, labour 424
- spinal–epidural analgesia, combined 424, **425**
- spiral arteries
 - failure of adaptation 73, 222
 - remodelling in pregnancy 6, 21–22, 22
- spiramycin 169
- spironolactone 642
- spontaneous miscarriage *see* miscarriage
- squamous cell carcinoma (SCC)
 - cervix 868
 - vagina 850
 - vulva 838, **839**
 - incidence 837
 - lichen planus and 802
 - lichen sclerosus and 799, 799, 838
 - presentation 838–840
 - spread 840–841, 841
- SRY gene 485
- Stages of Reproductive Aging Workshop + 10 (STRAW +10) 672, 673
- standard deviation (SD) 468, 469, 471
- standard error of the mean (SEM) 469, 471
- staphylococcal skin infections, neonatal 453
- statements, for the courts 980–981
- statins 92
- station, fetal 298
 - instrumental vaginal delivery 361
- statistical significance 465–466
- statistical tests 466
- statistics 464–472
 - descriptive 468–471
 - terms of significance 467
 - use of 471–472
- sterilization 949–950
 - assessment and counselling 950
 - female 949
 - chronic pelvic pain after 749
 - hysteroscopic 531, 532, 949
 - obesity 208
 - male 949–950
 - reversal 950
- steroids
 - biosynthesis 497
 - onset of labour 287
 - see also* corticosteroids
- Stevens–Johnson syndrome 805
- St George's NHS Trust v S* 992
- stillbirth 231, 413–420
 - aetiology 415–417, **416**
 - antepartum 413
 - diagnosis 417
 - management 417–418
 - see also* intrauterine fetal death
 - classification 414–415, **415–416**
 - definition 413, 461
 - fetal growth restriction 221, 233, 416
 - fetal macrosomia 237–238
 - follow-up investigations 419
 - induction of labour to prevent 332
 - intrahepatic cholestasis of pregnancy 122
 - intrapartum 373, 413, 414
 - lactation suppression 418
 - legal considerations 418
 - maternal age and 43, 415
 - maternal diabetes 100, 101, 109
 - obesity and 212, 416–417
 - post-term pregnancy **310**, 310–311, **312**
 - pre-eclampsia and 78, 416
 - prevention 419–420

- psychological aspects 418–419
 - rates 413–414, 414
 - subsequent pregnancies 419–420
 - Stillbirth Register 418
 - St John's wort 671
 - Stockholm trial 682
 - STOPPIT trial 274
 - straight wire excision of transformation zone (SWETZ) 865
 - strangulation, non-fatal 978, 979
 - strawberry cervix 812, 812, 919
 - streptomycin 201
 - stress
 - amenorrhoea 650
 - fertility effects 698
 - maternal prenatal 178–179
 - parents of preterm infants 390, 450
 - preterm labour risk 394
 - sexual function and 958–959
 - stress urinary incontinence (SUI) 766, 774–779
 - causes 774
 - conservative treatment 775
 - investigations 769, 771
 - medical therapy 775
 - NICE guidelines 778–779
 - surgery 775–778, 776
 - prolapse surgery with 758, 776
 - stroke
 - HRT-treated women 681
 - oral contraceptive users 947
 - in pregnancy 203
 - stroke volume
 - normal pregnancy 6, 7, 7
 - postpartum changes 434
 - ST-segment analysis, fetal ECG 382–383
 - Student's *t*-test 469, 471
 - Study of Women's Health Across the Nation (SWAN) 959
 - subfertility *see* infertility
 - submento-bregmatic diameter 359, 359
 - suction, laparoscopic 525
 - suction evacuation, uterus 564
 - sudden cardiac death, in pregnancy 92
 - sudden unexpected death in epilepsy (SUDEP) 202
 - suicide
 - postpartum 180, 186, 443
 - risk assessment 972, 977
 - sulfasalazine 196
 - superior epigastric vessels 477
 - superovulation, anti-Müllerian hormone testing 627, 704
 - supine hypotension of pregnancy 7, 86, 427
 - supraventricular tachycardia (SVT)
 - fetal 245, 246
 - pregnancy 94
 - surfactant
 - deficiency, preterm infants 389
 - fetal 285–287
 - surfactant-associated protein A (SP-A) 287, 392
 - surfactant-associated protein D (SP-D) 287
 - surgical management of miscarriage (SMM) 564–565
 - surgical site infections
 - obesity and 215
 - puerperium 437
 - surrogacy 716
 - sweats, menopausal 672
 - symphysis–fundal height (SFH)
 - gestational age estimation 33, 54, 223, 234
 - miscarriage 561
 - symphysis pubis 479, 481
 - syncytial knots 24
 - syncytiotrophoblast 23–24
 - differentiation 20, 20, 22
 - outer 20
 - placental development 20–21
 - turnover 24
 - villous 23–24
 - synthetic materials
 - prolapse repair 763
 - stress incontinence surgery 776–777
 - syphilis 927–928
 - antenatal screening 52, 161, 167, 928
 - clinical features 167, 927
 - congenital 167, 927–928
 - diagnosis 167, 813, 927
 - in pregnancy 166–168, 911–912, 927–928
 - prevalence 162, 166
 - treatment 168, 928
 - vaginal lesions 813
 - vertical transmission 166
 - syringomata, vulval 809
 - systematic reviews
 - critical appraisal 1010–1011, 1013
 - meta-analysis 463–464, 1011, 1011
 - searching the literature 1009
 - systemic inflammatory response
 - placental pathology 24
 - pregnancy 5
 - puerperal sepsis 437
 - systemic lupus erythematosus (SLE) 135, 192–194
 - effect on pregnancy 192
 - flares in pregnancy 134, 192–193, 193
 - long-term maternal health 194
 - neonatal adverse effects 193–194, 246
 - pre-pregnancy counselling 131, 192
 - renal disease *see* lupus nephritis
 - systemic sclerosis *see* scleroderma
- t**
- tachycardia
 - fetal 244, 245–246, 379–380
 - obstetric haemorrhage 342
 - tacrolimus
 - breastfeeding and 142
 - safety in pregnancy 141, 141, 193, 197
 - Takayasu's arteritis 199
 - tamoxifen 878
 - team working, obstetric emergencies 337
 - teenage pregnancy 39
 - teenagers *see* adolescents
 - telokin 291, 292
 - temperature control, preterm infants 450
 - tenofovir disoproxil fumarate 122
 - tension-free vaginal tape 776–777, 777
 - teratomas
 - fetal 264
 - mature cystic ovarian 505, 505, 819, 820
 - teratozoospermia 697
 - Term Breech Trial 356, 471
 - termination of pregnancy 597–608
 - aftercare 607
 - assessment for 599–600
 - capacity to consent 598–599, 990–991
 - choice of method 601
 - conscientious objection 598
 - demographic features 597
 - ethical issues 987–991
 - legal aspects 598, 598–599, 988–990, 1001–1004
 - medical abortion 605–607
 - after 9 weeks 606–607
 - complications 607
 - early 605–606
 - need for updated law 989–990

- termination of pregnancy (*cont'd*)
 - morality 987–988
 - pulmonary vascular disease 89
 - rape victims 988, 990
 - rates 597, 939
 - safety 597
 - selective, multiple pregnancy 271
 - sex-selective 990
 - surgical abortion 602–605
 - complications 605
 - first trimester 602–603
 - second trimester 603–605
 - time limits 988–989, 1002
- Term PROM trial 472
- testes
 - development 485, 486, 486, 487
 - disorders of development 488–489
- testicular sperm extraction (TESE) 717
- testosterone
 - biosynthesis 497
 - serum 633, **634**, 962
 - supplements, postmenopause 679–680
- tetanus, neonatal 453
- TE/TP chemotherapy regimen 584
- tetralogy of Fallot 88, 256–257
- thalassaemia 152–153
 - antenatal screening 52
 - dietary supplements 40, 152
- thalidomide 199
- theca cell layer 624, 625
- thelarche 544
 - premature 544
- thiazolidinediones 644
- third trimester fetal assessment 231–238
- Thomson, Judith Jarvis 987
- thoracic anomalies, congenital 263–264
- thrombin–antithrombin (TAT) III complex **10**
- thrombocytopenia 150–151
 - autoimmune 150–151
 - causes in pregnancy 150
 - fetal/neonatal alloimmune (FNAIT) **154**, 154–155, 247–248
 - fetal parvovirus infection 251
 - gestational 150
 - HELLP syndrome **120**
 - neonatal 151
- thromboembolism *see* venous thromboembolism
- thrombolytic therapy, in pregnancy 92, 157
- thrombophilia, recurrent miscarriage 571
- thrombosis
 - arterial, oral contraceptive users 947
 - cerebral vein 203
 - in pregnancy 155–157
- thrombotic thrombocytopenic purpura (TTP) 151
- thromboxane A₂, myometrial **296**
- thrush *see* candidiasis
- thyroid-binding globulin (TBG)
 - fetal 243
 - normal range **634**
 - pregnancy 14, 124
- thyroid disease
 - amenorrhoea 634
 - diabetes association 105
 - fetal 243–244
 - pregnancy in 124–125
 - recurrent miscarriage 571–572
- thyroid function
 - fetal 243
 - normal pregnancy 14, 124, **124**
 - puerperium 435
- thyroid-stimulating hormone (TSH)
 - fetal 243
 - normal pregnancy 14, **124**
 - normal range **634**
 - receptor-stimulating antibodies (TRAbs) 125, 243
- thyroxine (T4)
 - fetal 243
 - intra-amniotic therapy 244
 - normal pregnancy 14, **124**
 - normal range **634**
 - therapy in pregnancy 124
- tibolone 669, 962
- tidal volume, in pregnancy 8, 8
- tiredness, in pregnancy 49
- tissue plasminogen activator (tPA) **10**
- TNM staging system, vulval cancer 841, **842**
- TOBY study 454
- tocolysis
 - external cephalic version 356
 - multiple pregnancy 274
 - PPROM 403
 - symptomatic preterm labour 404, 405
- TOCOS study 132, 133, 136
- tolterodine 781, **781**, 783–784
- topiramate 187, 188
- topotecan 896, 897
- TORCH infections 161, **162**
- total body water, in pregnancy 11
- total peripheral resistance, in pregnancy 6, 7
- toxic epidermal necrolysis 805
- toxoplasmosis 168–169
 - clinical features 168–169
 - congenital 168, 169, 176
 - diagnosis 169
 - prevention 48, 169
 - treatment 169
- TP53 mutations 838, 885, 888
- trabectedin 896
- trachelectomy, radical 871–872
- tracheo-oesophageal fistula 455
- Traditional Herbal Registration (THR) scheme 684
- training
 - CPR in pregnancy 427
 - endoscopic surgery 536–537
 - obstetric emergencies 338–339
 - postgraduate 1004–1005
- tranexamic acid
 - heavy menstrual bleeding 658
 - postpartum haemorrhage 155, 344
- transcervical resection of fibroids (TCRF) 530–531, 533
- transdermal contraceptive patch 208, 945
- transfusion *see* blood transfusion
- transient tachypnoea of newborn 452
- transobturator mid-urethral sling procedure 777, 777
- trans people 957
- trans-sphenoidal adenectomy 649
- transvaginal oocyte retrieval (TVOR) 705, 709–710, 718
- transvaginal ultrasonography 500
 - see also* ultrasound
- transverse lie 359
- traumatic injuries
 - instrumental vaginal delivery 364
 - primary amenorrhoea 548
 - sexual assault victims 977
 - vaginal 813, 814
 - see also* birth injury
- Treponema pallidum* 166, 813, 927
 - see also* syphilis
- triage, obstetric 336
- trichomoniasis (*Trichomonas vaginalis*) 812, 812, 919–920
 - diagnosis 910, 920
 - pelvic inflammatory disease 615
- tricuspid regurgitation (TR), fetal 61
- tricyclic antidepressants (TCAs) 183, 184

- trigger points
 - myofascial 749
 - nerve entrapments 745
- trigone 483, 483
- triiodothyronine (T3)
 - fetal 243
 - normal pregnancy 14
 - normal range **634**
- trisomy 13
 - first-trimester combined screening 63
 - non-invasive prenatal testing 67
 - nuchal translucency 60
- trisomy 18
 - first-trimester combined screening 63
 - non-invasive prenatal testing 67
 - nuchal translucency 60
- trisomy 21 59
 - karyotyping 64
 - non-invasive prenatal testing 65–66
 - see also* Down's syndrome
- trocars, laparoscopic 524–525
- troglitazone 644
- trophoblast
 - differentiation 20, 20, 22
 - endoglandular 21
 - endovascular 21, 22
 - extravillous 21
 - fetal membranes 25, 25
 - HLA expression 5
 - invasion of spiral arteries 6, 21–22, 22
 - subtypes 21, 22
 - giant cells, multinucleated 21
 - interstitial 21, 22
 - intramural 21, 22
 - invasion of spiral arteries 6, 21–22, 22
 - release into maternal circulation 24
 - villous 22, 23–24, 25
 - HLA expression 5
 - materno-fetal barrier 18
 - release into maternal circulation 24
 - turnover 24
 - see also* cytotrophoblast; syncytiotrophoblast
- trophoblastic cell columns 21, 22
- trophoblast tumours *see* gestational trophoblast neoplasms
- tropomyosin 291
- troponin 92, 291
- tropium 781, **781**
- TruClear™ tissue removal system 524, 524, 530
- true negative 467
- true positive 467
- TRUFFLE study 228
- t*-test, Student's 469, 471
- tubal disease 692
 - chlamydia infection 617, 914–915
 - history taking 694
 - investigations 501, 696–697
 - treatment 531, 700
- tubal ectopic pregnancy (EP) 590
 - management 592–594
 - ultrasound diagnosis 591, 591
- tubal ligation *see* sterilization, female
- tubal patency testing 501, 501, 696, 705
- tuberculosis
 - pelvic inflammatory disease 613
 - in pregnancy 201
 - vaccination, newborn infants 453
- tubo-ovarian abscess 510, 510
- tubo-ovarian complex 510
- tumour necrosis factor- α (TNF- α) 287, 293–294
- Turner's syndrome (45X) 488
 - antenatal screening 63, 67
 - management 550–551
 - nuchal translucency 60, 63
 - primary amenorrhoea 548, 549
- 22q11.2 deletion syndrome 257
- twin anaemia polycythaemia sequence (TAPS) 276, 276
- twin pregnancy
 - dichorionic *see* dichorionic pregnancy
 - molar pregnancy 577–578
 - monoamniotic 277
 - monochorionic *see* monochorionic twins
 - non-invasive prenatal testing 68, 271
 - see also* multiple pregnancy
- twin reversed arterial perfusion (TRAP) sequence 276–277
- twin–twin transfusion syndrome (TTTS) **275**, 275–276
- two-cell, two gonadotrophin hypothesis 624
- type I error 466
- type II error 466
- u**
- UK Collaborative Trial of Ovarian Cancer Screening (UKTOCS) 888–889
- UK Familial Ovarian Cancer Screening Study (UKFOCSS) 889
- ulipristal acetate (UPA)
 - emergency contraception 948, 949
 - heavy menstrual bleeding 658–659
 - impact of obesity 208, 948
 - uterine fibroids 828–830
- ultrasonic scalpels 521, 526
- ultrasound
 - abnormal uterine bleeding 502, 502–504, 503
 - adenomyosis 503–504, 823, 824
 - adnexal masses 505, 505–507, 506, 508
 - amenorrhoea 634
 - amniotic fluid volume 235, 236, 315
 - antenatal Down's syndrome screening 60, 61, **61**
 - assisted conception 705, 707
 - cerebral, preterm infants 451
 - cervical length assessment *see* cervical length measurement
 - chorionicity determination 269–270
 - deep vein thrombosis 156
 - early pregnancy 512–514, 562, 562
 - ectopic pregnancy 512–513, 513, 591, 591–592, 592
 - endometrial polyps 502, 503, 825, 825
 - fetal anomaly scan 54, 254
 - diabetes 108
 - multiple pregnancy 270
 - fetal growth assessment 32–33, 33, 223, 234
 - gestational age estimation 32, 53, 512
 - abortion 600
 - accuracy 32, 308, 316–317
 - diabetes 106
 - guided gynaecological procedures 501
 - gynaecological 499–502
 - heavy menstrual bleeding 656
 - infertility 511, 511, 696, 696
 - intrauterine fetal death 417
 - IVF 709
 - miscarriage 512, 562–563, 563
 - non-invasive prenatal testing and 68
 - obese pregnant women 212
 - ovarian cancer screening 888, 889
 - pelvic inflammatory disease 510, 510, 615
 - pelvic pain 509–511
 - physical properties and settings 499

- ultrasound (*cont'd*)
 - placental assessment 26, 27, 232–233
 - polycystic ovaries 511, 511, 637–639, 638
 - third trimester fetal
 - assessment 231–238
 - transabdominal 500
 - transperitoneal 758
 - transvaginal 500
 - urinary tract 769
 - uterine fibroids 502–504, 503, 828, 829
 - see also* Doppler ultrasound
- umbilical artery Doppler 26
 - fetal growth restriction 222, 225–226, 226
 - multiple pregnancy 272–273
 - normal pregnancy 236
 - post-term pregnancy 316
 - third-trimester fetal assessment 236–237
- umbilical cord
 - clamping, preterm delivery 410
 - compression during labour 375, 375, 376
 - occlusion 376
 - paired blood samples 373, 374
 - stump infections 453
- umbilicus 477, 478
- underweight women, pre-conception
 - advice 41
- uniparental disomy (UPD) 64, 68, 222
- unplanned pregnancy 39, 597, 939
- UPBEAT trial 217
- urachus 477
- urea, serum (S_{urea}) 130, 137
- Ureaplasma parvum* 918
- Ureaplasma urealyticum* 393, 397
- ureteric injuries, surgical 437
- ureterovaginal fistulae 785
- ureters
 - anatomy 484
 - ectopic 496, 496
- urethra
 - anatomy 484
 - caruncle 785–786
 - lesions 785–786
 - mucosal prolapse 786
 - stenosis or stricture 786
- urethral bulking agents 777, 777–778, 778
- urethral diverticulum 785
- urethral pressure profilometry 769, 773
- urethritis
 - gonococcal 917
 - Mycoplasma genitalium* 918
- urgency, urinary 786–787
 - causes 786
 - pelvic organ prolapse 756
- urgency incontinence 786
- uric acid, serum 11, 193
- urinary diary 767, 768
- urinary diversion 783
- urinary fistulae 785
- urinary incontinence 766–788
 - after prolapse surgery 758
 - causes 767, 774–785
 - clinical presentation 766–767
 - conservative measures 785
 - detrusor overactivity *see* detrusor overactivity
 - investigations 767, 767–774
 - mixed 784
 - oestrogen therapy 785
 - overflow 784, 784–785
 - pelvic organ prolapse 756
 - postpartum 437
 - stress *see* stress urinary incontinence
- urinary retention
 - with overflow 784, 784–785
 - postnatal 437
- urinary tract
 - congenital anomalies 495, 495–496, 496
 - development 485–486, 486
 - disorders, cervical cancer 871, 873–874
 - fetal anomalies 261–262
 - imaging 769, 773
 - normal pregnancy 10, 10–11, 130
 - postpartum changes 434
 - postpartum complications 437
- urinary tract infections (UTI)
 - antenatal screening 52
 - chronic kidney disease 134
 - frequency of micturition 786
 - postnatal 437
- urinary tract obstruction
 - congenital lower 261–262
 - haematocolpos 493, 494
- urodynamics 768–769
 - ambulatory 773–774, 774
- urodynamic stress incontinence 767, 774–779
 - see also* stress urinary incontinence
- uroflowmetry 768, 769
- urogenital sinus 487, 487
- urogenital symptoms,
 - postmenopause 673
- urolithiasis 135
- urologic surgery, previous 135
- ursodeoxycholic acid (UDCA) 122
- urticaria, vulval 809–810
- uterine activity, excessive 376
- uterine adenomyosis *see* adenomyosis, uterine
- uterine artery 483
- uterine artery Doppler
 - antenatal screening 26, 76
 - fetal growth restriction 222, 223, 224, 224–225
- uterine artery embolization (UAE)
 - adenomyosis 824
 - complications 831, 831
 - infertility 700
 - postpartum haemorrhage 345
 - uterine fibroids 660, 830–831
- uterine contractility *see* myometrial contractility
- uterine contractions
 - fetal responses 374–375, 375, 376
 - mechanisms of onset 285–289, 290
 - physiological basis 290–295, 292
 - powers of labour 298
 - target frequency, induced labour 330, 376
- uterine evacuation
 - first-trimester abortion 602–603
 - hysteroscopic 532
 - miscarriage 564–565
 - molar pregnancy 577, 581
 - second-trimester abortion 603–605
- uterine fibroids 826–832
 - ablation procedures 831
 - aetiology 827
 - assisted conception and 706
 - control of growth 827
 - diagnosis 827–828, 829
 - FIGO classification 826, 826
 - heavy menstrual bleeding 654, 660
 - high-intensity focused ultrasound 831–832
 - hysteroscopic removal 530–531, 533, 830
 - imaging 502–504, 503, 505, 828, 829
 - incidence 826–827
 - infertility 693, 696, 700
 - laparoscopic surgery 526
 - malignancy risk 826
 - medical treatment 828–830
 - myomectomy *see* myomectomy
 - pathology 826, 826
 - recurrent miscarriage 570, 570

- surgical treatment 830
- symptoms 827, **828**
- treatment 828–832
- urinary incontinence 772
- uterine artery embolization 660, 830–831
- uterine hyperstimulation
 - fetal effects 376
 - induction of labour 328, 329, 330
- uterine inversion 347, 347
- uterine leiomyomata *see* uterine fibroids
- uterine leiomyosarcoma 826, 878–879
 - heavy menstrual bleeding 654–655
 - imaging 503, 828
- uterine nerve ablation, laparoscopic 734, 746
- uterine perforation
 - IUCD insertion 941
 - operative hysteroscopy 533
 - surgical abortion 605
 - surgical management of miscarriage 564
- uterine relaxation 295–298
 - cyclic nucleotides 295
 - endogenous and exogenous factors causing 297, **297**
 - gap junction proteins 298
 - G protein-coupled receptors 295–296, **296**
 - receptor desensitization 297
 - receptor-mediated 297
- uterine rupture
 - after upper uterine segment incisions 366
 - fetal blood sampling and 382
 - fetal monitoring in labour 376
 - induction of labour 333
 - management 347, 348
 - medical abortion 607
- uterine sarcoma 878–879
 - heavy menstrual bleeding 654–655
 - imaging 503, 503
- uterine scar, third-trimester assessment 233
- uterine tumours, imaging 502–503, 503
- uterosacral colpopexy 761
- uterosacral ligaments 483
- utero vaginal prolapse *see* prolapse, pelvic organ
- uterus
 - anatomy 481–482, 482
 - anteflexion 482
 - axis in relation to vagina 482, 482
 - bicornuate 492, 492–493
 - congenital absence 490–492, 549–550
 - congenital anomalies 492, 492–493
 - hysteroscopic metroplasty 531
 - imaging 511
 - recurrent miscarriage 570
 - development 486, 486
 - didelphys 492, 493
 - disorders
 - benign 823–832
 - infertility 692–693, 700–701
 - recurrent miscarriage 570
 - displacement during CPR 427
 - function in pregnancy 289, 290
 - instrumentation, infection risk 618–619
 - packing, postpartum haemorrhage 345
 - postpartum changes 433–434
 - pregnancy-related changes 6, 293, 391
 - retroflexion 482
 - rudimentary horn 492, 493
 - septate or subseptate 492, 492–493
 - ultrasound 500, 511, 705
- V**
- Vacca, Aldo 363
- vacuum aspiration
 - complications 605
 - first-trimester abortion 602, 602, 603
 - miscarriage 564–565
 - second-trimester abortion 603
- vacuum delivery 363, 363–364
 - indications 361
- vagina 811
 - anatomy 481, 811
 - benign diseases 811–816
 - benign tumours 816
 - congenital absence 490, 490–492, 546–547
 - cysts 495, 816
 - development 486
 - diethylstilbestrol-related lesions 816
 - double 495
 - foreign bodies 554
 - fusion anomalies 492, 492–493
 - longitudinal septum 494–495
 - microbial flora *see* vaginal microbiota/microbiome
 - pelvic supports 756
 - sexual response 956, 956–957
 - transverse septum 493–494, 546, 550
- vaginal atrophy *see* vulvovaginal atrophy
- vaginal biomarkers
 - PPROM 402
 - symptomatic preterm labour 232, 404–405, **405**
 - see also* fetal fibronectin test
- vaginal bleeding
 - childhood 554
 - ectopic pregnancy 589, 591
 - first-trimester, Down's syndrome screening and 62
 - HRT-related 678
 - medical abortion 606
 - miscarriage 561
 - normal puerperium 434
 - obstetric emergencies 342
 - surgical abortion 605
 - see also* abnormal uterine bleeding
- vaginal cancer 850–853
 - clear cell adenocarcinoma 816, 853
 - clinical features 850, 850
 - outcomes 852
 - staging 850–851, **851**
 - treatment 851–852
 - uncommon types 852–853
- vaginal cones, weighted 775
- vaginal devices, urinary incontinence 775
- vaginal dilators 491, 491, 492
- vaginal discharge
 - children 552, 553
 - gonorrhoea 917
 - normal physiological 811
 - pessary users 760–761
 - postnatal 434
 - pregnancy 49
- vaginal examination
 - children 552, 553
 - infertility 695
 - instrumental vaginal delivery 360–361
 - miscarriage 561
 - post-term pregnancy 320
- vaginal infections 811–813
 - recurrent 920–922
 - see also* sexually transmitted infections
- vaginal intraepithelial neoplasia (VAIN) 814, 814–816, 815
- vaginal lubricants/
 - moisturizers 683–684, 963, 965

- vaginal microbiota/microbiome
 - 811, **812**
 - bacterial vaginosis 920–921
 - pelvic inflammatory disease and 612
 - PPROM and 402
 - preterm labour and 394
- vaginal pessaries, pelvic organ prolapse 759, 759–761, 760
- vaginal ring, combined contraceptive 945
- vaginal swabs *see* vulvo-vaginal swabs
- vaginal trauma 813, 814
 - instrumental vaginal delivery 364
 - sexual assault 977
- vaginal vault, post-hysterectomy
 - endometrial cancer relapse 881
 - prolapse 761
 - vaginal intraepithelial neoplasia 814, 814, 815
- vaginectomy, vaginal intraepithelial neoplasia 815
- vaginismus 964–965
- vaginitis
 - candidal 812–813
 - gonococcal 813
 - non-specific 811
 - strawberry 812, 812
- vaginoscopic hysteroscopy 527, 528
- valaciclovir, genital herpes 923, 924, 925
- valproate 186–187, 188, 202
- valvular heart disease, in pregnancy 87–88, 89–91
- vanished twin 270
 - Down's syndrome screening 61
- variceal bleeding 123
- varicella (chickenpox) 174–175
 - congenital 174
 - neonatal 174, 175
 - pneumonia 201
- varicella-zoster virus (VZV) 174–175
- varicella-zoster virus immunoglobulin (VZIG) 174
- varicocele 693
- varicose veins, pregnancy-related 49
- varicosities, vulval 809
- vasa praevia, ultrasound 232–233
- vascular endothelial growth factor (VEGF) 13, 73–74
- vascular lesions, vulva 809
- vasculitides 135, 199
- vasectomy 949–950
- vasomotor symptoms
 - menopause 672
 - treatment 682–683, 683, 684
- vasopressin, myometrial effects **296**
- Vecchiotti's operation 492
- venlafaxine 684
- venous changes, in pregnancy 7
- venous thromboembolism (VTE)
 - antenatal risk factors **158**
 - combined hormonal contraception and 946–947
 - diagnosis 155–156
 - HRT-related risk 679, 681
 - postnatal risk factors **158**
 - in pregnancy 155–157
 - progestogen-only contraception users 944
 - prophylaxis
 - maternal obesity 215–216
 - pregnancy and puerperium 157, **158**
 - puerperium 436, **436**
 - treatment in pregnancy 156–157
- ventilation–perfusion (V/Q) scan 156, **205**
- ventouse delivery *see* vacuum delivery
- ventricular premature complexes, in pregnancy 93–94
- ventricular septal defect, in pregnancy 87
- ventriculomegaly 258
- verapamil 94
- Veress needle 524, 534
- verrucous carcinoma, vulva **839**
- Versapoint Bipolar Electrosurgery System™ 522–523, 523, 530
- vertex presentation 354
- very low birthweight 31, 387
 - stillbirth risk 416
- very low-density lipoprotein (VLDL), in pregnancy 13
- very preterm infants 387
 - survival and morbidity 389, 389–390, **390**
- vesico-amniotic shunting (VAS) 262
- vesico-ureteric reflux 772
- vesicovaginal fistulae 785
- vestibular papillae 796, 797
- videocystourethrography 769, 771–772
- video laparoscopes 520
- video recordings, endoscopic surgery 521–522
- villi, placental *see* placental villi
- villous trophoblast *see* trophoblast, villous
- vincristine, gestational trophoblastic tumours **582**, 582–583
- violence
 - domestic *see* domestic violence
 - sexual 967–981
- Virchow's triad 155
- virginity testing 977–978
- virilization
 - female fetus 245, 490
 - hyperandrogenism vs. 633
- viruses
 - pelvic inflammatory disease 613
 - vulvovaginitis in children 553
- visual impairment, preterm infants 390, 449, 451
- vitamin A 48
- vitamin B₆ 667
- vitamin B₁₂ 147, 149–150
- vitamin D supplements
 - dialysis patients 138
 - obesity 210
 - postmenopause 677
 - pregnancy 40, 44, 48
- vitamin K antagonists, in pregnancy 91, 156
- vitelline duct 477
- vitiligo 808, 808
- vitrification 714, 716
- voiding dysfunction, pelvic organ prolapse 756
- volume replacement, obstetric haemorrhage 344
- von Willebrand disease (vWD)
 - heavy menstrual bleeding 655
 - pregnancy 157–159
- von Willebrand factor (vWF)
 - concentrate 159
 - deficiency 157–159
 - normal pregnancy 147
- vulva
 - anatomy 478–479, 479, 480
 - benign diseases 795–810
 - examination 795–797
 - history-taking 795
 - investigations 797–798
 - benign tumours 808–809
 - biopsy 797, 840
 - bullous diseases 804–805
 - childhood skin diseases 553
 - cysts 809, 809
 - developmental anomalies 495
 - inflammatory diseases 798–804
 - lymphatic disorders 809–810
 - malignant disease *see* vulval cancer

- neonates 797
 - normal physiological changes 797
 - normal variants 796, 796
 - pigmentation disorders 807–808
 - ulceration 805
 - underlying diseases affecting 806–807
 - vascular lesions 809
 - vulval cancer 837–849
 - aetiology 838
 - assessment 840–843
 - chemotherapy 848
 - diagnosis 840
 - examination 840
 - groin node assessment 841, **842**
 - histology 838, **839**, 839
 - incidence 837, **838**
 - lichen planus and 802
 - lichen sclerosus and 799, 799, 837, 838, 849
 - lymph node involvement **844**, 844–845
 - presentation 838–840, **840**
 - radiotherapy 848–849
 - recurrence 849
 - risk factors 837–838
 - second field tumours 849
 - sentinel node biopsy 841–842, **843**, 843
 - spread 840–841, **841**
 - staging 841, **841**, **842**
 - surgery 843–847
 - advanced disease 844
 - complications 847, **847**
 - early stage disease 844
 - lymph nodes 845–847
 - vulval intraepithelial neoplasia (VIN) 837, 838
 - lichen sclerosus and 799, 838
 - vulval resection
 - complications 847, **847**
 - recurrent cancer 849
 - vulval cancer 844
 - vulval vestibulitis syndrome 964
 - vulvectomy, radical 844, 847
 - vulvodynia 964
 - vulvovaginal atrophy (VVA) 813
 - postmenopause 673
 - treatment 677–678, 683–684
 - vulvovaginal–gingival (VVG) syndrome 800
 - vulvo-vaginal infections 811–813
 - recurrent 920–922
 - see also* sexually transmitted infections
 - vulvo-vaginal swabs
 - children 553
 - sexually transmitted infections 910, 911
 - vulvovaginitis, childhood 552–553, **553**
- W**
- Walhard nests 888
 - warfarin, in pregnancy 91–92
 - Warnock Report 992
 - warts, genital *see* genital warts
 - weight
 - estimated fetal *see* estimated fetal weight
 - pre-conception advice 41–42
 - see also* birthweight; body mass index
 - weight gain
 - gestational 12, 210, **210**
 - IUCD users 942
 - perimenopausal 674
 - progestogen-only contraception 944
 - weight loss
 - amenorrhoea 547, 650
 - fertility benefits 208, 698
 - pelvic organ prolapse 759
 - postpartum 435
 - prior to assisted conception 707
 - weight management
 - diabetic pregnancy 105–106
 - obesity 210
 - polycystic ovary syndrome 641
 - weight-related amenorrhoea 547, 650
 - white cell count (WCC)
 - chorioamnionitis 403
 - normal pregnancy 9, 147
 - Wickham's striae 800, 801, **801**
 - Wilcoxon signed-rank test 470, 471
 - WNT4 gene **624**
 - Wolffian (mesonephric) duct 485, 486, 486
 - anomalies 495
 - Women's Health Initiative (WHI) study 680, 681, 759
 - Woods screw manoeuvre 349
 - work, physically demanding 49
 - World Health Organization (WHO)
 - classification of female genital mutilation **51**, **982**
 - fetal growth standards 34, 223
 - heart disease risk in pregnancy 87
 - medical eligibility criteria for contraceptive use 939–940
 - semen analysis reference values 697, **697**
 - wound breakdown, vulval cancer 847
 - WT1 knockouts **624**
- X**
- X chromosomes, ovarian differentiation 485
 - 45X karyotype *see* Turner's syndrome
 - 46XX disorders of sexual development **489**, 490–492, 548
 - 46XY disorders of sexual development 488–490, **489**, 548
 - XY females
 - anatomical anomalies 496
 - management 550
 - primary amenorrhoea 547, 549
- Y**
- Yasmin 642
 - Y chromosome 485
 - yolk sac 512
- Z**
- Zahara I score 87
 - zanamivir 201
 - zidovudine 163
 - zika virus (ZIKV) infection 175–177, **176**
 - zinc deficiency 807
 - zygosity 269, 270